JP2023521042A - 操作されたオリゴヌクレオチドを使用する標的化された阻害 - Google Patents
操作されたオリゴヌクレオチドを使用する標的化された阻害 Download PDFInfo
- Publication number
- JP2023521042A JP2023521042A JP2022560272A JP2022560272A JP2023521042A JP 2023521042 A JP2023521042 A JP 2023521042A JP 2022560272 A JP2022560272 A JP 2022560272A JP 2022560272 A JP2022560272 A JP 2022560272A JP 2023521042 A JP2023521042 A JP 2023521042A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- engineered
- salt
- rna
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 326
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title claims abstract description 116
- 230000005764 inhibitory process Effects 0.000 title description 3
- 230000000694 effects Effects 0.000 claims abstract description 69
- 238000000034 method Methods 0.000 claims abstract description 52
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 32
- 229920001184 polypeptide Polymers 0.000 claims abstract description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 29
- 230000014509 gene expression Effects 0.000 claims abstract description 23
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 9
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 9
- 239000002157 polynucleotide Substances 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims description 205
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 203
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 101
- 210000004027 cell Anatomy 0.000 claims description 99
- 206010028980 Neoplasm Diseases 0.000 claims description 88
- 201000010099 disease Diseases 0.000 claims description 81
- 108020004999 messenger RNA Proteins 0.000 claims description 81
- 125000003729 nucleotide group Chemical group 0.000 claims description 81
- 239000002773 nucleotide Substances 0.000 claims description 75
- 108091007431 miR-29 Proteins 0.000 claims description 67
- 108090000623 proteins and genes Proteins 0.000 claims description 64
- 201000011510 cancer Diseases 0.000 claims description 63
- -1 methoxyethyl group Chemical group 0.000 claims description 58
- 239000013598 vector Substances 0.000 claims description 55
- 150000007523 nucleic acids Chemical class 0.000 claims description 54
- 230000004048 modification Effects 0.000 claims description 53
- 238000012986 modification Methods 0.000 claims description 53
- 108700011259 MicroRNAs Proteins 0.000 claims description 49
- 102000039446 nucleic acids Human genes 0.000 claims description 46
- 108020004707 nucleic acids Proteins 0.000 claims description 46
- 210000004962 mammalian cell Anatomy 0.000 claims description 45
- 238000007385 chemical modification Methods 0.000 claims description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims description 41
- 235000000346 sugar Nutrition 0.000 claims description 38
- 239000002679 microRNA Substances 0.000 claims description 36
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 32
- 230000009385 viral infection Effects 0.000 claims description 30
- 208000036142 Viral infection Diseases 0.000 claims description 29
- 210000001519 tissue Anatomy 0.000 claims description 29
- 238000004422 calculation algorithm Methods 0.000 claims description 26
- 230000000295 complement effect Effects 0.000 claims description 26
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 25
- 238000003860 storage Methods 0.000 claims description 25
- 230000011664 signaling Effects 0.000 claims description 24
- 208000015181 infectious disease Diseases 0.000 claims description 23
- 238000002888 pairwise sequence alignment Methods 0.000 claims description 23
- 108020004417 Untranslated RNA Proteins 0.000 claims description 21
- 102000039634 Untranslated RNA Human genes 0.000 claims description 21
- 238000002347 injection Methods 0.000 claims description 21
- 239000007924 injection Substances 0.000 claims description 21
- 241000315672 SARS coronavirus Species 0.000 claims description 20
- 238000002560 therapeutic procedure Methods 0.000 claims description 20
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 17
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 17
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims description 17
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 17
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 17
- 241000711573 Coronaviridae Species 0.000 claims description 16
- 206010016654 Fibrosis Diseases 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 16
- 108700020796 Oncogene Proteins 0.000 claims description 16
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 16
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 16
- 230000004761 fibrosis Effects 0.000 claims description 16
- 210000005260 human cell Anatomy 0.000 claims description 16
- 108091027963 non-coding RNA Proteins 0.000 claims description 16
- 102000042567 non-coding RNA Human genes 0.000 claims description 16
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims description 15
- 102100032816 Integrin alpha-6 Human genes 0.000 claims description 15
- 229940104302 cytosine Drugs 0.000 claims description 15
- 201000006938 muscular dystrophy Diseases 0.000 claims description 15
- 239000002105 nanoparticle Substances 0.000 claims description 15
- 241001109669 Human coronavirus HKU1 Species 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- 229930024421 Adenine Natural products 0.000 claims description 12
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 12
- 102100031000 Hepatoma-derived growth factor Human genes 0.000 claims description 12
- 229960000643 adenine Drugs 0.000 claims description 12
- 108010052188 hepatoma-derived growth factor Proteins 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 12
- 101710163270 Nuclease Proteins 0.000 claims description 11
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 11
- 108020004459 Small interfering RNA Proteins 0.000 claims description 11
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 11
- 238000004458 analytical method Methods 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 150000008163 sugars Chemical class 0.000 claims description 11
- 102100021158 Double homeobox protein 4 Human genes 0.000 claims description 10
- 101000968549 Homo sapiens Double homeobox protein 4 Proteins 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 208000025721 COVID-19 Diseases 0.000 claims description 9
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 9
- 229910019142 PO4 Inorganic materials 0.000 claims description 9
- 230000002068 genetic effect Effects 0.000 claims description 9
- 238000003780 insertion Methods 0.000 claims description 9
- 230000037431 insertion Effects 0.000 claims description 9
- 239000010452 phosphate Substances 0.000 claims description 9
- 108700026220 vif Genes Proteins 0.000 claims description 9
- 239000013603 viral vector Substances 0.000 claims description 9
- 102000008186 Collagen Human genes 0.000 claims description 8
- 108010035532 Collagen Proteins 0.000 claims description 8
- 102100022640 Collagen alpha-1(XV) chain Human genes 0.000 claims description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 8
- 101000899935 Homo sapiens Collagen alpha-1(XV) chain Proteins 0.000 claims description 8
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 8
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 8
- 102000013814 Wnt Human genes 0.000 claims description 8
- 108050003627 Wnt Proteins 0.000 claims description 8
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 8
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- 230000037369 collagen remodeling Effects 0.000 claims description 8
- 210000002744 extracellular matrix Anatomy 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- 238000007634 remodeling Methods 0.000 claims description 8
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 8
- 229940035893 uracil Drugs 0.000 claims description 8
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 7
- 108091012583 BCL2 Proteins 0.000 claims description 7
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 7
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 7
- 208000031886 HIV Infections Diseases 0.000 claims description 7
- 208000037357 HIV infectious disease Diseases 0.000 claims description 7
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 claims description 7
- 101000912957 Homo sapiens Protein DEK Proteins 0.000 claims description 7
- 101001111742 Homo sapiens Rhombotin-2 Proteins 0.000 claims description 7
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 claims description 7
- 101000691578 Homo sapiens Zinc finger protein PLAG1 Proteins 0.000 claims description 7
- 108700012912 MYCN Proteins 0.000 claims description 7
- 101150022024 MYCN gene Proteins 0.000 claims description 7
- 108091093085 MiR-338 Proteins 0.000 claims description 7
- 108091062154 Mir-205 Proteins 0.000 claims description 7
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 claims description 7
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 claims description 7
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 claims description 7
- 102100026113 Protein DEK Human genes 0.000 claims description 7
- 108010019674 Proto-Oncogene Proteins c-sis Proteins 0.000 claims description 7
- 102100023876 Rhombotin-2 Human genes 0.000 claims description 7
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 claims description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 7
- 102100026200 Zinc finger protein PLAG1 Human genes 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 201000010881 cervical cancer Diseases 0.000 claims description 7
- 238000012217 deletion Methods 0.000 claims description 7
- 230000037430 deletion Effects 0.000 claims description 7
- 238000002405 diagnostic procedure Methods 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 7
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 7
- 238000007913 intrathecal administration Methods 0.000 claims description 7
- 239000002502 liposome Substances 0.000 claims description 7
- 108091046553 miR-26 stem-loop Proteins 0.000 claims description 7
- 108091023821 miR-26-1 stem-loop Proteins 0.000 claims description 7
- 108091045094 miR-26-2 stem-loop Proteins 0.000 claims description 7
- 102100031173 CCN family member 4 Human genes 0.000 claims description 6
- 102100029136 Collagen alpha-1(II) chain Human genes 0.000 claims description 6
- 102100028257 Collagen alpha-1(XVI) chain Human genes 0.000 claims description 6
- 102100031576 Collagen alpha-1(XXV) chain Human genes 0.000 claims description 6
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 claims description 6
- 101000777560 Homo sapiens CCN family member 4 Proteins 0.000 claims description 6
- 101000771163 Homo sapiens Collagen alpha-1(II) chain Proteins 0.000 claims description 6
- 101000860648 Homo sapiens Collagen alpha-1(XVI) chain Proteins 0.000 claims description 6
- 101000940250 Homo sapiens Collagen alpha-1(XXV) chain Proteins 0.000 claims description 6
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 claims description 6
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 claims description 6
- 108091007419 MiR-27 Proteins 0.000 claims description 6
- 108091028684 Mir-145 Proteins 0.000 claims description 6
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims description 6
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims description 6
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 6
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 6
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 210000003098 myoblast Anatomy 0.000 claims description 6
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 claims description 5
- 102100040512 Collagen alpha-1(IX) chain Human genes 0.000 claims description 5
- 102100031457 Collagen alpha-1(V) chain Human genes 0.000 claims description 5
- 102100024335 Collagen alpha-1(VII) chain Human genes 0.000 claims description 5
- 102100024337 Collagen alpha-1(VIII) chain Human genes 0.000 claims description 5
- 102100033825 Collagen alpha-1(XI) chain Human genes 0.000 claims description 5
- 102100031161 Collagen alpha-1(XIX) chain Human genes 0.000 claims description 5
- 102100040995 Collagen alpha-1(XXI) chain Human genes 0.000 claims description 5
- 102100037296 Collagen alpha-1(XXII) chain Human genes 0.000 claims description 5
- 102100037285 Collagen alpha-1(XXIV) chain Human genes 0.000 claims description 5
- 102100033781 Collagen alpha-2(IV) chain Human genes 0.000 claims description 5
- 102100031502 Collagen alpha-2(V) chain Human genes 0.000 claims description 5
- 102100031518 Collagen alpha-2(VI) chain Human genes 0.000 claims description 5
- 102100033780 Collagen alpha-3(IV) chain Human genes 0.000 claims description 5
- 102100031501 Collagen alpha-3(V) chain Human genes 0.000 claims description 5
- 102100033779 Collagen alpha-4(IV) chain Human genes 0.000 claims description 5
- 102100033773 Collagen alpha-6(IV) chain Human genes 0.000 claims description 5
- 101000749901 Homo sapiens Collagen alpha-1(IX) chain Proteins 0.000 claims description 5
- 101000941708 Homo sapiens Collagen alpha-1(V) chain Proteins 0.000 claims description 5
- 101000909498 Homo sapiens Collagen alpha-1(VII) chain Proteins 0.000 claims description 5
- 101000909492 Homo sapiens Collagen alpha-1(VIII) chain Proteins 0.000 claims description 5
- 101000710623 Homo sapiens Collagen alpha-1(XI) chain Proteins 0.000 claims description 5
- 101000940120 Homo sapiens Collagen alpha-1(XIX) chain Proteins 0.000 claims description 5
- 101000748976 Homo sapiens Collagen alpha-1(XXI) chain Proteins 0.000 claims description 5
- 101000952998 Homo sapiens Collagen alpha-1(XXII) chain Proteins 0.000 claims description 5
- 101000952969 Homo sapiens Collagen alpha-1(XXIV) chain Proteins 0.000 claims description 5
- 101000710876 Homo sapiens Collagen alpha-2(IV) chain Proteins 0.000 claims description 5
- 101000941594 Homo sapiens Collagen alpha-2(V) chain Proteins 0.000 claims description 5
- 101000941585 Homo sapiens Collagen alpha-2(VI) chain Proteins 0.000 claims description 5
- 101000710873 Homo sapiens Collagen alpha-3(IV) chain Proteins 0.000 claims description 5
- 101000941596 Homo sapiens Collagen alpha-3(V) chain Proteins 0.000 claims description 5
- 101000710870 Homo sapiens Collagen alpha-4(IV) chain Proteins 0.000 claims description 5
- 101000710885 Homo sapiens Collagen alpha-6(IV) chain Proteins 0.000 claims description 5
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 claims description 5
- 101000800488 Homo sapiens T-cell leukemia homeobox protein 1 Proteins 0.000 claims description 5
- 108091093189 Mir-375 Proteins 0.000 claims description 5
- 208000021642 Muscular disease Diseases 0.000 claims description 5
- 201000009623 Myopathy Diseases 0.000 claims description 5
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 5
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 5
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 claims description 5
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims description 5
- 102100033111 T-cell leukemia homeobox protein 1 Human genes 0.000 claims description 5
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 5
- 238000010253 intravenous injection Methods 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims description 4
- 108010080691 Alcohol O-acetyltransferase Proteins 0.000 claims description 4
- 108700009171 B-Cell Lymphoma 3 Proteins 0.000 claims description 4
- 102100021570 B-cell lymphoma 3 protein Human genes 0.000 claims description 4
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 claims description 4
- 102100022976 B-cell lymphoma/leukemia 11A Human genes 0.000 claims description 4
- 101150072667 Bcl3 gene Proteins 0.000 claims description 4
- 102100026008 Breakpoint cluster region protein Human genes 0.000 claims description 4
- 101710098191 C-4 methylsterol oxidase ERG25 Proteins 0.000 claims description 4
- 108010083123 CDX2 Transcription Factor Proteins 0.000 claims description 4
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 claims description 4
- 102100028914 Catenin beta-1 Human genes 0.000 claims description 4
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims description 4
- 102100031203 Centrosomal protein 43 Human genes 0.000 claims description 4
- 108010058546 Cyclin D1 Proteins 0.000 claims description 4
- 102100021122 DNA damage-binding protein 2 Human genes 0.000 claims description 4
- 102100035273 E3 ubiquitin-protein ligase CBL-B Human genes 0.000 claims description 4
- 102100035275 E3 ubiquitin-protein ligase CBL-C Human genes 0.000 claims description 4
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims description 4
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims description 4
- 102100023792 ETS domain-containing protein Elk-4 Human genes 0.000 claims description 4
- 102100039578 ETS translocation variant 4 Human genes 0.000 claims description 4
- 201000006107 Familial adenomatous polyposis Diseases 0.000 claims description 4
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims description 4
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims description 4
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 claims description 4
- 102100024185 G1/S-specific cyclin-D2 Human genes 0.000 claims description 4
- 102100037859 G1/S-specific cyclin-D3 Human genes 0.000 claims description 4
- 102100029974 GTPase HRas Human genes 0.000 claims description 4
- 102100033295 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 4
- 102100033495 Glycine dehydrogenase (decarboxylating), mitochondrial Human genes 0.000 claims description 4
- 102100036675 Golgi-associated PDZ and coiled-coil motif-containing protein Human genes 0.000 claims description 4
- 102100041032 Golgin subfamily A member 5 Human genes 0.000 claims description 4
- 108700039143 HMGA2 Proteins 0.000 claims description 4
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 claims description 4
- 102100029009 High mobility group protein HMG-I/HMG-Y Human genes 0.000 claims description 4
- 102100028999 High mobility group protein HMGI-C Human genes 0.000 claims description 4
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 claims description 4
- 102100039121 Histone-lysine N-methyltransferase MECOM Human genes 0.000 claims description 4
- 101150073387 Hmga2 gene Proteins 0.000 claims description 4
- 102100031671 Homeobox protein CDX-2 Human genes 0.000 claims description 4
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 claims description 4
- 101000903703 Homo sapiens B-cell lymphoma/leukemia 11A Proteins 0.000 claims description 4
- 101000933320 Homo sapiens Breakpoint cluster region protein Proteins 0.000 claims description 4
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 claims description 4
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 claims description 4
- 101000776477 Homo sapiens Centrosomal protein 43 Proteins 0.000 claims description 4
- 101001041466 Homo sapiens DNA damage-binding protein 2 Proteins 0.000 claims description 4
- 101000737265 Homo sapiens E3 ubiquitin-protein ligase CBL-B Proteins 0.000 claims description 4
- 101000737269 Homo sapiens E3 ubiquitin-protein ligase CBL-C Proteins 0.000 claims description 4
- 101001048716 Homo sapiens ETS domain-containing protein Elk-4 Proteins 0.000 claims description 4
- 101000813747 Homo sapiens ETS translocation variant 4 Proteins 0.000 claims description 4
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 claims description 4
- 101000980741 Homo sapiens G1/S-specific cyclin-D2 Proteins 0.000 claims description 4
- 101000738559 Homo sapiens G1/S-specific cyclin-D3 Proteins 0.000 claims description 4
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 claims description 4
- 101001072499 Homo sapiens Golgi-associated PDZ and coiled-coil motif-containing protein Proteins 0.000 claims description 4
- 101001039330 Homo sapiens Golgin subfamily A member 5 Proteins 0.000 claims description 4
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 claims description 4
- 101000986380 Homo sapiens High mobility group protein HMG-I/HMG-Y Proteins 0.000 claims description 4
- 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 claims description 4
- 101001033728 Homo sapiens Histone-lysine N-methyltransferase MECOM Proteins 0.000 claims description 4
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 claims description 4
- 101001005667 Homo sapiens Mastermind-like protein 2 Proteins 0.000 claims description 4
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 claims description 4
- 101000979338 Homo sapiens Nuclear factor NF-kappa-B p100 subunit Proteins 0.000 claims description 4
- 101000996563 Homo sapiens Nuclear pore complex protein Nup214 Proteins 0.000 claims description 4
- 101000974343 Homo sapiens Nuclear receptor coactivator 4 Proteins 0.000 claims description 4
- 101000801664 Homo sapiens Nucleoprotein TPR Proteins 0.000 claims description 4
- 101000601664 Homo sapiens Paired box protein Pax-8 Proteins 0.000 claims description 4
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 claims description 4
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims description 4
- 101000585703 Homo sapiens Protein L-Myc Proteins 0.000 claims description 4
- 101000642815 Homo sapiens Protein SSXT Proteins 0.000 claims description 4
- 101000800847 Homo sapiens Protein TFG Proteins 0.000 claims description 4
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 claims description 4
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 claims description 4
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 claims description 4
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 claims description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 4
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 4
- 101000837401 Homo sapiens T-cell leukemia/lymphoma protein 1A Proteins 0.000 claims description 4
- 101000799466 Homo sapiens Thrombopoietin receptor Proteins 0.000 claims description 4
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 claims description 4
- 101000813738 Homo sapiens Transcription factor ETV6 Proteins 0.000 claims description 4
- 101000962461 Homo sapiens Transcription factor Maf Proteins 0.000 claims description 4
- 101000979190 Homo sapiens Transcription factor MafB Proteins 0.000 claims description 4
- 101000636213 Homo sapiens Transcriptional activator Myb Proteins 0.000 claims description 4
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 claims description 4
- 101000823271 Homo sapiens Tyrosine-protein kinase ABL2 Proteins 0.000 claims description 4
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims description 4
- 101000643895 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 6 Proteins 0.000 claims description 4
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 4
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 claims description 4
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 claims description 4
- 102100025130 Mastermind-like protein 2 Human genes 0.000 claims description 4
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 claims description 4
- 102100030157 Microphthalmia-associated transcription factor Human genes 0.000 claims description 4
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 4
- 102100023059 Nuclear factor NF-kappa-B p100 subunit Human genes 0.000 claims description 4
- 102100033819 Nuclear pore complex protein Nup214 Human genes 0.000 claims description 4
- 102100022927 Nuclear receptor coactivator 4 Human genes 0.000 claims description 4
- 102100033615 Nucleoprotein TPR Human genes 0.000 claims description 4
- 102100037502 Paired box protein Pax-8 Human genes 0.000 claims description 4
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims description 4
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 102100030128 Protein L-Myc Human genes 0.000 claims description 4
- 102100035586 Protein SSXT Human genes 0.000 claims description 4
- 102100033661 Protein TFG Human genes 0.000 claims description 4
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 claims description 4
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims description 4
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 claims description 4
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 claims description 4
- 108090000740 RNA-binding protein EWS Proteins 0.000 claims description 4
- 102000004229 RNA-binding protein EWS Human genes 0.000 claims description 4
- 102000003890 RNA-binding protein FUS Human genes 0.000 claims description 4
- 108090000292 RNA-binding protein FUS Proteins 0.000 claims description 4
- 101000613608 Rattus norvegicus Monocyte to macrophage differentiation factor Proteins 0.000 claims description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 4
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 102000013380 Smoothened Receptor Human genes 0.000 claims description 4
- 101710090597 Smoothened homolog Proteins 0.000 claims description 4
- 102100028676 T-cell leukemia/lymphoma protein 1A Human genes 0.000 claims description 4
- 102100034196 Thrombopoietin receptor Human genes 0.000 claims description 4
- 102100024026 Transcription factor E2F1 Human genes 0.000 claims description 4
- 102100039580 Transcription factor ETV6 Human genes 0.000 claims description 4
- 102100039189 Transcription factor Maf Human genes 0.000 claims description 4
- 102100023234 Transcription factor MafB Human genes 0.000 claims description 4
- 102100030780 Transcriptional activator Myb Human genes 0.000 claims description 4
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 claims description 4
- 102100022651 Tyrosine-protein kinase ABL2 Human genes 0.000 claims description 4
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims description 4
- 102100021015 Ubiquitin carboxyl-terminal hydrolase 6 Human genes 0.000 claims description 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 4
- 239000000090 biomarker Substances 0.000 claims description 4
- 238000004820 blood count Methods 0.000 claims description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 4
- 238000007489 histopathology method Methods 0.000 claims description 4
- 238000003384 imaging method Methods 0.000 claims description 4
- 238000010255 intramuscular injection Methods 0.000 claims description 4
- 239000007927 intramuscular injection Substances 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 210000000663 muscle cell Anatomy 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- 238000010254 subcutaneous injection Methods 0.000 claims description 4
- 239000007929 subcutaneous injection Substances 0.000 claims description 4
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 3
- 102100040634 Actin filament-associated protein 1-like 2 Human genes 0.000 claims description 3
- 102100020823 Autophagy-related protein 9A Human genes 0.000 claims description 3
- 102100039551 Collagen triple helix repeat-containing protein 1 Human genes 0.000 claims description 3
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 3
- 102100025176 Cyclin-A1 Human genes 0.000 claims description 3
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims description 3
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims description 3
- 102000016942 Elastin Human genes 0.000 claims description 3
- 108010014258 Elastin Proteins 0.000 claims description 3
- 102100030708 GTPase KRas Human genes 0.000 claims description 3
- 102100039788 GTPase NRas Human genes 0.000 claims description 3
- 102100021337 Gap junction alpha-1 protein Human genes 0.000 claims description 3
- 101710088083 Glomulin Proteins 0.000 claims description 3
- 102100023696 Histone-lysine N-methyltransferase SETDB1 Human genes 0.000 claims description 3
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 3
- 101000892366 Homo sapiens Actin filament-associated protein 1-like 2 Proteins 0.000 claims description 3
- 101000785057 Homo sapiens Autophagy-related protein 9A Proteins 0.000 claims description 3
- 101000746121 Homo sapiens Collagen triple helix repeat-containing protein 1 Proteins 0.000 claims description 3
- 101000934314 Homo sapiens Cyclin-A1 Proteins 0.000 claims description 3
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 3
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 3
- 101000894966 Homo sapiens Gap junction alpha-1 protein Proteins 0.000 claims description 3
- 101000998096 Homo sapiens Glycine dehydrogenase (decarboxylating), mitochondrial Proteins 0.000 claims description 3
- 101000684609 Homo sapiens Histone-lysine N-methyltransferase SETDB1 Proteins 0.000 claims description 3
- 101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 claims description 3
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 3
- 101000994378 Homo sapiens Integrin alpha-3 Proteins 0.000 claims description 3
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 claims description 3
- 101000593405 Homo sapiens Myb-related protein B Proteins 0.000 claims description 3
- 101000611888 Homo sapiens Platelet-derived growth factor C Proteins 0.000 claims description 3
- 101000804792 Homo sapiens Protein Wnt-5a Proteins 0.000 claims description 3
- 101000798007 Homo sapiens RAC-gamma serine/threonine-protein kinase Proteins 0.000 claims description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 3
- 101000633605 Homo sapiens Thrombospondin-2 Proteins 0.000 claims description 3
- 101000635958 Homo sapiens Transforming growth factor beta-2 proprotein Proteins 0.000 claims description 3
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 claims description 3
- 101000785626 Homo sapiens Zinc finger E-box-binding homeobox 1 Proteins 0.000 claims description 3
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 claims description 3
- 102100032819 Integrin alpha-3 Human genes 0.000 claims description 3
- 102100020881 Interleukin-1 alpha Human genes 0.000 claims description 3
- 101710159002 L-lactate oxidase Proteins 0.000 claims description 3
- 102100034670 Myb-related protein B Human genes 0.000 claims description 3
- 102100040681 Platelet-derived growth factor C Human genes 0.000 claims description 3
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims description 3
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 claims description 3
- 102100032314 RAC-gamma serine/threonine-protein kinase Human genes 0.000 claims description 3
- 108010044012 STAT1 Transcription Factor Proteins 0.000 claims description 3
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 claims description 3
- 101150045565 Socs1 gene Proteins 0.000 claims description 3
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 claims description 3
- 102100024779 Suppressor of cytokine signaling 1 Human genes 0.000 claims description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 3
- 102100029529 Thrombospondin-2 Human genes 0.000 claims description 3
- 102100030737 Transforming growth factor beta-2 proprotein Human genes 0.000 claims description 3
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 claims description 3
- 102000043366 Wnt-5a Human genes 0.000 claims description 3
- 102100026457 Zinc finger E-box-binding homeobox 1 Human genes 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 150000001735 carboxylic acids Chemical class 0.000 claims description 3
- 229920002549 elastin Polymers 0.000 claims description 3
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 210000002950 fibroblast Anatomy 0.000 claims description 3
- 210000000265 leukocyte Anatomy 0.000 claims description 3
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 3
- 208000018360 neuromuscular disease Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 102100029005 ATP-dependent RNA helicase SUPV3L1, mitochondrial Human genes 0.000 claims description 2
- 102100038048 ATPase WRNIP1 Human genes 0.000 claims description 2
- 102100022094 Acid-sensing ion channel 2 Human genes 0.000 claims description 2
- 101710099902 Acid-sensing ion channel 2 Proteins 0.000 claims description 2
- 102100034111 Activin receptor type-1 Human genes 0.000 claims description 2
- 102100037151 Barrier-to-autointegration factor Human genes 0.000 claims description 2
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims description 2
- 102100026324 Beclin 1-associated autophagy-related key regulator Human genes 0.000 claims description 2
- 102100021390 C-terminal-binding protein 1 Human genes 0.000 claims description 2
- 102100024080 CASP8-associated protein 2 Human genes 0.000 claims description 2
- 102100033849 CCHC-type zinc finger nucleic acid binding protein Human genes 0.000 claims description 2
- 101710116319 CCHC-type zinc finger nucleic acid binding protein Proteins 0.000 claims description 2
- 102100031033 CCR4-NOT transcription complex subunit 3 Human genes 0.000 claims description 2
- 102100029396 CLIP-associating protein 1 Human genes 0.000 claims description 2
- 102100028228 COUP transcription factor 1 Human genes 0.000 claims description 2
- 102100033210 CUGBP Elav-like family member 2 Human genes 0.000 claims description 2
- 102100032539 Calpain-3 Human genes 0.000 claims description 2
- 102100037828 Charged multivesicular body protein 7 Human genes 0.000 claims description 2
- 101710153987 Charged multivesicular body protein 7 Proteins 0.000 claims description 2
- 102100023457 Chloride channel protein 1 Human genes 0.000 claims description 2
- 102100033283 Creatine kinase U-type, mitochondrial Human genes 0.000 claims description 2
- 102100029375 Crk-like protein Human genes 0.000 claims description 2
- 102100039768 DDB1- and CUL4-associated factor 15 Human genes 0.000 claims description 2
- 102100035784 Decorin Human genes 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 102100024105 DnaJ homolog subfamily C member 27 Human genes 0.000 claims description 2
- 102100021212 Double homeobox protein 1 Human genes 0.000 claims description 2
- 102100021213 Double homeobox protein 5 Human genes 0.000 claims description 2
- 102100027275 Dual specificity protein phosphatase 7 Human genes 0.000 claims description 2
- 102100032248 Dysferlin Human genes 0.000 claims description 2
- 108010069091 Dystrophin Proteins 0.000 claims description 2
- 102100024108 Dystrophin Human genes 0.000 claims description 2
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 claims description 2
- 102100032059 EMILIN-1 Human genes 0.000 claims description 2
- 102100030281 Ectopic P granules protein 5 homolog Human genes 0.000 claims description 2
- 102100027699 F-box and leucine-rich protein 22 Human genes 0.000 claims description 2
- 102100028406 FERM and PDZ domain-containing protein 2 Human genes 0.000 claims description 2
- 102100035441 FRAS1-related extracellular matrix protein 2 Human genes 0.000 claims description 2
- 102100032596 Fibrocystin Human genes 0.000 claims description 2
- 102100032789 Formin-like protein 3 Human genes 0.000 claims description 2
- 102100021195 G-protein coupled receptor family C group 6 member A Human genes 0.000 claims description 2
- 108010013942 GMP Reductase Proteins 0.000 claims description 2
- 102100021188 GMP reductase 1 Human genes 0.000 claims description 2
- 102100028463 Galactose-3-O-sulfotransferase 3 Human genes 0.000 claims description 2
- 102100025624 Gap junction delta-3 protein Human genes 0.000 claims description 2
- 102100036255 Glucose-6-phosphatase 2 Human genes 0.000 claims description 2
- 102100039684 Glucose-6-phosphate exchanger SLC37A4 Human genes 0.000 claims description 2
- 102100028650 Glucose-induced degradation protein 4 homolog Human genes 0.000 claims description 2
- 102100029492 Glycogen phosphorylase, muscle form Human genes 0.000 claims description 2
- 102100023324 Golgi SNAP receptor complex member 1 Human genes 0.000 claims description 2
- 102100031150 Growth arrest and DNA damage-inducible protein GADD45 alpha Human genes 0.000 claims description 2
- 102100039261 Guanine nucleotide-binding protein G(t) subunit alpha-1 Human genes 0.000 claims description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims description 2
- 102100035616 Heterogeneous nuclear ribonucleoproteins A2/B1 Human genes 0.000 claims description 2
- 102100033994 Heterogeneous nuclear ribonucleoproteins C1/C2 Human genes 0.000 claims description 2
- 102100031670 Homeobox protein CDX-4 Human genes 0.000 claims description 2
- 102100022373 Homeobox protein DLX-5 Human genes 0.000 claims description 2
- 102100022597 Homeobox protein Hox-C9 Human genes 0.000 claims description 2
- 101000696694 Homo sapiens ATP-dependent RNA helicase SUPV3L1, mitochondrial Proteins 0.000 claims description 2
- 101000742815 Homo sapiens ATPase WRNIP1 Proteins 0.000 claims description 2
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 claims description 2
- 101000740067 Homo sapiens Barrier-to-autointegration factor Proteins 0.000 claims description 2
- 101000766227 Homo sapiens Beclin 1-associated autophagy-related key regulator Proteins 0.000 claims description 2
- 101000910382 Homo sapiens CASP8-associated protein 2 Proteins 0.000 claims description 2
- 101000919663 Homo sapiens CCR4-NOT transcription complex subunit 3 Proteins 0.000 claims description 2
- 101000990005 Homo sapiens CLIP-associating protein 1 Proteins 0.000 claims description 2
- 101000860854 Homo sapiens COUP transcription factor 1 Proteins 0.000 claims description 2
- 101000944442 Homo sapiens CUGBP Elav-like family member 2 Proteins 0.000 claims description 2
- 101000867715 Homo sapiens Calpain-3 Proteins 0.000 claims description 2
- 101000906651 Homo sapiens Chloride channel protein 1 Proteins 0.000 claims description 2
- 101000642971 Homo sapiens Cohesin subunit SA-1 Proteins 0.000 claims description 2
- 101001135413 Homo sapiens Creatine kinase U-type, mitochondrial Proteins 0.000 claims description 2
- 101000919315 Homo sapiens Crk-like protein Proteins 0.000 claims description 2
- 101000885463 Homo sapiens DDB1- and CUL4-associated factor 15 Proteins 0.000 claims description 2
- 101001000206 Homo sapiens Decorin Proteins 0.000 claims description 2
- 101001054007 Homo sapiens DnaJ homolog subfamily C member 27 Proteins 0.000 claims description 2
- 101000968544 Homo sapiens Double homeobox protein 1 Proteins 0.000 claims description 2
- 101000968547 Homo sapiens Double homeobox protein 5 Proteins 0.000 claims description 2
- 101001057603 Homo sapiens Dual specificity protein phosphatase 7 Proteins 0.000 claims description 2
- 101001016184 Homo sapiens Dysferlin Proteins 0.000 claims description 2
- 101000921280 Homo sapiens EMILIN-1 Proteins 0.000 claims description 2
- 101000938359 Homo sapiens Ectopic P granules protein 5 homolog Proteins 0.000 claims description 2
- 101000862061 Homo sapiens F-box and leucine-rich protein 22 Proteins 0.000 claims description 2
- 101001060993 Homo sapiens FERM and PDZ domain-containing protein 2 Proteins 0.000 claims description 2
- 101000877894 Homo sapiens FRAS1-related extracellular matrix protein 2 Proteins 0.000 claims description 2
- 101000730595 Homo sapiens Fibrocystin Proteins 0.000 claims description 2
- 101000847535 Homo sapiens Formin-like protein 3 Proteins 0.000 claims description 2
- 101001040710 Homo sapiens G-protein coupled receptor family C group 6 member A Proteins 0.000 claims description 2
- 101000856663 Homo sapiens Gap junction delta-3 protein Proteins 0.000 claims description 2
- 101000930907 Homo sapiens Glucose-6-phosphatase 2 Proteins 0.000 claims description 2
- 101001058369 Homo sapiens Glucose-induced degradation protein 4 homolog Proteins 0.000 claims description 2
- 101000700475 Homo sapiens Glycogen phosphorylase, muscle form Proteins 0.000 claims description 2
- 101000829933 Homo sapiens Golgi SNAP receptor complex member 1 Proteins 0.000 claims description 2
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 claims description 2
- 101000888178 Homo sapiens Guanine nucleotide-binding protein G(t) subunit alpha-1 Proteins 0.000 claims description 2
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims description 2
- 101000854026 Homo sapiens Heterogeneous nuclear ribonucleoproteins A2/B1 Proteins 0.000 claims description 2
- 101001017574 Homo sapiens Heterogeneous nuclear ribonucleoproteins C1/C2 Proteins 0.000 claims description 2
- 101000777790 Homo sapiens Homeobox protein CDX-4 Proteins 0.000 claims description 2
- 101000901627 Homo sapiens Homeobox protein DLX-5 Proteins 0.000 claims description 2
- 101001045140 Homo sapiens Homeobox protein Hox-C9 Proteins 0.000 claims description 2
- 101000580021 Homo sapiens Inactive rhomboid protein 2 Proteins 0.000 claims description 2
- 101001078149 Homo sapiens Integrin alpha-10 Proteins 0.000 claims description 2
- 101001035232 Homo sapiens Integrin alpha-9 Proteins 0.000 claims description 2
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 claims description 2
- 101001032341 Homo sapiens Interferon regulatory factor 9 Proteins 0.000 claims description 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 2
- 101000977762 Homo sapiens Iroquois-class homeodomain protein IRX-5 Proteins 0.000 claims description 2
- 101000605522 Homo sapiens Kallikrein-1 Proteins 0.000 claims description 2
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 claims description 2
- 101001045824 Homo sapiens Kelch-like protein 3 Proteins 0.000 claims description 2
- 101001046589 Homo sapiens Krueppel-like factor 17 Proteins 0.000 claims description 2
- 101001137978 Homo sapiens La-related protein 6 Proteins 0.000 claims description 2
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 claims description 2
- 101001018147 Homo sapiens Mitogen-activated protein kinase kinase kinase 4 Proteins 0.000 claims description 2
- 101001023043 Homo sapiens Myoblast determination protein 1 Proteins 0.000 claims description 2
- 101001030243 Homo sapiens Myosin-7 Proteins 0.000 claims description 2
- 101000588491 Homo sapiens NADH dehydrogenase (ubiquinone) complex I, assembly factor 6 Proteins 0.000 claims description 2
- 101000995194 Homo sapiens Nebulette Proteins 0.000 claims description 2
- 101000934489 Homo sapiens Nucleosome-remodeling factor subunit BPTF Proteins 0.000 claims description 2
- 101000610034 Homo sapiens PCI domain-containing protein 2 Proteins 0.000 claims description 2
- 101000609211 Homo sapiens Polyadenylate-binding protein 2 Proteins 0.000 claims description 2
- 101000730585 Homo sapiens Polycystic kidney disease protein 1-like 2 Proteins 0.000 claims description 2
- 101001135496 Homo sapiens Potassium voltage-gated channel subfamily C member 3 Proteins 0.000 claims description 2
- 101001003584 Homo sapiens Prelamin-A/C Proteins 0.000 claims description 2
- 101000872514 Homo sapiens Probable E3 ubiquitin-protein ligase HERC1 Proteins 0.000 claims description 2
- 101001062760 Homo sapiens Protein FAM13A Proteins 0.000 claims description 2
- 101001061041 Homo sapiens Protein FRG1 Proteins 0.000 claims description 2
- 101000866633 Homo sapiens Protein Hook homolog 3 Proteins 0.000 claims description 2
- 101000986265 Homo sapiens Protein MTSS 1 Proteins 0.000 claims description 2
- 101000620365 Homo sapiens Protein TMEPAI Proteins 0.000 claims description 2
- 101000617017 Homo sapiens Protein scribble homolog Proteins 0.000 claims description 2
- 101001106821 Homo sapiens Rab11 family-interacting protein 1 Proteins 0.000 claims description 2
- 101001081220 Homo sapiens RanBP-type and C3HC4-type zinc finger-containing protein 1 Proteins 0.000 claims description 2
- 101000738765 Homo sapiens Receptor-type tyrosine-protein phosphatase N2 Proteins 0.000 claims description 2
- 101001091984 Homo sapiens Rho GTPase-activating protein 26 Proteins 0.000 claims description 2
- 101000598783 Homo sapiens SCRIB overlapping open reading frame protein Proteins 0.000 claims description 2
- 101000650667 Homo sapiens SET domain-containing protein 4 Proteins 0.000 claims description 2
- 101000632270 Homo sapiens Semaphorin-3B Proteins 0.000 claims description 2
- 101000783377 Homo sapiens Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform Proteins 0.000 claims description 2
- 101000701334 Homo sapiens Sodium/potassium-transporting ATPase subunit alpha-1 Proteins 0.000 claims description 2
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims description 2
- 101000702112 Homo sapiens Sperm flagellar protein 1 Proteins 0.000 claims description 2
- 101000651288 Homo sapiens Sprouty-related, EVH1 domain-containing protein 3 Proteins 0.000 claims description 2
- 101000825933 Homo sapiens Structural maintenance of chromosomes flexible hinge domain-containing protein 1 Proteins 0.000 claims description 2
- 101000630720 Homo sapiens Supervillin Proteins 0.000 claims description 2
- 101000788541 Homo sapiens TBC1 domain family member 26 Proteins 0.000 claims description 2
- 101000663000 Homo sapiens TNFAIP3-interacting protein 1 Proteins 0.000 claims description 2
- 101000835731 Homo sapiens Transcription elongation factor A protein 2 Proteins 0.000 claims description 2
- 101000596772 Homo sapiens Transcription factor 7-like 1 Proteins 0.000 claims description 2
- 101000666382 Homo sapiens Transcription factor E2-alpha Proteins 0.000 claims description 2
- 101000756787 Homo sapiens Transcription factor RFX3 Proteins 0.000 claims description 2
- 101000648534 Homo sapiens Transmembrane 6 superfamily member 1 Proteins 0.000 claims description 2
- 101000852860 Homo sapiens Transmembrane protein 108 Proteins 0.000 claims description 2
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 claims description 2
- 101000836755 Homo sapiens Type 2 lactosamine alpha-2,3-sialyltransferase Proteins 0.000 claims description 2
- 101000805943 Homo sapiens Usher syndrome type-1G protein Proteins 0.000 claims description 2
- 101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 claims description 2
- 102100027537 Inactive rhomboid protein 2 Human genes 0.000 claims description 2
- 102100025310 Integrin alpha-10 Human genes 0.000 claims description 2
- 102100039903 Integrin alpha-9 Human genes 0.000 claims description 2
- 102100022337 Integrin alpha-V Human genes 0.000 claims description 2
- 102100038251 Interferon regulatory factor 9 Human genes 0.000 claims description 2
- 102100023529 Iroquois-class homeodomain protein IRX-5 Human genes 0.000 claims description 2
- 102100034866 Kallikrein-6 Human genes 0.000 claims description 2
- 102100022101 Kelch-like protein 3 Human genes 0.000 claims description 2
- 102100022249 Krueppel-like factor 17 Human genes 0.000 claims description 2
- 102100020870 La-related protein 6 Human genes 0.000 claims description 2
- 102100034710 Laminin subunit gamma-1 Human genes 0.000 claims description 2
- 101150113681 MALT1 gene Proteins 0.000 claims description 2
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 claims description 2
- 102100033060 Mitogen-activated protein kinase kinase kinase 4 Human genes 0.000 claims description 2
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 claims description 2
- 108700026676 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Proteins 0.000 claims description 2
- 102100038732 Mucosa-associated lymphoid tissue lymphoma translocation protein 1 Human genes 0.000 claims description 2
- 102100035077 Myoblast determination protein 1 Human genes 0.000 claims description 2
- 102100038934 Myosin-7 Human genes 0.000 claims description 2
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 claims description 2
- 102100022437 Myotonin-protein kinase Human genes 0.000 claims description 2
- 102100031377 NADH dehydrogenase (ubiquinone) complex I, assembly factor 6 Human genes 0.000 claims description 2
- 102100034431 Nebulette Human genes 0.000 claims description 2
- 102100025062 Nucleosome-remodeling factor subunit BPTF Human genes 0.000 claims description 2
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 claims description 2
- 102100040140 PCI domain-containing protein 2 Human genes 0.000 claims description 2
- 102100029909 Peptide YY Human genes 0.000 claims description 2
- 108010088847 Peptide YY Proteins 0.000 claims description 2
- 102100039427 Polyadenylate-binding protein 2 Human genes 0.000 claims description 2
- 102100032597 Polycystic kidney disease protein 1-like 2 Human genes 0.000 claims description 2
- 102100033172 Potassium voltage-gated channel subfamily C member 3 Human genes 0.000 claims description 2
- 102100026531 Prelamin-A/C Human genes 0.000 claims description 2
- 102100034747 Probable E3 ubiquitin-protein ligase HERC1 Human genes 0.000 claims description 2
- 102100030557 Protein FAM13A Human genes 0.000 claims description 2
- 102100028387 Protein FRG1 Human genes 0.000 claims description 2
- 102100031717 Protein Hook homolog 3 Human genes 0.000 claims description 2
- 102100028951 Protein MTSS 1 Human genes 0.000 claims description 2
- 102100022429 Protein TMEPAI Human genes 0.000 claims description 2
- 102100021315 Rab11 family-interacting protein 1 Human genes 0.000 claims description 2
- 102100027716 RanBP-type and C3HC4-type zinc finger-containing protein 1 Human genes 0.000 claims description 2
- 102100037404 Receptor-type tyrosine-protein phosphatase N2 Human genes 0.000 claims description 2
- 102100035744 Rho GTPase-activating protein 26 Human genes 0.000 claims description 2
- 102100037779 SCRIB overlapping open reading frame protein Human genes 0.000 claims description 2
- 102100027707 SET domain-containing protein 4 Human genes 0.000 claims description 2
- 108091006924 SLC37A4 Proteins 0.000 claims description 2
- 108091006658 SLC9A8 Proteins 0.000 claims description 2
- 101700032040 SMAD1 Proteins 0.000 claims description 2
- 102100027979 Semaphorin-3B Human genes 0.000 claims description 2
- 102100036141 Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform Human genes 0.000 claims description 2
- 102100029950 Shiftless antiviral inhibitor of ribosomal frameshifting protein Human genes 0.000 claims description 2
- 101710146741 Shiftless antiviral inhibitor of ribosomal frameshifting protein Proteins 0.000 claims description 2
- 101710201844 Shiftless antiviral inhibitor of ribosomal frameshifting protein homolog Proteins 0.000 claims description 2
- 102100029970 Sodium/hydrogen exchanger 8 Human genes 0.000 claims description 2
- 102100030458 Sodium/potassium-transporting ATPase subunit alpha-1 Human genes 0.000 claims description 2
- 102100021796 Sonic hedgehog protein Human genes 0.000 claims description 2
- 101710113849 Sonic hedgehog protein Proteins 0.000 claims description 2
- 102100030294 Sperm flagellar protein 1 Human genes 0.000 claims description 2
- 102100027646 Sprouty-related, EVH1 domain-containing protein 3 Human genes 0.000 claims description 2
- 102100022770 Structural maintenance of chromosomes flexible hinge domain-containing protein 1 Human genes 0.000 claims description 2
- 102100026344 Supervillin Human genes 0.000 claims description 2
- 102100025224 TBC1 domain family member 26 Human genes 0.000 claims description 2
- 102100037667 TNFAIP3-interacting protein 1 Human genes 0.000 claims description 2
- 102100026428 Transcription elongation factor A protein 2 Human genes 0.000 claims description 2
- 102100038313 Transcription factor E2-alpha Human genes 0.000 claims description 2
- 102100022821 Transcription factor RFX3 Human genes 0.000 claims description 2
- 102100028864 Transmembrane 6 superfamily member 1 Human genes 0.000 claims description 2
- 102100036709 Transmembrane protein 108 Human genes 0.000 claims description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 2
- 102100027107 Type 2 lactosamine alpha-2,3-sialyltransferase Human genes 0.000 claims description 2
- 102100037929 Usher syndrome type-1G protein Human genes 0.000 claims description 2
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 102100036377 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Human genes 0.000 claims description 2
- 101150118453 ctbp-1 gene Proteins 0.000 claims description 2
- 201000009338 distal myopathy Diseases 0.000 claims description 2
- 108010004142 galactose-3-O-sulfotransferase 3 Proteins 0.000 claims description 2
- 108010090909 laminin gamma 1 Proteins 0.000 claims description 2
- 108091077076 miR-4661 stem-loop Proteins 0.000 claims description 2
- 108091063295 miR-8078 stem-loop Proteins 0.000 claims description 2
- 241001678559 COVID-19 virus Species 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 101100234553 Arabidopsis thaliana KO gene Proteins 0.000 claims 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims 1
- 102100029721 DnaJ homolog subfamily B member 1 Human genes 0.000 claims 1
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 claims 1
- 101000963131 Homo sapiens Membralin Proteins 0.000 claims 1
- 101001000069 Homo sapiens Protein phosphatase 1 regulatory subunit 12B Proteins 0.000 claims 1
- 102100039605 Membralin Human genes 0.000 claims 1
- 102100038436 Neuronal pentraxin-1 Human genes 0.000 claims 1
- 101710155145 Neuronal pentraxin-1 Proteins 0.000 claims 1
- 101710111966 Non-structural protein NP-1 Proteins 0.000 claims 1
- 101710102575 Pre-neck appendage protein Proteins 0.000 claims 1
- 102100036545 Protein phosphatase 1 regulatory subunit 12B Human genes 0.000 claims 1
- 101150101279 Serbp1 gene Proteins 0.000 claims 1
- 101150050705 ZNF574 gene Proteins 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 58
- 239000000203 mixture Substances 0.000 description 57
- 108091028043 Nucleic acid sequence Proteins 0.000 description 49
- 208000011580 syndromic disease Diseases 0.000 description 38
- 238000009472 formulation Methods 0.000 description 33
- 108060001084 Luciferase Proteins 0.000 description 24
- 239000005089 Luciferase Substances 0.000 description 24
- 241000711549 Hepacivirus C Species 0.000 description 21
- 230000015654 memory Effects 0.000 description 20
- 108091043187 miR-30a stem-loop Proteins 0.000 description 20
- 230000000259 anti-tumor effect Effects 0.000 description 17
- 208000035475 disorder Diseases 0.000 description 17
- 229960000106 biosimilars Drugs 0.000 description 16
- 108020005345 3' Untranslated Regions Proteins 0.000 description 15
- 108091088477 miR-29a stem-loop Proteins 0.000 description 15
- 108091057475 miR-29b-1 stem-loop Proteins 0.000 description 15
- 125000005647 linker group Chemical group 0.000 description 13
- 239000001226 triphosphate Substances 0.000 description 13
- 238000003556 assay Methods 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 230000003833 cell viability Effects 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 108091025088 miR-29b-2 stem-loop Proteins 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 241000725303 Human immunodeficiency virus Species 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 108091043946 miR-29b-4 stem-loop Proteins 0.000 description 10
- 108091080274 miR-29b3 stem-loop Proteins 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 208000023275 Autoimmune disease Diseases 0.000 description 9
- 208000026350 Inborn Genetic disease Diseases 0.000 description 9
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 230000000840 anti-viral effect Effects 0.000 description 9
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 9
- 229960004316 cisplatin Drugs 0.000 description 9
- 208000016361 genetic disease Diseases 0.000 description 9
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 108091029716 miR-29a-1 stem-loop Proteins 0.000 description 9
- 108091092089 miR-29a-2 stem-loop Proteins 0.000 description 9
- 108091066559 miR-29a-3 stem-loop Proteins 0.000 description 9
- 108091029750 miR-30a-1 stem-loop Proteins 0.000 description 9
- 108091030035 miR-30a-2 stem-loop Proteins 0.000 description 9
- 230000001603 reducing effect Effects 0.000 description 9
- 230000037390 scarring Effects 0.000 description 9
- 238000004891 communication Methods 0.000 description 8
- 108091007432 miR-29b Proteins 0.000 description 8
- 238000007747 plating Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 7
- 208000007465 Giant cell arteritis Diseases 0.000 description 7
- 208000009956 adenocarcinoma Diseases 0.000 description 7
- 230000001363 autoimmune Effects 0.000 description 7
- 230000003176 fibrotic effect Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 108091091870 miR-30a-3 stem-loop Proteins 0.000 description 7
- 108091067477 miR-30a-4 stem-loop Proteins 0.000 description 7
- 108091070501 miRNA Proteins 0.000 description 7
- 208000033808 peripheral neuropathy Diseases 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000012800 visualization Methods 0.000 description 7
- GFYLSDSUCHVORB-IOSLPCCCSA-N 1-methyladenosine Chemical compound C1=NC=2C(=N)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O GFYLSDSUCHVORB-IOSLPCCCSA-N 0.000 description 6
- RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 description 6
- 208000035657 Abasia Diseases 0.000 description 6
- 101000653360 Homo sapiens Methylcytosine dioxygenase TET1 Proteins 0.000 description 6
- 102100030819 Methylcytosine dioxygenase TET1 Human genes 0.000 description 6
- 208000001089 Multiple system atrophy Diseases 0.000 description 6
- 102000043276 Oncogene Human genes 0.000 description 6
- 206010033799 Paralysis Diseases 0.000 description 6
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 6
- 208000002980 facial hemiatrophy Diseases 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- RHFUOMFWUGWKKO-UHFFFAOYSA-N s2C Natural products S=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 RHFUOMFWUGWKKO-UHFFFAOYSA-N 0.000 description 6
- 206010043207 temporal arteritis Diseases 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
- 206010061666 Autonomic neuropathy Diseases 0.000 description 5
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 5
- 206010058314 Dysplasia Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 5
- 229930010555 Inosine Natural products 0.000 description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 5
- 208000012902 Nervous system disease Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 229960005305 adenosine Drugs 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 229960003786 inosine Drugs 0.000 description 5
- 230000011987 methylation Effects 0.000 description 5
- 238000007069 methylation reaction Methods 0.000 description 5
- 201000000585 muscular atrophy Diseases 0.000 description 5
- 201000001119 neuropathy Diseases 0.000 description 5
- 230000007823 neuropathy Effects 0.000 description 5
- 231100000590 oncogenic Toxicity 0.000 description 5
- 230000002246 oncogenic effect Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 208000021090 palsy Diseases 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 229940096913 pseudoisocytidine Drugs 0.000 description 5
- 208000002320 spinal muscular atrophy Diseases 0.000 description 5
- 206010041823 squamous cell carcinoma Diseases 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- UTAIYTHAJQNQDW-KQYNXXCUSA-N 1-methylguanosine Chemical compound C1=NC=2C(=O)N(C)C(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UTAIYTHAJQNQDW-KQYNXXCUSA-N 0.000 description 4
- MPDKOGQMQLSNOF-GBNDHIKLSA-N 2-amino-5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrimidin-6-one Chemical compound O=C1NC(N)=NC=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 MPDKOGQMQLSNOF-GBNDHIKLSA-N 0.000 description 4
- QXDXBKZJFLRLCM-UAKXSSHOSA-N 5-hydroxyuridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(O)=C1 QXDXBKZJFLRLCM-UAKXSSHOSA-N 0.000 description 4
- 108091032955 Bacterial small RNA Proteins 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
- 208000014644 Brain disease Diseases 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- 201000003883 Cystic fibrosis Diseases 0.000 description 4
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 4
- 208000024412 Friedreich ataxia Diseases 0.000 description 4
- 208000015872 Gaucher disease Diseases 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 description 4
- 101001065541 Homo sapiens Protein LYRIC Proteins 0.000 description 4
- 208000016604 Lyme disease Diseases 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 description 4
- 208000016285 Movement disease Diseases 0.000 description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 4
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 4
- VQAYFKKCNSOZKM-UHFFFAOYSA-N NSC 29409 Natural products C1=NC=2C(NC)=NC=NC=2N1C1OC(CO)C(O)C1O VQAYFKKCNSOZKM-UHFFFAOYSA-N 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- 241000097929 Porphyria Species 0.000 description 4
- 208000010642 Porphyrias Diseases 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 102100032133 Protein LYRIC Human genes 0.000 description 4
- 201000000582 Retinoblastoma Diseases 0.000 description 4
- 206010042953 Systemic sclerosis Diseases 0.000 description 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 4
- 208000024799 Thyroid disease Diseases 0.000 description 4
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 4
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 4
- 206010047115 Vasculitis Diseases 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000029918 bioluminescence Effects 0.000 description 4
- 238000005415 bioluminescence Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 229960005395 cetuximab Drugs 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 206010014599 encephalitis Diseases 0.000 description 4
- 230000004049 epigenetic modification Effects 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 230000030279 gene silencing Effects 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000003463 hyperproliferative effect Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000001428 peripheral nervous system Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 229940045145 uridine Drugs 0.000 description 4
- RKSLVDIXBGWPIS-UAKXSSHOSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 RKSLVDIXBGWPIS-UAKXSSHOSA-N 0.000 description 3
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 3
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 3
- OTDJAMXESTUWLO-UUOKFMHZSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]-3H-purine-6-thione Chemical compound C12=NC(N)=NC(S)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OTDJAMXESTUWLO-UUOKFMHZSA-N 0.000 description 3
- RDPUKVRQKWBSPK-UHFFFAOYSA-N 3-Methylcytidine Natural products O=C1N(C)C(=N)C=CN1C1C(O)C(O)C(CO)O1 RDPUKVRQKWBSPK-UHFFFAOYSA-N 0.000 description 3
- RDPUKVRQKWBSPK-ZOQUXTDFSA-N 3-methylcytidine Chemical compound O=C1N(C)C(=N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RDPUKVRQKWBSPK-ZOQUXTDFSA-N 0.000 description 3
- ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 description 3
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 3
- USVMJSALORZVDV-UHFFFAOYSA-N 6-(gamma,gamma-dimethylallylamino)purine riboside Natural products C1=NC=2C(NCC=C(C)C)=NC=NC=2N1C1OC(CO)C(O)C1O USVMJSALORZVDV-UHFFFAOYSA-N 0.000 description 3
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 3
- RYYIULNRIVUMTQ-UHFFFAOYSA-N 6-chloroguanine Chemical compound NC1=NC(Cl)=C2N=CNC2=N1 RYYIULNRIVUMTQ-UHFFFAOYSA-N 0.000 description 3
- OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 3
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 3
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 3
- 101100014154 Arabidopsis thaliana RACK1A gene Proteins 0.000 description 3
- 206010003591 Ataxia Diseases 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 3
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 206010008748 Chorea Diseases 0.000 description 3
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 3
- 208000015943 Coeliac disease Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 208000032274 Encephalopathy Diseases 0.000 description 3
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 3
- 208000007514 Herpes zoster Diseases 0.000 description 3
- 101000688606 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 Proteins 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 208000028226 Krabbe disease Diseases 0.000 description 3
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 3
- 208000012583 Menkes disease Diseases 0.000 description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 3
- 108020005196 Mitochondrial DNA Proteins 0.000 description 3
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 201000002481 Myositis Diseases 0.000 description 3
- RSPURTUNRHNVGF-IOSLPCCCSA-N N(2),N(2)-dimethylguanosine Chemical compound C1=NC=2C(=O)NC(N(C)C)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RSPURTUNRHNVGF-IOSLPCCCSA-N 0.000 description 3
- SLEHROROQDYRAW-KQYNXXCUSA-N N(2)-methylguanosine Chemical compound C1=NC=2C(=O)NC(NC)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O SLEHROROQDYRAW-KQYNXXCUSA-N 0.000 description 3
- USVMJSALORZVDV-SDBHATRESA-N N(6)-(Delta(2)-isopentenyl)adenosine Chemical compound C1=NC=2C(NCC=C(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O USVMJSALORZVDV-SDBHATRESA-N 0.000 description 3
- 208000003019 Neurofibromatosis 1 Diseases 0.000 description 3
- 208000014060 Niemann-Pick disease Diseases 0.000 description 3
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 3
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 3
- 102100024242 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 Human genes 0.000 description 3
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 208000024777 Prion disease Diseases 0.000 description 3
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 3
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 3
- 208000005587 Refsum Disease Diseases 0.000 description 3
- 208000006289 Rett Syndrome Diseases 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000022292 Tay-Sachs disease Diseases 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 201000003639 autosomal recessive cerebellar ataxia Diseases 0.000 description 3
- 229960002756 azacitidine Drugs 0.000 description 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 3
- 239000013060 biological fluid Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 208000002458 carcinoid tumor Diseases 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 3
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 201000001981 dermatomyositis Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940029575 guanosine Drugs 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 239000005414 inactive ingredient Substances 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000007914 intraventricular administration Methods 0.000 description 3
- 201000003723 learning disability Diseases 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 108091029162 miR-29 stem-loop Proteins 0.000 description 3
- 208000005264 motor neuron disease Diseases 0.000 description 3
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 208000008795 neuromyelitis optica Diseases 0.000 description 3
- 230000002981 neuropathic effect Effects 0.000 description 3
- 201000006958 oropharynx cancer Diseases 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 208000007056 sickle cell anemia Diseases 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 206010044412 transitional cell carcinoma Diseases 0.000 description 3
- HDZZVAMISRMYHH-KCGFPETGSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HDZZVAMISRMYHH-KCGFPETGSA-N 0.000 description 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- BIXYYZIIJIXVFW-UUOKFMHZSA-N (2R,3R,4S,5R)-2-(6-amino-2-chloro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O BIXYYZIIJIXVFW-UUOKFMHZSA-N 0.000 description 2
- JLWUWXCKSOIFPS-KQYNXXCUSA-N (2r,3r,4r,5r)-5-(2,6-diaminopurin-9-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-ol Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(N)=NC(N)=C2N=C1 JLWUWXCKSOIFPS-KQYNXXCUSA-N 0.000 description 2
- ZGYYPTJWJBEXBC-QYYRPYCUSA-N (2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1F ZGYYPTJWJBEXBC-QYYRPYCUSA-N 0.000 description 2
- JVOJULURLCZUDE-JXOAFFINSA-N (2r,3r,4s,5r)-2-(2-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C12=NC(N)=NC=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JVOJULURLCZUDE-JXOAFFINSA-N 0.000 description 2
- XHRJGHCQQPETRH-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(Cl)=C2N=C1 XHRJGHCQQPETRH-KQYNXXCUSA-N 0.000 description 2
- CQKMBZHLOYVGHW-QYYRPYCUSA-N (2r,3s,4r,5r)-4-amino-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol Chemical compound N[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CQKMBZHLOYVGHW-QYYRPYCUSA-N 0.000 description 2
- IFVJLCHSLGMHEY-QYYRPYCUSA-N (2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-azido-2-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1N=[N+]=[N-] IFVJLCHSLGMHEY-QYYRPYCUSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- UIYWFOZZIZEEKJ-XVFCMESISA-N 1-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound F[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 UIYWFOZZIZEEKJ-XVFCMESISA-N 0.000 description 2
- LLIPTMWIZVIUSX-XVFCMESISA-N 1-[(2r,3r,4s,5r)-3-amino-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound N[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 LLIPTMWIZVIUSX-XVFCMESISA-N 0.000 description 2
- MRUKYOQQKHNMFI-XVFCMESISA-N 1-[(2r,3r,4s,5r)-3-azido-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound [N-]=[N+]=N[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MRUKYOQQKHNMFI-XVFCMESISA-N 0.000 description 2
- GBBJCSTXCAQSSJ-JVZYCSMKSA-N 1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@@H](F)[C@H](O)[C@@H](CO)O1 GBBJCSTXCAQSSJ-JVZYCSMKSA-N 0.000 description 2
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 description 2
- CQKMBZHLOYVGHW-UHFFFAOYSA-N 10407-64-4 Natural products NC1C(O)C(CO)OC1N1C2=NC=NC(N)=C2N=C1 CQKMBZHLOYVGHW-UHFFFAOYSA-N 0.000 description 2
- YHRRPHCORALGKQ-FDDDBJFASA-N 2'-O-methyl-5-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C)=C1 YHRRPHCORALGKQ-FDDDBJFASA-N 0.000 description 2
- HPHXOIULGYVAKW-IOSLPCCCSA-N 2'-O-methylinosine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HPHXOIULGYVAKW-IOSLPCCCSA-N 0.000 description 2
- HPHXOIULGYVAKW-UHFFFAOYSA-N 2'-O-methylinosine Natural products COC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 HPHXOIULGYVAKW-UHFFFAOYSA-N 0.000 description 2
- WGNUTGFETAXDTJ-OOJXKGFFSA-N 2'-O-methylpseudouridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O WGNUTGFETAXDTJ-OOJXKGFFSA-N 0.000 description 2
- ROPTVRLUGSPXNH-UHFFFAOYSA-N 2'-amino-2'-deoxy-guanosine Natural products NC1C(O)C(CO)OC1N1C(NC(N)=NC2=O)=C2N=C1 ROPTVRLUGSPXNH-UHFFFAOYSA-N 0.000 description 2
- IQZWKGWOBPJWMX-UHFFFAOYSA-N 2-Methyladenosine Natural products C12=NC(C)=NC(N)=C2N=CN1C1OC(CO)C(O)C1O IQZWKGWOBPJWMX-UHFFFAOYSA-N 0.000 description 2
- YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
- SVBOROZXXYRWJL-UHFFFAOYSA-N 2-[(4-oxo-2-sulfanylidene-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=S)NC1=O SVBOROZXXYRWJL-UHFFFAOYSA-N 0.000 description 2
- PFCLMNDDPTZJHQ-XLPZGREQSA-N 2-amino-7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PFCLMNDDPTZJHQ-XLPZGREQSA-N 0.000 description 2
- UXUZARPLRQRNNX-DXTOWSMRSA-N 2-amino-9-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1F UXUZARPLRQRNNX-DXTOWSMRSA-N 0.000 description 2
- KZELNMSPWPFAEB-UMMCILCDSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-8-sulfanylidene-3,7-dihydropurin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2NC(=S)N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O KZELNMSPWPFAEB-UMMCILCDSA-N 0.000 description 2
- ROPTVRLUGSPXNH-DXTOWSMRSA-N 2-amino-9-[(2r,3r,4s,5r)-3-amino-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound N[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC(N)=NC2=O)=C2N=C1 ROPTVRLUGSPXNH-DXTOWSMRSA-N 0.000 description 2
- PHGQZPFEHQOLJM-DXTOWSMRSA-N 2-amino-9-[(2r,3r,4s,5r)-3-azido-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1N=[N+]=[N-] PHGQZPFEHQOLJM-DXTOWSMRSA-N 0.000 description 2
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 2
- IQZWKGWOBPJWMX-IOSLPCCCSA-N 2-methyladenosine Chemical compound C12=NC(C)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O IQZWKGWOBPJWMX-IOSLPCCCSA-N 0.000 description 2
- BCZUPRDAAVVBSO-MJXNYTJMSA-N 4-acetylcytidine Chemical compound C1=CC(C(=O)C)(N)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 BCZUPRDAAVVBSO-MJXNYTJMSA-N 0.000 description 2
- NVZFZMCNALTPBY-XVFCMESISA-N 4-amino-1-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](F)[C@H](O)[C@@H](CO)O1 NVZFZMCNALTPBY-XVFCMESISA-N 0.000 description 2
- FECRKKQKJNKYNF-XVFCMESISA-N 4-amino-1-[(2r,3r,4s,5r)-3-amino-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound N[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 FECRKKQKJNKYNF-XVFCMESISA-N 0.000 description 2
- UVGCZRPOXXYZKH-QADQDURISA-N 5-(carboxyhydroxymethyl)uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(O)C(O)=O)=C1 UVGCZRPOXXYZKH-QADQDURISA-N 0.000 description 2
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 2
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 2
- YIZYCHKPHCPKHZ-PNHWDRBUSA-N 5-methoxycarbonylmethyluridine Chemical compound O=C1NC(=O)C(CC(=O)OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 YIZYCHKPHCPKHZ-PNHWDRBUSA-N 0.000 description 2
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 description 2
- SNNBPMAXGYBMHM-JXOAFFINSA-N 5-methyl-2-thiouridine Chemical compound S=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SNNBPMAXGYBMHM-JXOAFFINSA-N 0.000 description 2
- ZDRFDHHANOYUTE-IOSLPCCCSA-N 6-methylthioinosine Chemical compound C1=NC=2C(SC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDRFDHHANOYUTE-IOSLPCCCSA-N 0.000 description 2
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 2
- HCGHYQLFMPXSDU-UHFFFAOYSA-N 7-methyladenine Chemical compound C1=NC(N)=C2N(C)C=NC2=N1 HCGHYQLFMPXSDU-UHFFFAOYSA-N 0.000 description 2
- SYPRQIWERSQQNL-KQYNXXCUSA-O 7-methylxanthosine Chemical compound C1=2NC(=O)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O SYPRQIWERSQQNL-KQYNXXCUSA-O 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- OAUKGFJQZRGECT-UUOKFMHZSA-N 8-Azaadenosine Chemical compound N1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OAUKGFJQZRGECT-UUOKFMHZSA-N 0.000 description 2
- VJUPMOPLUQHMLE-UUOKFMHZSA-N 8-Bromoadenosine Chemical compound BrC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VJUPMOPLUQHMLE-UUOKFMHZSA-N 0.000 description 2
- ASUCSHXLTWZYBA-UMMCILCDSA-N 8-Bromoguanosine Chemical compound C1=2NC(N)=NC(=O)C=2N=C(Br)N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ASUCSHXLTWZYBA-UMMCILCDSA-N 0.000 description 2
- 239000013607 AAV vector Substances 0.000 description 2
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 201000010028 Acrocephalosyndactylia Diseases 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 2
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 description 2
- 208000024341 Aicardi syndrome Diseases 0.000 description 2
- 208000011403 Alexander disease Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000009575 Angelman syndrome Diseases 0.000 description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
- 206010002941 Apallic syndrome Diseases 0.000 description 2
- 241001421757 Arcas Species 0.000 description 2
- 206010003101 Arnold-Chiari Malformation Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 108010078286 Ataxins Proteins 0.000 description 2
- 102000014461 Ataxins Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010003805 Autism Diseases 0.000 description 2
- 208000020706 Autistic disease Diseases 0.000 description 2
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 208000006373 Bell palsy Diseases 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 2
- 208000022526 Canavan disease Diseases 0.000 description 2
- 241000218236 Cannabis Species 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 101710197658 Capsid protein VP1 Proteins 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 208000005024 Castleman disease Diseases 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 2
- 201000006867 Charcot-Marie-Tooth disease type 4 Diseases 0.000 description 2
- 208000015321 Chiari malformation Diseases 0.000 description 2
- 206010008723 Chondrodystrophy Diseases 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 208000001353 Coffin-Lowry syndrome Diseases 0.000 description 2
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- 208000012514 Cumulative Trauma disease Diseases 0.000 description 2
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 208000021866 Dressler syndrome Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000024720 Fabry Disease Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 208000021309 Germ cell tumor Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 2
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 2
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 description 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- 206010021750 Infantile Spasms Diseases 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 201000008645 Joubert syndrome Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 208000027747 Kennedy disease Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- UBORTCNDUKBEOP-UHFFFAOYSA-N L-xanthosine Natural products OC1C(O)C(CO)OC1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UHFFFAOYSA-N 0.000 description 2
- 201000005802 Landau-Kleffner Syndrome Diseases 0.000 description 2
- 206010023825 Laryngeal cancer Diseases 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 description 2
- 208000012309 Linear IgA disease Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 201000005027 Lynch syndrome Diseases 0.000 description 2
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 2
- 208000001826 Marfan syndrome Diseases 0.000 description 2
- 208000021964 McLeod neuroacanthocytosis syndrome Diseases 0.000 description 2
- 208000026486 McLeod syndrome Diseases 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 2
- 208000027530 Meniere disease Diseases 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- 208000026072 Motor neurone disease Diseases 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 208000003452 Multiple Hereditary Exostoses Diseases 0.000 description 2
- 208000002740 Muscle Rigidity Diseases 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 206010028424 Myasthenic syndrome Diseases 0.000 description 2
- 208000003926 Myelitis Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 208000002033 Myoclonus Diseases 0.000 description 2
- 208000010316 Myotonia congenita Diseases 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- 208000009905 Neurofibromatoses Diseases 0.000 description 2
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 description 2
- 208000035544 Nonketotic hyperglycinaemia Diseases 0.000 description 2
- 208000003435 Optic Neuritis Diseases 0.000 description 2
- 206010031127 Orthostatic hypotension Diseases 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
- 201000009928 Patau syndrome Diseases 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 201000011152 Pemphigus Diseases 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 201000011252 Phenylketonuria Diseases 0.000 description 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- 206010036182 Porphyria acute Diseases 0.000 description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- 208000007932 Progeria Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 108091005685 RIG-I-like receptors Proteins 0.000 description 2
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 206010071141 Rasmussen encephalitis Diseases 0.000 description 2
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 2
- 208000021811 Sandhoff disease Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
- 208000027077 Stickler syndrome Diseases 0.000 description 2
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 206010042276 Subacute endocarditis Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
- 208000000728 Thymus Neoplasms Diseases 0.000 description 2
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 206010044686 Trisomy 13 Diseases 0.000 description 2
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 description 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 2
- 208000026928 Turner syndrome Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 2
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 101710108545 Viral protein 1 Proteins 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 201000006791 West syndrome Diseases 0.000 description 2
- 208000018839 Wilson disease Diseases 0.000 description 2
- 210000001766 X chromosome Anatomy 0.000 description 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 2
- 108700029631 X-Linked Genes Proteins 0.000 description 2
- UBORTCNDUKBEOP-HAVMAKPUSA-N Xanthosine Natural products O[C@@H]1[C@H](O)[C@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-HAVMAKPUSA-N 0.000 description 2
- 208000008919 achondroplasia Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000002431 aminoalkoxy group Chemical group 0.000 description 2
- 201000008279 amyotrophic lateral sclerosis type 4 Diseases 0.000 description 2
- 208000000252 angiomatosis Diseases 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 2
- 208000021024 autosomal recessive inheritance Diseases 0.000 description 2
- 210000002457 barrier cell Anatomy 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000012601 choreatic disease Diseases 0.000 description 2
- 208000016532 chronic granulomatous disease Diseases 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013500 data storage Methods 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 201000011205 glycine encephalopathy Diseases 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 201000010928 hereditary multiple exostoses Diseases 0.000 description 2
- 208000003074 hypochondrogenesis Diseases 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 201000008319 inclusion body myositis Diseases 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 208000019715 inherited Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 208000036546 leukodystrophy Diseases 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 208000006178 malignant mesothelioma Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 239000002082 metal nanoparticle Substances 0.000 description 2
- 208000005135 methemoglobinemia Diseases 0.000 description 2
- IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 108091047189 miR-29c stem-loop Proteins 0.000 description 2
- 208000004141 microcephaly Diseases 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 208000028260 mitochondrial inheritance Diseases 0.000 description 2
- 230000023202 mitochondrion inheritance Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000002643 mouth floor Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- LALUHJOWIKDRQY-XKLVTHTNSA-N n-(6-aminohexyl)-2-[[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]amino]acetamide Chemical compound C1=NC=2C(NCC(=O)NCCCCCCN)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O LALUHJOWIKDRQY-XKLVTHTNSA-N 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 201000003631 narcolepsy Diseases 0.000 description 2
- 208000007538 neurilemmoma Diseases 0.000 description 2
- 201000004931 neurofibromatosis Diseases 0.000 description 2
- 208000002761 neurofibromatosis 2 Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 201000006790 nonsyndromic deafness Diseases 0.000 description 2
- RUUFMHUAHUPZSS-UHFFFAOYSA-N oxido-oxo-sulfinophosphanium Chemical compound P(=O)(=O)S(=O)O RUUFMHUAHUPZSS-UHFFFAOYSA-N 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 210000000277 pancreatic duct Anatomy 0.000 description 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 208000005026 persistent vegetative state Diseases 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 150000008298 phosphoramidates Chemical class 0.000 description 2
- 125000005642 phosphothioate group Chemical group 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 208000010916 pituitary tumor Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000007824 polyneuropathy Effects 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 2
- 206010039667 schwannoma Diseases 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 208000008467 subacute bacterial endocarditis Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 2
- 208000009174 transverse myelitis Diseases 0.000 description 2
- 208000006961 tropical spastic paraparesis Diseases 0.000 description 2
- 208000009999 tuberous sclerosis Diseases 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- YIZYCHKPHCPKHZ-UHFFFAOYSA-N uridine-5-acetic acid methyl ester Natural products COC(=O)Cc1cn(C2OC(CO)C(O)C2O)c(=O)[nH]c1=O YIZYCHKPHCPKHZ-UHFFFAOYSA-N 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- UBORTCNDUKBEOP-UUOKFMHZSA-N xanthosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UUOKFMHZSA-N 0.000 description 2
- YZSZLBRBVWAXFW-LNYQSQCFSA-N (2R,3R,4S,5R)-2-(2-amino-6-hydroxy-6-methoxy-3H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC1(O)NC(N)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YZSZLBRBVWAXFW-LNYQSQCFSA-N 0.000 description 1
- IRBSRWVXPGHGGK-LNYQSQCFSA-N (2R,3R,4S,5R)-2-(2-amino-6-hydroxy-6-methyl-3H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound CC1(O)NC(N)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O IRBSRWVXPGHGGK-LNYQSQCFSA-N 0.000 description 1
- TXWHPSZYRUHEGT-UUOKFMHZSA-N (2r,3r,4s,5r)-2-(2-amino-6-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C12=NC(N)=NC(Cl)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O TXWHPSZYRUHEGT-UUOKFMHZSA-N 0.000 description 1
- KYJLJOJCMUFWDY-UUOKFMHZSA-N (2r,3r,4s,5r)-2-(6-amino-8-azidopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound [N-]=[N+]=NC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O KYJLJOJCMUFWDY-UUOKFMHZSA-N 0.000 description 1
- MYUOTPIQBPUQQU-CKTDUXNWSA-N (2s,3r)-2-amino-n-[[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-methylsulfanylpurin-6-yl]carbamoyl]-3-hydroxybutanamide Chemical compound C12=NC(SC)=NC(NC(=O)NC(=O)[C@@H](N)[C@@H](C)O)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O MYUOTPIQBPUQQU-CKTDUXNWSA-N 0.000 description 1
- DJAHKBBSJCDSOZ-AJLBTXRUSA-N (5z,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one;(5e,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C/CCC(C)=O.CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O DJAHKBBSJCDSOZ-AJLBTXRUSA-N 0.000 description 1
- MPCAJMNYNOGXPB-UHFFFAOYSA-N 1,5-anhydrohexitol Chemical class OCC1OCC(O)C(O)C1O MPCAJMNYNOGXPB-UHFFFAOYSA-N 0.000 description 1
- OYTVCAGSWWRUII-DWJKKKFUSA-N 1-Methyl-1-deazapseudouridine Chemical compound CC1C=C(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O OYTVCAGSWWRUII-DWJKKKFUSA-N 0.000 description 1
- MIXBUOXRHTZHKR-XUTVFYLZSA-N 1-Methylpseudoisocytidine Chemical compound CN1C=C(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O MIXBUOXRHTZHKR-XUTVFYLZSA-N 0.000 description 1
- KYEKLQMDNZPEFU-KVTDHHQDSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)N=C1 KYEKLQMDNZPEFU-KVTDHHQDSA-N 0.000 description 1
- UTQUILVPBZEHTK-ZOQUXTDFSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3-methylpyrimidine-2,4-dione Chemical compound O=C1N(C)C(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UTQUILVPBZEHTK-ZOQUXTDFSA-N 0.000 description 1
- QLOCVMVCRJOTTM-TURQNECASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 QLOCVMVCRJOTTM-TURQNECASA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- GUNOEKASBVILNS-UHFFFAOYSA-N 1-methyl-1-deaza-pseudoisocytidine Chemical compound CC(C=C1C(C2O)OC(CO)C2O)=C(N)NC1=O GUNOEKASBVILNS-UHFFFAOYSA-N 0.000 description 1
- UVBYMVOUBXYSFV-UHFFFAOYSA-N 1-methylpseudouridine Natural products O=C1NC(=O)N(C)C=C1C1C(O)C(O)C(CO)O1 UVBYMVOUBXYSFV-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000026120 1p36 deletion syndrome Diseases 0.000 description 1
- JCNGYIGHEUKAHK-DWJKKKFUSA-N 2-Thio-1-methyl-1-deazapseudouridine Chemical compound CC1C=C(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O JCNGYIGHEUKAHK-DWJKKKFUSA-N 0.000 description 1
- BVLGKOVALHRKNM-XUTVFYLZSA-N 2-Thio-1-methylpseudouridine Chemical compound CN1C=C(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O BVLGKOVALHRKNM-XUTVFYLZSA-N 0.000 description 1
- CWXIOHYALLRNSZ-JWMKEVCDSA-N 2-Thiodihydropseudouridine Chemical compound C1C(C(=O)NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O CWXIOHYALLRNSZ-JWMKEVCDSA-N 0.000 description 1
- NUBJGTNGKODGGX-YYNOVJQHSA-N 2-[5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-1-yl]acetic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CN(CC(O)=O)C(=O)NC1=O NUBJGTNGKODGGX-YYNOVJQHSA-N 0.000 description 1
- VJKJOPUEUOTEBX-TURQNECASA-N 2-[[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-5-yl]methylamino]ethanesulfonic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CNCCS(O)(=O)=O)=C1 VJKJOPUEUOTEBX-TURQNECASA-N 0.000 description 1
- LCKIHCRZXREOJU-KYXWUPHJSA-N 2-[[5-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-1-yl]methylamino]ethanesulfonic acid Chemical compound C(NCCS(=O)(=O)O)N1C=C([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C(NC1=O)=O LCKIHCRZXREOJU-KYXWUPHJSA-N 0.000 description 1
- IBKZHHCJWDWGAJ-FJGDRVTGSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1-methylpurine-6-thione Chemical compound C1=NC=2C(=S)N(C)C(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O IBKZHHCJWDWGAJ-FJGDRVTGSA-N 0.000 description 1
- HPKQEMIXSLRGJU-UUOKFMHZSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-methyl-3h-purine-6,8-dione Chemical compound O=C1N(C)C(C(NC(N)=N2)=O)=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HPKQEMIXSLRGJU-UUOKFMHZSA-N 0.000 description 1
- BGTXMQUSDNMLDW-AEHJODJJSA-N 2-amino-9-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@]1(O)F BGTXMQUSDNMLDW-AEHJODJJSA-N 0.000 description 1
- PBFLIOAJBULBHI-JJNLEZRASA-N 2-amino-n-[[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]carbamoyl]acetamide Chemical compound C1=NC=2C(NC(=O)NC(=O)CN)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O PBFLIOAJBULBHI-JJNLEZRASA-N 0.000 description 1
- RLZMYTZDQAVNIN-ZOQUXTDFSA-N 2-methoxy-4-thio-uridine Chemical compound COC1=NC(=S)C=CN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O RLZMYTZDQAVNIN-ZOQUXTDFSA-N 0.000 description 1
- QCPQCJVQJKOKMS-VLSMUFELSA-N 2-methoxy-5-methyl-cytidine Chemical compound CC(C(N)=N1)=CN([C@@H]([C@@H]2O)O[C@H](CO)[C@H]2O)C1OC QCPQCJVQJKOKMS-VLSMUFELSA-N 0.000 description 1
- TUDKBZAMOFJOSO-UHFFFAOYSA-N 2-methoxy-7h-purin-6-amine Chemical compound COC1=NC(N)=C2NC=NC2=N1 TUDKBZAMOFJOSO-UHFFFAOYSA-N 0.000 description 1
- STISOQJGVFEOFJ-MEVVYUPBSA-N 2-methoxy-cytidine Chemical compound COC(N([C@@H]([C@@H]1O)O[C@H](CO)[C@H]1O)C=C1)N=C1N STISOQJGVFEOFJ-MEVVYUPBSA-N 0.000 description 1
- WBVPJIKOWUQTSD-ZOQUXTDFSA-N 2-methoxyuridine Chemical compound COC1=NC(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 WBVPJIKOWUQTSD-ZOQUXTDFSA-N 0.000 description 1
- FXGXEFXCWDTSQK-UHFFFAOYSA-N 2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(N)=C2NC=NC2=N1 FXGXEFXCWDTSQK-UHFFFAOYSA-N 0.000 description 1
- QEWSGVMSLPHELX-UHFFFAOYSA-N 2-methylthio-N6-(cis-hydroxyisopentenyl) adenosine Chemical compound C12=NC(SC)=NC(NCC=C(C)CO)=C2N=CN1C1OC(CO)C(O)C1O QEWSGVMSLPHELX-UHFFFAOYSA-N 0.000 description 1
- JUMHLCXWYQVTLL-KVTDHHQDSA-N 2-thio-5-aza-uridine Chemical compound [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C(=S)NC(=O)N=C1 JUMHLCXWYQVTLL-KVTDHHQDSA-N 0.000 description 1
- VRVXMIJPUBNPGH-XVFCMESISA-N 2-thio-dihydrouridine Chemical compound OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(=O)NC1=S VRVXMIJPUBNPGH-XVFCMESISA-N 0.000 description 1
- ZVGONGHIVBJXFC-WCTZXXKLSA-N 2-thio-zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)N=CC=C1 ZVGONGHIVBJXFC-WCTZXXKLSA-N 0.000 description 1
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 description 1
- 206010000021 21-hydroxylase deficiency Diseases 0.000 description 1
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
- UTQUILVPBZEHTK-UHFFFAOYSA-N 3-Methyluridine Natural products O=C1N(C)C(=O)C=CN1C1C(O)C(O)C(CO)O1 UTQUILVPBZEHTK-UHFFFAOYSA-N 0.000 description 1
- FGFVODMBKZRMMW-XUTVFYLZSA-N 4-Methoxy-2-thiopseudouridine Chemical compound COC1=C(C=NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O FGFVODMBKZRMMW-XUTVFYLZSA-N 0.000 description 1
- HOCJTJWYMOSXMU-XUTVFYLZSA-N 4-Methoxypseudouridine Chemical compound COC1=C(C=NC(=O)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O HOCJTJWYMOSXMU-XUTVFYLZSA-N 0.000 description 1
- VTGBLFNEDHVUQA-XUTVFYLZSA-N 4-Thio-1-methyl-pseudouridine Chemical compound S=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 VTGBLFNEDHVUQA-XUTVFYLZSA-N 0.000 description 1
- DMUQOPXCCOBPID-XUTVFYLZSA-N 4-Thio-1-methylpseudoisocytidine Chemical compound CN1C=C(C(=S)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O DMUQOPXCCOBPID-XUTVFYLZSA-N 0.000 description 1
- OCMSXKMNYAHJMU-JXOAFFINSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidine-5-carbaldehyde Chemical compound C1=C(C=O)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 OCMSXKMNYAHJMU-JXOAFFINSA-N 0.000 description 1
- OZHIJZYBTCTDQC-JXOAFFINSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2-thione Chemical compound S=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 OZHIJZYBTCTDQC-JXOAFFINSA-N 0.000 description 1
- FEOYKPQEERVCAV-XVFCMESISA-N 4-amino-1-[(2r,3r,4s,5r)-3-azido-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](N=[N+]=[N-])[C@H](O)[C@@H](CO)O1 FEOYKPQEERVCAV-XVFCMESISA-N 0.000 description 1
- LZINOQJQXIEBNN-UHFFFAOYSA-N 4-hydroxybutyl dihydrogen phosphate Chemical compound OCCCCOP(O)(O)=O LZINOQJQXIEBNN-UHFFFAOYSA-N 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- LOICBOXHPCURMU-UHFFFAOYSA-N 4-methoxy-pseudoisocytidine Chemical compound COC1NC(N)=NC=C1C(C1O)OC(CO)C1O LOICBOXHPCURMU-UHFFFAOYSA-N 0.000 description 1
- FIWQPTRUVGSKOD-UHFFFAOYSA-N 4-thio-1-methyl-1-deaza-pseudoisocytidine Chemical compound CC(C=C1C(C2O)OC(CO)C2O)=C(N)NC1=S FIWQPTRUVGSKOD-UHFFFAOYSA-N 0.000 description 1
- SJVVKUMXGIKAAI-UHFFFAOYSA-N 4-thio-pseudoisocytidine Chemical compound NC(N1)=NC=C(C(C2O)OC(CO)C2O)C1=S SJVVKUMXGIKAAI-UHFFFAOYSA-N 0.000 description 1
- FAWQJBLSWXIJLA-VPCXQMTMSA-N 5-(carboxymethyl)uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CC(O)=O)=C1 FAWQJBLSWXIJLA-VPCXQMTMSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- NFEXJLMYXXIWPI-JXOAFFINSA-N 5-Hydroxymethylcytidine Chemical compound C1=C(CO)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NFEXJLMYXXIWPI-JXOAFFINSA-N 0.000 description 1
- ITGWEVGJUSMCEA-KYXWUPHJSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)N(C#CC)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ITGWEVGJUSMCEA-KYXWUPHJSA-N 0.000 description 1
- DDHOXEOVAJVODV-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=S)NC1=O DDHOXEOVAJVODV-GBNDHIKLSA-N 0.000 description 1
- BNAWMJKJLNJZFU-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-sulfanylidene-1h-pyrimidin-2-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=S BNAWMJKJLNJZFU-GBNDHIKLSA-N 0.000 description 1
- OZQDLJNDRVBCST-SHUUEZRQSA-N 5-amino-2-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazin-3-one Chemical compound O=C1N=C(N)C=NN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 OZQDLJNDRVBCST-SHUUEZRQSA-N 0.000 description 1
- XUNBIDXYAUXNKD-DBRKOABJSA-N 5-aza-2-thio-zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)N=CN=C1 XUNBIDXYAUXNKD-DBRKOABJSA-N 0.000 description 1
- OSLBPVOJTCDNEF-DBRKOABJSA-N 5-aza-zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=CN=C1 OSLBPVOJTCDNEF-DBRKOABJSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- IWFHOSULCAJGRM-UAKXSSHOSA-N 5-bromouridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=O)NC(=O)C(Br)=C1 IWFHOSULCAJGRM-UAKXSSHOSA-N 0.000 description 1
- OOMLBPVHGFQCCL-RRKCRQDMSA-N 5-iododeoxycytidine triphosphate Chemical compound C1=C(I)C(N)=NC(=O)N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 OOMLBPVHGFQCCL-RRKCRQDMSA-N 0.000 description 1
- RPQQZHJQUBDHHG-FNCVBFRFSA-N 5-methyl-zebularine Chemical compound C1=C(C)C=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RPQQZHJQUBDHHG-FNCVBFRFSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 1
- OZTOEARQSSIFOG-MWKIOEHESA-N 6-Thio-7-deaza-8-azaguanosine Chemical compound Nc1nc(=S)c2cnn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1 OZTOEARQSSIFOG-MWKIOEHESA-N 0.000 description 1
- XYVLZAYJHCECPN-UHFFFAOYSA-L 6-aminohexyl phosphate Chemical compound NCCCCCCOP([O-])([O-])=O XYVLZAYJHCECPN-UHFFFAOYSA-L 0.000 description 1
- CBNRZZNSRJQZNT-IOSLPCCCSA-O 6-thio-7-deaza-guanosine Chemical compound CC1=C[NH+]([C@@H]([C@@H]2O)O[C@H](CO)[C@H]2O)C(NC(N)=N2)=C1C2=S CBNRZZNSRJQZNT-IOSLPCCCSA-O 0.000 description 1
- RFHIWBUKNJIBSE-KQYNXXCUSA-O 6-thio-7-methyl-guanosine Chemical compound C1=2NC(N)=NC(=S)C=2N(C)C=[N+]1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RFHIWBUKNJIBSE-KQYNXXCUSA-O 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- MJJUWOIBPREHRU-MWKIOEHESA-N 7-Deaza-8-azaguanosine Chemical compound NC=1NC(C2=C(N=1)N(N=C2)[C@H]1[C@H](O)[C@H](O)[C@H](O1)CO)=O MJJUWOIBPREHRU-MWKIOEHESA-N 0.000 description 1
- ISSMDAFGDCTNDV-UHFFFAOYSA-N 7-deaza-2,6-diaminopurine Chemical compound NC1=NC(N)=C2NC=CC2=N1 ISSMDAFGDCTNDV-UHFFFAOYSA-N 0.000 description 1
- YVVMIGRXQRPSIY-UHFFFAOYSA-N 7-deaza-2-aminopurine Chemical compound N1C(N)=NC=C2C=CN=C21 YVVMIGRXQRPSIY-UHFFFAOYSA-N 0.000 description 1
- ZTAWTRPFJHKMRU-UHFFFAOYSA-N 7-deaza-8-aza-2,6-diaminopurine Chemical compound NC1=NC(N)=C2NN=CC2=N1 ZTAWTRPFJHKMRU-UHFFFAOYSA-N 0.000 description 1
- SMXRCJBCWRHDJE-UHFFFAOYSA-N 7-deaza-8-aza-2-aminopurine Chemical compound NC1=NC=C2C=NNC2=N1 SMXRCJBCWRHDJE-UHFFFAOYSA-N 0.000 description 1
- LHCPRYRLDOSKHK-UHFFFAOYSA-N 7-deaza-8-aza-adenine Chemical compound NC1=NC=NC2=C1C=NN2 LHCPRYRLDOSKHK-UHFFFAOYSA-N 0.000 description 1
- VJNXUFOTKNTNPG-IOSLPCCCSA-O 7-methylinosine Chemical compound C1=2NC=NC(=O)C=2N(C)C=[N+]1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VJNXUFOTKNTNPG-IOSLPCCCSA-O 0.000 description 1
- ABXGJJVKZAAEDH-IOSLPCCCSA-N 9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-(dimethylamino)-3h-purine-6-thione Chemical compound C1=NC=2C(=S)NC(N(C)C)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ABXGJJVKZAAEDH-IOSLPCCCSA-N 0.000 description 1
- ADPMAYFIIFNDMT-KQYNXXCUSA-N 9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-(methylamino)-3h-purine-6-thione Chemical compound C1=NC=2C(=S)NC(NC)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ADPMAYFIIFNDMT-KQYNXXCUSA-N 0.000 description 1
- 201000007994 Aceruloplasminemia Diseases 0.000 description 1
- 206010052075 Acquired epileptic aphasia Diseases 0.000 description 1
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 description 1
- 208000005452 Acute intermittent porphyria Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 208000006696 Adrenocorticotropic hormone deficiency Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 201000002882 Agraphia Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 description 1
- 241000004176 Alphacoronavirus Species 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 201000005932 Alstrom Syndrome Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 208000025490 Apert syndrome Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 208000022316 Arachnoid cyst Diseases 0.000 description 1
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
- 241000180579 Arca Species 0.000 description 1
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 206010071576 Autoimmune aplastic anaemia Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010071577 Autoimmune hyperlipidaemia Diseases 0.000 description 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 description 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000034577 Benign intracranial hypertension Diseases 0.000 description 1
- 241000008904 Betacoronavirus Species 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000033929 Birt-Hogg-Dubé syndrome Diseases 0.000 description 1
- 208000005692 Bloom Syndrome Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 206010006074 Brachial plexus injury Diseases 0.000 description 1
- 208000004020 Brain Abscess Diseases 0.000 description 1
- 206010048409 Brain malformation Diseases 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102100022361 CAAX prenyl protease 1 homolog Human genes 0.000 description 1
- 108010077333 CAP1-6D Proteins 0.000 description 1
- 101710180456 CD-NTase-associated protein 4 Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010064012 Central pain syndrome Diseases 0.000 description 1
- 208000023442 Cephalocele Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008096 Cerebral atrophy Diseases 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 201000006892 Charcot-Marie-Tooth disease type 1 Diseases 0.000 description 1
- 208000035758 Charcot-Marie-Tooth disease type 2S Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 206010008513 Child maltreatment syndrome Diseases 0.000 description 1
- 206010061041 Chlamydial infection Diseases 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010060774 Chondrosis Diseases 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 208000010200 Cockayne syndrome Diseases 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000011038 Cold agglutinin disease Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 208000006992 Color Vision Defects Diseases 0.000 description 1
- 208000009802 Colorado tick fever Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 208000003606 Congenital Rubella Syndrome Diseases 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 206010010510 Congenital hypothyroidism Diseases 0.000 description 1
- 206010010543 Congenital methaemoglobinaemia Diseases 0.000 description 1
- 208000029323 Congenital myotonia Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000012437 Copper-Transporting ATPases Human genes 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- 206010066946 Craniofacial dysostosis Diseases 0.000 description 1
- 208000009283 Craniosynostoses Diseases 0.000 description 1
- 206010049889 Craniosynostosis Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 201000006526 Crouzon syndrome Diseases 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 108010068106 Cyclin T Proteins 0.000 description 1
- 102100024109 Cyclin-T1 Human genes 0.000 description 1
- 206010061802 Cyclosporidium infection Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 description 1
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 description 1
- 201000003863 Dandy-Walker Syndrome Diseases 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 208000024940 Dent disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- YKWUPFSEFXSGRT-JWMKEVCDSA-N Dihydropseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1C(=O)NC(=O)NC1 YKWUPFSEFXSGRT-JWMKEVCDSA-N 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 208000001708 Dupuytren contracture Diseases 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 206010049669 Dyscalculia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 208000030820 Ebola disease Diseases 0.000 description 1
- 206010014096 Echinococciasis Diseases 0.000 description 1
- 208000009366 Echinococcosis Diseases 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 208000002403 Encephalocele Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000003727 FG syndrome Diseases 0.000 description 1
- 208000028771 Facial injury Diseases 0.000 description 1
- 206010063006 Facial spasm Diseases 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 208000005050 Familial Hypophosphatemic Rickets Diseases 0.000 description 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
- 108700000224 Familial apoceruloplasmin deficiency Proteins 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 208000002091 Febrile Seizures Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 208000025499 G6PD deficiency Diseases 0.000 description 1
- 208000027472 Galactosemias Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 208000007223 Gerstmann syndrome Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000009396 Group II Malformations of Cortical Development Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 101100285983 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) htpX gene Proteins 0.000 description 1
- 206010019143 Hantavirus pulmonary infection Diseases 0.000 description 1
- 208000031797 Harlequin ichthyosis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019263 Heart block congenital Diseases 0.000 description 1
- 208000004095 Hemifacial Spasm Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 201000000361 Hemochromatosis type 2 Diseases 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000025164 Hendra virus infection Diseases 0.000 description 1
- 208000000464 Henipavirus Infections Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 208000000627 Hereditary Coproporphyria Diseases 0.000 description 1
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
- 206010019939 Herpes gestationis Diseases 0.000 description 1
- 206010063491 Herpes zoster oticus Diseases 0.000 description 1
- 208000013260 Hirata disease Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000897856 Homo sapiens Adenylyl cyclase-associated protein 2 Proteins 0.000 description 1
- 101000824531 Homo sapiens CAAX prenyl protease 1 homolog Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 description 1
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 1
- 101000653369 Homo sapiens Methylcytosine dioxygenase TET3 Proteins 0.000 description 1
- 101001133656 Homo sapiens Plasminogen activator inhibitor 1 RNA-binding protein Proteins 0.000 description 1
- 101001077015 Homo sapiens Rab GTPase-activating protein 1-like Proteins 0.000 description 1
- 101001077011 Homo sapiens Rab GTPase-activating protein 1-like, isoform 10 Proteins 0.000 description 1
- 101000836079 Homo sapiens Serpin B8 Proteins 0.000 description 1
- 101000836075 Homo sapiens Serpin B9 Proteins 0.000 description 1
- 101000661807 Homo sapiens Suppressor of tumorigenicity 14 protein Proteins 0.000 description 1
- 101000648832 Homo sapiens TMF-regulated nuclear protein 1 Proteins 0.000 description 1
- 101000798702 Homo sapiens Transmembrane protease serine 4 Proteins 0.000 description 1
- 101000760235 Homo sapiens Zinc finger protein 574 Proteins 0.000 description 1
- 206010020365 Homocystinuria Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000282596 Hylobatidae Species 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 208000001021 Hyperlipoproteinemia Type I Diseases 0.000 description 1
- 208000008852 Hyperoxaluria Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 210000005131 Hürthle cell Anatomy 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 101150034559 IGF1R gene Proteins 0.000 description 1
- 101150030450 IRS1 gene Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 description 1
- 206010053574 Immunoblastic lymphoma Diseases 0.000 description 1
- 208000035899 Infantile spasms syndrome Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010022472 Insulin autoimmune syndrome Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010022557 Intermediate uveitis Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 206010061246 Intervertebral disc degeneration Diseases 0.000 description 1
- 208000018650 Intervertebral disc disease Diseases 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- 208000009289 Jackson-Weiss syndrome Diseases 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 208000017924 Klinefelter Syndrome Diseases 0.000 description 1
- 208000001182 Kniest dysplasia Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 206010023567 Labyrinthitis Diseases 0.000 description 1
- 208000005870 Lafora disease Diseases 0.000 description 1
- 208000014161 Lafora myoclonic epilepsy Diseases 0.000 description 1
- 208000001913 Lamellar ichthyosis Diseases 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 208000006136 Leigh Disease Diseases 0.000 description 1
- 208000017507 Leigh syndrome Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 201000004462 Leydig Cell Tumor Diseases 0.000 description 1
- 201000011062 Li-Fraumeni syndrome Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010048911 Lissencephaly Diseases 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 101150105382 MET gene Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000030162 Maple syrup disease Diseases 0.000 description 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000005767 Megalencephaly Diseases 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 201000002571 Melkersson-Rosenthal syndrome Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 206010027193 Meningioma malignant Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100030812 Methylcytosine dioxygenase TET3 Human genes 0.000 description 1
- 208000037431 Micro syndrome Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 201000002983 Mobius syndrome Diseases 0.000 description 1
- 208000034167 Moebius syndrome Diseases 0.000 description 1
- 208000037699 Monosomy 18p Diseases 0.000 description 1
- 208000003090 Mowat-Wilson syndrome Diseases 0.000 description 1
- 208000009433 Moyamoya Disease Diseases 0.000 description 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
- 208000007326 Muenke Syndrome Diseases 0.000 description 1
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 1
- NIDVTARKFBZMOT-PEBGCTIMSA-N N(4)-acetylcytidine Chemical compound O=C1N=C(NC(=O)C)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NIDVTARKFBZMOT-PEBGCTIMSA-N 0.000 description 1
- WVGPGNPCZPYCLK-WOUKDFQISA-N N(6),N(6)-dimethyladenosine Chemical compound C1=NC=2C(N(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WVGPGNPCZPYCLK-WOUKDFQISA-N 0.000 description 1
- WVGPGNPCZPYCLK-UHFFFAOYSA-N N-Dimethyladenosine Natural products C1=NC=2C(N(C)C)=NC=NC=2N1C1OC(CO)C(O)C1O WVGPGNPCZPYCLK-UHFFFAOYSA-N 0.000 description 1
- UNUYMBPXEFMLNW-DWVDDHQFSA-N N-[(9-beta-D-ribofuranosylpurin-6-yl)carbamoyl]threonine Chemical compound C1=NC=2C(NC(=O)N[C@@H]([C@H](O)C)C(O)=O)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UNUYMBPXEFMLNW-DWVDDHQFSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- LZCNWAXLJWBRJE-ZOQUXTDFSA-N N4-Methylcytidine Chemical compound O=C1N=C(NC)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LZCNWAXLJWBRJE-ZOQUXTDFSA-N 0.000 description 1
- GOSWTRUMMSCNCW-UHFFFAOYSA-N N6-(cis-hydroxyisopentenyl)adenosine Chemical compound C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1OC(CO)C(O)C1O GOSWTRUMMSCNCW-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028933 Neonatal diabetes mellitus Diseases 0.000 description 1
- 208000031790 Neonatal hemochromatosis Diseases 0.000 description 1
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 description 1
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 description 1
- 208000003521 Nervous System Paraneoplastic Syndromes Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
- 241000526636 Nipah henipavirus Species 0.000 description 1
- 206010029748 Noonan syndrome Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- TTZMPOZCBFTTPR-UHFFFAOYSA-N O=P1OCO1 Chemical class O=P1OCO1 TTZMPOZCBFTTPR-UHFFFAOYSA-N 0.000 description 1
- XMIFBEZRFMTGRL-TURQNECASA-N OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(CNCCS(O)(=O)=O)c(=O)[nH]c1=S Chemical compound OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(CNCCS(O)(=O)=O)c(=O)[nH]c1=S XMIFBEZRFMTGRL-TURQNECASA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010068106 Occipital neuralgia Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 208000019851 Opitz G/BBB syndrome Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 102100024127 Pantothenate kinase 2, mitochondrial Human genes 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 description 1
- 206010069587 Paraneoplastic encephalomyelitis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000027086 Pemphigus foliaceus Diseases 0.000 description 1
- 208000004843 Pendred Syndrome Diseases 0.000 description 1
- 208000004362 Penile Induration Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
- 206010034764 Peutz-Jeghers syndrome Diseases 0.000 description 1
- 208000020758 Peyronie disease Diseases 0.000 description 1
- 201000004014 Pfeiffer syndrome Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000000766 Pityriasis Lichenoides Diseases 0.000 description 1
- 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 102100034055 Plasminogen activator inhibitor 1 RNA-binding protein Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 206010036172 Porencephaly Diseases 0.000 description 1
- 206010057244 Post viral fatigue syndrome Diseases 0.000 description 1
- 206010052469 Postictal paralysis Diseases 0.000 description 1
- 208000004347 Postpericardiotomy Syndrome Diseases 0.000 description 1
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 102100029500 Prostasin Human genes 0.000 description 1
- 201000005660 Protein C Deficiency Diseases 0.000 description 1
- 206010051292 Protein S Deficiency Diseases 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 description 1
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 102100025165 Rab GTPase-activating protein 1-like, isoform 10 Human genes 0.000 description 1
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 description 1
- 208000032831 Ramsay Hunt syndrome Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010038584 Repetitive strain injury Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 201000007981 Reye syndrome Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 208000000705 Rift Valley Fever Diseases 0.000 description 1
- 206010039281 Rubinstein-Taybi syndrome Diseases 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 206010048871 Sensory integrative dysfunction Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100025517 Serpin B9 Human genes 0.000 description 1
- 208000003274 Sertoli cell tumor Diseases 0.000 description 1
- 208000002108 Shaken Baby Syndrome Diseases 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000032383 Soft tissue cancer Diseases 0.000 description 1
- 201000003696 Sotos syndrome Diseases 0.000 description 1
- 206010041415 Spastic paralysis Diseases 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010042265 Sturge-Weber Syndrome Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000027522 Sydenham chorea Diseases 0.000 description 1
- 241001661355 Synapsis Species 0.000 description 1
- 208000035239 Synesthesia Diseases 0.000 description 1
- 206010042928 Syringomyelia Diseases 0.000 description 1
- 208000004732 Systemic Vasculitis Diseases 0.000 description 1
- 208000012827 T-B+ severe combined immunodeficiency due to gamma chain deficiency Diseases 0.000 description 1
- 102100028172 TMF-regulated nuclear protein 1 Human genes 0.000 description 1
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010069116 Tetrahydrobiopterin deficiency Diseases 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010051526 Tolosa-Hunt syndrome Diseases 0.000 description 1
- 206010044041 Tooth hypoplasia Diseases 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 102100032471 Transmembrane protease serine 4 Human genes 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010044608 Trichiniasis Diseases 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 208000014769 Usher Syndromes Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010063661 Vascular encephalopathy Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000035562 Wallenberg syndrome Diseases 0.000 description 1
- 201000002916 Warburg micro syndrome Diseases 0.000 description 1
- 208000026481 Werdnig-Hoffmann disease Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 206010049644 Williams syndrome Diseases 0.000 description 1
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 1
- 208000016174 X-linked dominant disease Diseases 0.000 description 1
- 208000021020 X-linked dominant inheritance Diseases 0.000 description 1
- 208000031878 X-linked hypophosphatemia Diseases 0.000 description 1
- 208000035724 X-linked hypophosphatemic rickets Diseases 0.000 description 1
- 208000024967 X-linked recessive disease Diseases 0.000 description 1
- 208000021022 X-linked recessive inheritance Diseases 0.000 description 1
- 201000007146 X-linked severe combined immunodeficiency Diseases 0.000 description 1
- 208000006756 X-linked sideroblastic anemia Diseases 0.000 description 1
- 208000022440 X-linked sideroblastic anemia 1 Diseases 0.000 description 1
- CAEFEWVYEZABLA-UUOKFMHZSA-N XTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 CAEFEWVYEZABLA-UUOKFMHZSA-N 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- 108700029634 Y-Linked Genes Proteins 0.000 description 1
- 208000028258 Y-linked inheritance Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 201000004525 Zellweger Syndrome Diseases 0.000 description 1
- RUKRVHYQIIURNV-RLKNHCSUSA-N [[(2R,3R,5R)-4-fluoro-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound Cc1cn([C@@H]2O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C2F)c(=O)[nH]c1=O RUKRVHYQIIURNV-RLKNHCSUSA-N 0.000 description 1
- GKVHYBAWZAYQDO-XVFCMESISA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-(2-oxo-4-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=O)NC(=S)C=C1 GKVHYBAWZAYQDO-XVFCMESISA-N 0.000 description 1
- KHYOUGAATNYCAZ-XVFCMESISA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=S)NC(=O)C=C1 KHYOUGAATNYCAZ-XVFCMESISA-N 0.000 description 1
- ABOQIBZHFFLOGM-UAKXSSHOSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-(5-iodo-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=O)NC(=O)C(I)=C1 ABOQIBZHFFLOGM-UAKXSSHOSA-N 0.000 description 1
- QTWNSBVFPSAMPO-IOSLPCCCSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-(6-imino-1-methylpurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=NC=2C(=N)N(C)C=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QTWNSBVFPSAMPO-IOSLPCCCSA-N 0.000 description 1
- LCQWKKZWHQFOAH-IOSLPCCCSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[6-(methylamino)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O LCQWKKZWHQFOAH-IOSLPCCCSA-N 0.000 description 1
- WNVZQYHBHSLUHJ-XVFCMESISA-N [[(2r,3s,4r,5r)-4-amino-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound N[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)N=C(N)C=C1 WNVZQYHBHSLUHJ-XVFCMESISA-N 0.000 description 1
- YWHNPOKVSACYOQ-KQYNXXCUSA-N [[(2r,3s,4r,5r)-5-(2-amino-1-methyl-6-oxopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=NC=2C(=O)N(C)C(N)=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O YWHNPOKVSACYOQ-KQYNXXCUSA-N 0.000 description 1
- NCKFQXVRKKNRBB-SHUUEZRQSA-N [[(2r,3s,4r,5r)-5-(3,5-dioxo-1,2,4-triazin-2-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=N1 NCKFQXVRKKNRBB-SHUUEZRQSA-N 0.000 description 1
- WJUFDWJKJXOYSB-XVFCMESISA-N [[(2r,3s,4r,5r)-5-(4-amino-2-sulfanylidenepyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 WJUFDWJKJXOYSB-XVFCMESISA-N 0.000 description 1
- DBFUQOZREOHGAV-UAKXSSHOSA-N [[(2r,3s,4r,5r)-5-(4-amino-5-bromo-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=C(Br)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 DBFUQOZREOHGAV-UAKXSSHOSA-N 0.000 description 1
- ZPZGYYNOHSQDQC-UAKXSSHOSA-N [[(2r,3s,4r,5r)-5-(4-amino-5-iodo-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=C(I)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 ZPZGYYNOHSQDQC-UAKXSSHOSA-N 0.000 description 1
- YIJVOACVHQZMKI-JXOAFFINSA-N [[(2r,3s,4r,5r)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 YIJVOACVHQZMKI-JXOAFFINSA-N 0.000 description 1
- GVVRDIINMFAFEO-KCGFPETGSA-N [[(2r,3s,4r,5r)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O GVVRDIINMFAFEO-KCGFPETGSA-N 0.000 description 1
- PQISXOFEOCLOCT-UUOKFMHZSA-N [[(2r,3s,4r,5r)-5-(6-amino-8-azidopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound [N-]=[N+]=NC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O PQISXOFEOCLOCT-UUOKFMHZSA-N 0.000 description 1
- WDPOFPOWJQWIPX-UUOKFMHZSA-N [[(2r,3s,4r,5r)-5-(7-aminotriazolo[4,5-d]pyrimidin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound N1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O WDPOFPOWJQWIPX-UUOKFMHZSA-N 0.000 description 1
- GIYJFUYCSKNMOE-IVZWLZJFSA-N [[(2r,3s,5r)-5-(2,4-dioxo-5-prop-1-ynylpyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 GIYJFUYCSKNMOE-IVZWLZJFSA-N 0.000 description 1
- QCUUXXCLJLZGLD-IVZWLZJFSA-N [[(2r,3s,5r)-5-(4-amino-2-oxo-5-prop-1-ynylpyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C(C#CC)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 QCUUXXCLJLZGLD-IVZWLZJFSA-N 0.000 description 1
- UYPHYZSNRPGPAN-RRKCRQDMSA-N [[(2r,3s,5r)-5-(4-amino-5-bromo-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=C(Br)C(N)=NC(=O)N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 UYPHYZSNRPGPAN-RRKCRQDMSA-N 0.000 description 1
- BLQCQNFLEGAHPA-RRKCRQDMSA-N [[(2r,3s,5r)-5-(5-bromo-2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(Br)=C1 BLQCQNFLEGAHPA-RRKCRQDMSA-N 0.000 description 1
- ODAFAEFSKRENSW-IOSLPCCCSA-N [hydroxy-[[(2r,3r,4r,5r)-3-hydroxy-4-methoxy-5-(6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy]phosphoryl] phosphono hydrogen phosphate Chemical compound CO[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C2=NC=NC(O)=C2N=C1 ODAFAEFSKRENSW-IOSLPCCCSA-N 0.000 description 1
- ZWDWDTXYXXJLJB-RRKCRQDMSA-N [hydroxy-[[(2r,3s,5r)-3-hydroxy-5-(5-iodo-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(I)=C1 ZWDWDTXYXXJLJB-RRKCRQDMSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 208000030597 adult Refsum disease Diseases 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 206010001689 alkaptonuria Diseases 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- 208000011916 alternating hemiplegia Diseases 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 201000008266 amyotrophic lateral sclerosis type 2 Diseases 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 206010002320 anencephaly Diseases 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003074 arachnoiditis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 208000021900 auditory perceptual disease Diseases 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 201000011385 autoimmune polyendocrine syndrome Diseases 0.000 description 1
- 206010071578 autoimmune retinopathy Diseases 0.000 description 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 208000021018 autosomal dominant inheritance Diseases 0.000 description 1
- 208000031375 autosomal dominant myotonia congenita Diseases 0.000 description 1
- 201000001286 autosomal recessive congenital ichthyosis 4B Diseases 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000012056 cerebral malformation Diseases 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 201000004308 chancroid Diseases 0.000 description 1
- 201000002797 childhood leukemia Diseases 0.000 description 1
- 238000009232 chiropractic Methods 0.000 description 1
- 201000000902 chlamydia Diseases 0.000 description 1
- 208000012538 chlamydia trachomatis infectious disease Diseases 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 208000004664 chromosome 18p deletion syndrome Diseases 0.000 description 1
- 201000004723 chromosome 1p36 deletion syndrome Diseases 0.000 description 1
- 208000030949 chronic idiopathic urticaria Diseases 0.000 description 1
- 208000033630 chronic polyneuropathy Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 206010072757 chronic spontaneous urticaria Diseases 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 208000031214 ciliopathy Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000035722 classic type Ehlers-Danlos syndrome Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 208000030251 communication disease Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 201000004395 congenital heart block Diseases 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 201000008230 cutaneous porphyria Diseases 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 201000002641 cyclosporiasis Diseases 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 229960005449 daclatasvir Drugs 0.000 description 1
- FKRSSPOQAMALKA-CUPIEXAXSA-N daclatasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)=CN1 FKRSSPOQAMALKA-CUPIEXAXSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 208000018180 degenerative disc disease Diseases 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 201000001098 delayed sleep phase syndrome Diseases 0.000 description 1
- 208000033921 delayed sleep phase type circadian rhythm sleep disease Diseases 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 201000002268 dental enamel hypoplasia Diseases 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000013916 distal hereditary motor neuronopathy type 5 Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 206010058319 dysgraphia Diseases 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 208000000292 ehrlichiosis Diseases 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 230000005221 enamel hypoplasia Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000036566 epidermal hyperplasia Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 108700021358 erbB-1 Genes Proteins 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000002449 erythroblastic effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002907 exocrine cell Anatomy 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 108010091897 factor V Leiden Proteins 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 201000004260 follicular adenoma Diseases 0.000 description 1
- 208000030878 follicular thyroid adenoma Diseases 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 201000011349 geniculate herpes zoster Diseases 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 238000002873 global sequence alignment Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000008605 glucosephosphate dehydrogenase deficiency Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 208000030316 grade III meningioma Diseases 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000005648 hantavirus pulmonary syndrome Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 201000000388 hemochromatosis type 4 Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 208000024977 hereditary methemoglobinemia Diseases 0.000 description 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
- 208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 description 1
- PHNWGDTYCJFUGZ-UHFFFAOYSA-L hexyl phosphate Chemical compound CCCCCCOP([O-])([O-])=O PHNWGDTYCJFUGZ-UHFFFAOYSA-L 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 208000009624 holoprosencephaly Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 208000029080 human African trypanosomiasis Diseases 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 208000013094 juvenile primary lateral sclerosis Diseases 0.000 description 1
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000011977 language disease Diseases 0.000 description 1
- 208000004343 lateral medullary syndrome Diseases 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000014817 lissencephaly spectrum disease Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 208000026807 lung carcinoid tumor Diseases 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000024393 maple syrup urine disease Diseases 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 208000037941 meningococcal disease Diseases 0.000 description 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 201000003694 methylmalonic acidemia Diseases 0.000 description 1
- 108091048549 miR-29b stem-loop Proteins 0.000 description 1
- 108091079151 miR-29c-1 stem-loop Proteins 0.000 description 1
- 108091054490 miR-29c-2 stem-loop Proteins 0.000 description 1
- 108091063344 miR-30b stem-loop Proteins 0.000 description 1
- 108091072917 miR-30c-1 stem-loop Proteins 0.000 description 1
- 108091066131 miR-30c-2 stem-loop Proteins 0.000 description 1
- 108091057431 miR-30d stem-loop Proteins 0.000 description 1
- 108091023108 miR-30e stem-loop Proteins 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 208000005871 monkeypox Diseases 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 230000002151 myoclonic effect Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 208000037830 nasal cancer Diseases 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 108700004028 nef Genes Proteins 0.000 description 1
- 101150023385 nef gene Proteins 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 208000022032 neurofibromatosis type 2 Diseases 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000013651 non-24-hour sleep-wake syndrome Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000001915 nurse cell Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 208000015200 ocular cicatricial pemphigoid Diseases 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- NENPYTRHICXVCS-YNEHKIRRSA-N oseltamivir acid Chemical compound CCC(CC)O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O NENPYTRHICXVCS-YNEHKIRRSA-N 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 208000011937 ovarian epithelial tumor Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 206010057056 paraneoplastic pemphigus Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 208000029308 periodic paralysis Diseases 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 208000001061 polyostotic fibrous dysplasia Diseases 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000012934 primary antiphospholipid syndrome Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000004012 propionic acidemia Diseases 0.000 description 1
- 108010031970 prostasin Proteins 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000001381 pseudotumor cerebri Diseases 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000012124 rapid diagnostic test Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 201000000757 red-green color blindness Diseases 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 208000009169 relapsing polychondritis Diseases 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- JRPHGDYSKGJTKZ-UHFFFAOYSA-N selenophosphoric acid Chemical class OP(O)([SeH])=O JRPHGDYSKGJTKZ-UHFFFAOYSA-N 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
- 230000009209 sensory transmission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 201000007245 sideroblastic anemia 1 Diseases 0.000 description 1
- 208000037968 sinus cancer Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000031019 skin pigmentation disease Diseases 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 239000010454 slate Substances 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 201000002612 sleeping sickness Diseases 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 description 1
- 229960002063 sofosbuvir Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 208000005198 spinal stenosis Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 208000023366 superficial siderosis Diseases 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229950006156 teprenone Drugs 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000005451 thionucleotide Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 206010048627 thoracic outlet syndrome Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000003982 trichinellosis Diseases 0.000 description 1
- 201000007588 trichinosis Diseases 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 208000026485 trisomy X Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 201000007423 tubular adenocarcinoma Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 208000032471 type 1 spinal muscular atrophy Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 208000032527 type III spinal muscular atrophy Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000023747 urothelial carcinoma Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 201000004822 varicocele Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- FHCUMDQMBHQXKK-CDIODLITSA-N velpatasvir Chemical compound C1([C@@H](NC(=O)OC)C(=O)N2[C@@H](C[C@@H](C2)COC)C=2NC(=CN=2)C=2C=C3C(C4=CC5=CC=C6NC(=NC6=C5C=C4OC3)[C@H]3N([C@@H](C)CC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)=CC=CC=C1 FHCUMDQMBHQXKK-CDIODLITSA-N 0.000 description 1
- 229960000863 velpatasvir Drugs 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000007371 visceral function Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- RPQZTTQVRYEKCR-WCTZXXKLSA-N zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=CC=C1 RPQZTTQVRYEKCR-WCTZXXKLSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/316—Phosphonothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medical Informatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Databases & Information Systems (AREA)
- Evolutionary Biology (AREA)
- Pathology (AREA)
- Data Mining & Analysis (AREA)
- Theoretical Computer Science (AREA)
- Primary Health Care (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
Abstract
Description
本発明は、米国国立がん研究所により与えられた認可番号U43CA221567下の政府支援、および米国国立アレルギー感染症研究所により与えられたSBIR契約番号HHSN272201800034Cからの支援を受けて行われたものである。政府は本発明における一定の権利を有する。
本出願は、両出願に共通する全ての主題に対して、2020年4月2日に出願された米国仮出願第63/004,045号の優先権および利益を主張する。前記仮出願の開示内容は参照により全体として本明細書に組み込まれる。
53、配列番号354、配列番号355、配列番号356、配列番号357、配列番号358、配列番号359、配列番号360、配列番号361、配列番号362、配列番号363、配列番号364、配列番号365、配列番号366、配列番号367、配列番号368、配列番号369、配列番号370、配列番号371、配列番号372、配列番号373、配列番号374、配列番号375、配列番号376、配列番号377、配列番号378、配列番号379、配列番号380、配列番号381、配列番号382、配列番号383、配列番号384、配列番号385、配列番号386、配列番号387、配列番号388、配列番号389、配列番号390、配列番号391、配列番号392、配列番号393、配列番号394、配列番号395、配列番号396、配列番号397、配列番号398、配列番号399、配列番号400、配列番号401、配列番号402、配列番号403、配列番号404、配列番号405、配列番号406、配列番号407、配列番号408、配列番号409、配列番号410、配列番号411、配列番号412、配列番号413、配列番号414、配列番号415、配列番号416、配列番号417、配列番号418、配列番号419、配列番号420、配列番号421、配列番号422、配列番号423、配列番号424、配列番号425、配列番号426、配列番号427、配列番号428、配列番号429、配列番号430、配列番号431、配列番号432、配列番号433、配列番号434、配列番号435、配列番号436、配列番号437、配列番号438、配列番号439、配列番号440、配列番号441、配列番号442、配列番号443、配列番号445、配列番号446、配列番号447、配列番号448、配列番号449、配列番号450、配列番号451、配列番号452、配列番号453、配列番号455、配列番号456、配列番号457、配列番号458、配列番号459、配列番号460、配列番号461、配列番号462、配列番号463、配列番号620、配列番号644、配列番号645、配列番号646、配列番号647、配列番号648、配列番号649、配列番号650、配列番号651、配列番号652、配列番号653、配列番号654、配列番号655、配列番号656、配列番号657、配列番号658、配列番号659、配列番号660、配列番号661、配列番号662、配列番号663、配列番号664、配列番号665、配列番号666、配列番号667、配列番号668、配列番号669、配列番号670、配列番号671、配列番号672、配列番号673、配列番号674、配列番号675、配列番号676、配列番号677、配列番号678、配列番号679、配列番号680、配列番号681、配列番号682、配列番号683、配列番号684、配列番号685、配列番号686、配列番号687、配列番号688、配列番号689、配列番号690、配列番号691、配列番号692、配列番号693、配列番号694、配列番号695、配列番号696、配列番号697、配列番号698、配列番号699、配列番号700、配列番号701、配列番号702、配列番号703、配列番号704、配列番号705、配列番号706、配列番号707、配列番号708、配列番号709、配列番号710、配列番号711、配列番号712、配列番号713、配列番号714、配列番号715、配列番号716、配列番号717、配列番号718、配列番号719、配列番号720、配列番号721、配列番号722、配列番号723、配列番号724、配列番号725、配列番号726、配列番号727、配列番号728、配列番号729、配列番号730、配列番号731、配列番号732、配列番号733、配列番号734、配列番号735、配列番号736、配列番号737、配列番号738、配列番号739、配列番号740、配列番号741、配列番号742、配列番号743、配列番号744、配列番号745、配列番号746、配列番号747、配列番号748、配列番号749、配列番号750、配列番号751、配列番号752、配列番号753、配列番号754、配列番号755、配列番号756、配列番号757、配列番号758、配列番号759、配列番号760、配列番号761、配列番号762、配列番号763、配列番号764、配列番号765、配列番号766、配列番号767、配列番号768、配列番号769、配列番号770、配列番号771、配列番号772、配列番号773、配列番号774、配列番号775、配列番号776、配列番号777、配列番号778、配列番号779、配列番号780、配列番号781、配列番号782、配列番号783、配列番号784、配列番号785、配列番号786、配列番号787、配列番号788、配列番号789、配列番号790、配列番号791、配列番号792、配列番号793、配列番号794、配列番号795、配列番号796、配列番号797、配列番号798、配列番号799、配列番号800、配列番号801、配列番号802、配列番号803、配列番号804、配列番号805、配列番号806、配列番号807、配列番号808、配列番号809、配列番号810、配列番号811、配列番号812、配列番号813、配列番号814、配列番号815、配列番号816、配列番号817、配列番号818、配列番号819、配列番号820、配列番号821、配列番号822、配列番号823、配列番号824、配列番号825、配列番号835、配列番号836、配列番号837、配列番号846、配列番号847、配列番号848、配列番号849、配列番号850、配列番号851、配列番号852、配列番号853、配列番号854、配列番号855、配列番号856、配列番号857、配列番号858、配列番号859、配列番号860、配列番号861、配列番号862、配列番号863、配列番号864、配列番号865、配列番号866、配列番号867、配列番号868、配列番号869、配列番号870、配列番号871、配列番号872、配列番号873、配列番号874、配列番号875、配列番号876、配列番号877、配列番号878、配列番号879、配列番号880、配列番号881、配列番号882、配列番号883、配列番号884、配列番号885、配列番号886、配列番号887、配列番号888、配列番号889、配列番号890、配列番号891、配列番号892、配列番号893、配列番号894、配列番号895、配列番号896、配列番号897、配列番号898、または配列番号899のいずれか1つに対して少なくとも90%の配列同一性を有し得る。いくつかの実施形態では、操作されたオリゴヌクレオチド配列は、糖、塩基、または骨格の修飾を含み得る。いくつかの実施形態では、修飾は、リンカーを含み得る。いくつかの実施形態では、リンカーは、共有結合性リンカーであり得る。いくつかの実施形態では、リンカーは、切断可能なリンカーであり得る。いくつかの実施形態では、リンカーは、コンジュゲートを含むようにさらに修飾され得る。いくつかの実施形態では、コンジュゲートは、抗体、天然に存在するリガンド、低分子、またはペプチドであり得る。いくつかの実施形態では、コンジュゲートは、薬物またはその塩であり得る。いくつかの実施形態では、操作されたオリゴヌクレオチドは、グリカンでグリコシル化されているヌクレオチドの塩基を含み得る。いくつかの実施形態では、第1のRNAまたは第2のRNAは、mRNA配列を少なくとも部分的に含み得る。いくつかの実施形態では、操作されたオリゴヌクレオチドまたはその塩は、mRNA配列と接触させた場合、(a)mRNA配列を含む第1の単離された哺乳動物細胞に、操作されたオリゴヌクレオチドまたはその塩をトランスフェクトし、(b)mRNA配列を含む第2の単離された哺乳動物細胞に、ncRNAをトランスフェクトし、(c)同じタイプの哺乳動物細胞である、第1の単離された哺乳動物細胞および第2の単離された哺乳動物細胞中に発現するポリペプチドの量を測定することにより決定した時に、等量のncRNAをmRNA配列と接触させた場合と比較して、mRNA配列によりコードされるポリペプチドの発現が約1.2分の1以下となるように産生し得る。いくつかの実施形態では、操作されたオリゴヌクレオチドまたはその塩は、mRNA配列と接触させた場合、(a)mRNA配列を含む第1の単離された哺乳動物細胞に、操作されたオリゴヌクレオチドまたはその塩をトランスフェクトし、(b)mRNA配列を含む第2の単離された哺乳動物細胞に、ncRNAをトランスフェクトし、(c)同じタイプの哺乳動物細胞である、第1の単離された哺乳動物細胞および第2の単離された哺乳動物細胞中に発現するポリペプチドからの活性量を測定することにより決定した時に、等量のncRNAをmRNA配列と接触させた場合と比較して、mRNA配列によりコードされるポリペプチドの活性が約1.2分の1以下となるように産生し得る。いくつかの実施形態では、操作されたオリゴヌクレオチドまたはその塩は、mRNA配列と接触させた場合、(a)mRNA配列を含む第1の単離された哺乳動物細胞に、操作されたオリゴヌクレオチドまたはその塩をトランスフェクトし、(b)mRNA配列を含む第2の単離された哺乳動物細胞に、ncRNAをトランスフェクトし、(c)第1の単離された哺乳動物細胞および第2の単離された哺乳動物細胞中に発現するポリペプチドの量を測定することにより決定した時に、等量のncRNAを接触させた場合と比較して、mRNA配列によりコードされるポリペプチドの発現が約1.2分の1~約10分の1となるように産生し得る。いくつかの実施形態では、操作されたオリゴヌクレオチドまたはその塩は、mRNA配列と接触させた場合、(a)mRNA配列を含む第1の単離された哺乳動物細胞に、操作されたオリゴヌクレオチドまたはその塩をトランスフェクトし、(b)mRNA配列を含む第2の単離された哺乳動物細胞に、ncRNAをトランスフェクトし、(c)第1の単離された哺乳動物細胞および第2の単離された哺乳動物細胞中に発現するポリペプチドからの活性量を測定することにより決定した時に、等量のncRNAを接触させた場合と比較して、mRNA配列によりコードされるポリペプチドの活性が約1.2分の1~約10分の1となるように産生し得る。いくつかの実施形態では、第1の単離された哺乳動物細胞および第2の単離された哺乳動物細胞は、ヒト細胞またはマウス細胞であり得る。いくつかの実施形態では、第1の単離された哺乳動物細胞はヒト細胞であってもよく、ヒト細胞は、がん細胞、線維芽細胞、白血球、上皮細胞、扁平上皮細胞、筋芽細胞、筋肉細胞であり得る。いくつかの実施形態では、約23℃、相対大気湿度約50%で少なくとも約1カ月の期間、閉鎖した保存容器中で保存する場合、操作されたオリゴヌクレオチドまたはその塩の初期量の少なくとも約80%が残存し得る。いくつかの実施形態では、期間は約1カ月~約1年であり得る。いくつかの実施形態では、疾患または状態はがんを含み得る。いくつかの実施形態では、第1のRNAまたは第2のRNAの少なくとも一部はがん遺伝子によってコードされ得る。いくつかの実施形態では、がん遺伝子は、ABL1、ABL2、AKT1、AKT2、AKT3、ATF1、BCL11A、BCL2、BCL3、BCL6、BCR、BRAF、CARD11、CBLB、CBLC、CCND1、CCND2、CCND3、CDX2、CTNNB1、DDB2、BBIT3、BBX6、DEK、EGFR、ELK4、ERBB2、ERBB3、E2F1、ZEB1、ETV4、ETV6、EVI1、EWSR1、FEV、FGFR1、FGFR1OP、FGR2、FUS、GOLGA5、GOPC、HMGA1、HMGA2、HRAS、IRF4、ITGA6、JUN、KIT、KRAS、LCK、LMO2、MAF、MAFB、MAML2、MDM2、MET、MITF、MLL、MPL、MYB、MYC、MYCL1、MYCN、NCOA4、NFKB2、NR
AS、NTRK1、NUP214、PAX8、PDGFB、PIK3CA、PIM1、PLAG1、PPARG、PTPN11、RAF1、REL、RET、ROS1、SETDB1、SERPINE1、SMO、SS18、TCL1A、TET2、TFG、CDK6、ATG9A、TLX1、TPR、USP6、CSNK1G、KLF17、ARHGAP26、RAB11FIP1、RBJ、SERBP1、CTBP1、CRKL、ITGA3、ITGAV、LAMC1、G6PC2、PPP2R5Eまたはそれらのあらゆる組み合わせを含み得る。いくつかの実施形態では、がん遺伝子は、ITGA6、BCL2、DEK、PLAG1、SERPINE1、MYCN、LMO2、PIM1、EGFR、IRS1、NT5E、GLDC、SOCS1、STAT1、LOX、PDGFRB、WNT5A、CD80、CCNA1、THBS2、IGF1R、AFAP1L2、CTHRC1、MET、FAP、IL1A、GJA1、MYBL2またはそれらのあらゆる組み合わせを含み得る。いくつかの実施形態では、操作されたオリゴヌクレオチドまたはその塩は、多数のRNA配列のうち、ITGA6、SERPINE1、EGFR、MDTHまたはそれらのあらゆる組み合わせをコードするRNA配列に対して選択的であり得る。いくつかの実施形態では、疾患または状態は線維症を含み得る。いくつかの実施形態では、第1のRNAまたは第2のRNAの少なくとも一部は、コラーゲンスーパーファミリー遺伝子、血小板由来成長因子遺伝子、TGF-βシグナル伝達遺伝子、コラーゲンリモデリング遺伝子、細胞外マトリックスリモデリング遺伝子、Wntシグナル伝達遺伝子、肝癌由来成長因子(HDGF)シグナル伝達遺伝子またはそれらのあらゆる組み合わせによってコードされ得る。いくつかの実施形態では、第1のRNAまたは第2のRNAの少なくとも一部はコラーゲンスーパーファミリー遺伝子によってコードすることができ、コラーゲンスーパーファミリー遺伝子はCOL1A1、COL11A1、COL2A1、COL5A3、COL5A2、COL4A4、COL21A1、COL7A1、COL9A1、COL19A1、COL5A1、COL22A1、COL8A1、COL4A2、COL6A2、COL24A1、COL4A3、COL4A6、COL25A1、COL16A1、COL15A1およびこれらのあらゆる組み合わせからなる群から選択される。いくつかの実施形態では、第1のRNAまたは第2のRNAの少なくとも一部は血小板由来成長因子遺伝子によってコードされ、血小板由来成長因子遺伝子は、PDGFB、PDGFC、PDGFRB、およびそれらのあらゆる組み合わせからなる群から選択され得る。いくつかの実施形態では、第1のRNAまたは第2のRNAの少なくとも一部はTGF-βシグナル伝達遺伝子によってコードすることができ、TGF-βシグナル伝達遺伝子は、WISP1、TGFB2、またはそれらのあらゆる組み合わせである。いくつかの実施形態では、第1のRNAまたは第2のRNAの少なくとも一部はコラーゲンリモデリング遺伝子によってコードすることができ、コラーゲンリモデリング遺伝子はLOXL2である。いくつかの実施形態では、第1のRNAまたは第2のRNAの少なくとも一部は細胞外マトリックスリモデリング遺伝子によってコードすることができ、細胞外マトリックスリモデリング遺伝子は、COL1A1、COL11A1、COL2A1、COL5A3、COL5A2、COL4A4、COL21A1、COL7A1、COL9A1、COL19A1、COL5A1、COL22A1、COL8A1、COL4A2、COL6A2、COL24A1、COL4A3、COL4A6、COL25A1、COL16A1、COL15A1、LOXL2、エラスチン、およびそれらのあらゆる組み合わせからなる群から選択される。いくつかの実施形態では、第1のRNAまたは第2のRNAの少なくとも一部は、Wntシグナル伝達遺伝子によってコードすることができ、Wntシグナル伝達遺伝子はWISP1を含む。いくつかの実施形態では、第1のRNAまたは第2のRNAの少なくとも一部はHDGFシグナル伝達遺伝子によってコードすることができ、HDGFシグナル伝達遺伝子はHDGFを含む。いくつかの実施形態では、疾患または状態はウイルス感染を含み得る。いくつかの実施形態では、ウイルス感染はHCV遺伝子型1感染であり得る。いくつかの実施形態では、第1のRNAまたは第2のRNAの少なくとも一部はHCV遺伝子型1ゲノムにコードされ得る。いくつかの実施形態では、第1のRNAまたは第2のRNAは、BLASTペアワイズ配列アラインメントアルゴリズムによって決定した時に、配列番号587、配列番号588、または配列番号589に対して少なくとも約90%の配列同一性を含み得る。いくつかの実施形態では、ウイルス感染はコロナウイルス感染であり得る。いくつかの実施形態では、コロナウイルスはSARS-CoV-2であり得る。いくつかの実施形態では、第1のRNAまたは第2のRNAの少なくとも一部はSARS-CoV-2ゲノムにコードされ得る。いくつかの実施形態では、第1のRNAまたは第2のRNAは、配列番号500~配列番号531、配列番号829、配列番号830、または配列番号831のいずれか1つに対して少なくとも約90%の配列同一性を含み得る。いくつかの実施形態では、第1のRNAまたは第2のRNAは、BLASTペアワイズ配列アラインメントアルゴリズムによって決定した時に、配列番号500、配列番号513、または配列番号518に対して少なくとも約90%の配列同一性を含み得る。いくつかの実施形態では、コロナウイルスはSARS-CoVであり得る。いくつかの実施形態では、第1のRNAまたは第2のRNAの少なくとも一部はSARS-CoVゲノムにコードされ得る。いくつかの実施形態では、第1のRNAまたは第2のRNAは、配列番号474~配列番号499、配列番号826、配列番号827、または配列番号828のいずれか1つに対して少なくとも約90%の配列同一性を含み得る。いくつかの実施形態では、第1のRNAまたは第2のRNAは、BLASTペアワイズ配列アラインメントアルゴリズムによって決定した時に、配列番号476、配列番号481、または配列番号495に対して少なくとも約90%の配列同一性を含み得る。いくつかの実施形態では、コロナウイルスはMERS-CoVであり得る。いくつかの実施形態では、第1のRNAまたは第2のRNAの少なくとも一部はMERS-CoVゲノムにコードされ得る。いくつかの実施形態では、第1のRNAまたは第2のRNAは、配列番号532~配列番号554のいずれか1つに対して少なくとも約90%の配列同一性を含み得る。いくつかの実施形態では、コロナウイルスはCoV-HKU1であり得る。いくつかの実施形態では、第1のRNAまたは第2のRNAの少なくとも一部はCoV-HKU1ゲノムにコードされ得る。いくつかの実施形態では、第1のRNAまたは第2のRNAは、配列番号555~配列番号586のいずれか1つに対して少なくとも約90%の配列同一性を含み得る。いくつかの実施形態では、ウイルス感染はHIV感染であり得る。いくつかの実施形態では、第1のRNAまたは第2のRNAの少なくとも一部はHIVゲノムによってコードされ得る。いくつかの実施形態では、第1のRNAまたは第2のRNAは、BLASTペアワイズ配列アラインメントアルゴリズムによって決定した時に、配列番号470に対して少なくとも約90%の配列同一性を含み得る。いくつかの実施形態では、第1のRNAまたは第2のRNAは、BLASTペアワイズ配列アラインメントアルゴリズムによって決定した時に、配列番号471、配列番号472、または配列番号473に対して少なくとも約90%の配列同一性を含み得る。いくつかの実施形態では、疾患または状態は、筋ジストロフィーまたはミオパチーを含む神経筋障害を含み得る。いくつかの実施形態では、疾患または状態は、デュシェンヌ筋ジストロフィー(DMD)、筋緊張性ジストロフィー(MD)、顔面肩甲上腕筋ジストロフィー(FSHD)、肢帯型筋ジストロフィー(LGMD)、ベッカー筋ジストロフィー、眼咽頭型筋ジストロフィー、エメリ・ドレフュス筋ジストロフィー、または遠位型筋ジストフィーであり得る。いくつかの実施形態では、疾患または状態は、遺伝性または自然発生の常染色体優性突然変異に起因し得る。いくつかの実施形態では、第1のRNAまたは第2のRNAの少なくとも一部は、ジストロフィン、DMPK、CLCN1、CNBP、D4Z4リピート、DUX4、SMCHD1、DBET、SVIL、GAL3ST2、FRG1、CAPN3、DYSF、LMNA、PABPN1、PYGM、MYOD1、MYH7、HNRNPC、HNRNPA2B1、ACVR1、ASIC2、ATG14、ATP1A1、B3GTNL1、BANF1、BPTF、CASP8AP2、CDX4、CELF2、CHMP7、CKMT1B、CLASP1、CNOT3、COL15A1、CYP3A4、DCAF15、DCN、DLX5、DUSP7、DUX1、DUX5、EMILIN1、EPG5、FAM13A、FBX03、FBXL22、FMNL3、FREM2、FRMPD2、GADD45A、GID4、GJD3、GMPR、GNAT1、GOSR1、GPRC6A、HERC1、HGF、HOOK3、HOXC9、HSP40、IRF9、IRX5、ITGA10、ITGA3、ITGA9、KCNC3、KLHL3、KLK6、LARP6、MALT1、MAP3K4、MAPK10、MIR4661、MIR8078、MTSS1、NDUFAF6、NEBL、NKX2、NR2F1、PCID2、PDE10A、PKD1L2、PKHD1、PPP1R12B、PTPRN2、PYY、RABGAP1L、RBCK1、RFX3、RHBDF2、SCRIB、SEMA3B、SETD4、SHFL、SHH、SLC37A4、SLC9A8、SMAD1、SPEF1、SPRED3、ST3GAL6、STAG1、SUPV3L1、TBC1D26、TCEA2、TCF3、TM6SF1、TMEM108、TMEM259、TNFSF4、TNIP1、TRNP1、USH1G、WRNIP1、XIAP、ZNF574遺伝子またはそれらのあらゆる組み合わせにコードされ得る。いくつかの実施形態では、第1のRNAまたは第2のRNAは、BLASTペアワイズ配列アラインメントアルゴリズムによって決定した時に、配列番号901~配列番号949のいずれか1つに対して少なくとも約90%の配列同一性を含み得る。いくつかの実施形態では、操作されたオリゴヌクレオチド中のヌクレオチドの少なくとも1個の塩基は、第1のRNAまたは第2のRNAに相補的でなくてもよい。
また、本明細書では、本明細書に記載の操作されたオリゴヌクレオチドもしくはその塩、本明細書に記載の核酸構築物、または本明細書に記載のベクターを含み得る単離された細胞が開示される。
また、本明細書では、容器内の本明細書に記載の操作されたオリゴヌクレオチドまたはその塩、容器内の本明細書に記載の核酸構築物、容器内の本明細書に記載のベクター、または容器内の本明細書に記載の医薬組成物を含み得る、本明細書に記載のキットが開示される。
本明細書で言及されている全ての出版物、特許、および特許出願は、個々の出版物、特許、または特許出願が参照により組み込まれるように具体的かつ個別に示されている場合と同じ程度に、参照により本明細書に組み込まれる。参照により組み込まれる出版物および特許または特許出願が、本明細書に含まれる開示と矛盾する範囲において、本明細書は、そのような矛盾する材料に取って代わることおよび/または優先することが意図される。
例示的な実施形態の新規な特徴は、添付の特許請求の範囲に具体的に説明されている。特徴および利点のより良好な理解は、例示的な実施形態の原理が利用される例示的な実施形態を説明する以下の詳細な説明、およびその添付図面を参照することによって得られるであろう。
本明細書または添付の配列表に記載された、あらゆる核酸およびアミノ酸の配列は、米国特許法施行規則1.822に定義されるように、ヌクレオチド塩基およびアミノ酸の標準文字略号を用いて表示される。
配列番号1~37は、典型的な成熟miRNAのヌクレオチド配列である。
配列番号38~45、52~89、および624~825は、修飾されたmiR-30ガイド鎖ヌクレオチド配列である。
配列番号46~51、90~99、および900は、修飾されたmiR-30パッセンジャー鎖ヌクレオチド配列である。
配列番号100~154、620、および835~837は、修飾されたmiR-29ガイド鎖ヌクレオチド配列である。
配列番号155~183および838~839は、修飾されたmiR-29パッセンジャー鎖ヌクレオチド配列である。
配列番号184~201は、修飾されたmiR-26ガイド鎖ヌクレオチド配列である。
配列番号202~204は、修飾されたmiR-26パッセンジャー鎖ヌクレオチド配列である。
配列番号205~222は、修飾されたmiR-27ガイド鎖ヌクレオチド配列である。
配列番号223~224は、修飾されたmiR-27パッセンジャー鎖ヌクレオチド配列である。
配列番号225~233は、修飾されたmiR-101ガイド鎖ヌクレオチド配列である。
配列番号234は、修飾されたmiR-101パッセンジャー鎖ヌクレオチド配列である。
配列番号235~243は、修飾されたmiR-145ガイド鎖ヌクレオチド配列である。
配列番号244は、修飾されたmiR-145パッセンジャー鎖ヌクレオチド配列である。
配列番号245~443および840~899は、修飾されたmiR-205ガイド鎖ヌクレオチド配列である。
配列番号444は、修飾されたmiR-205パッセンジャー鎖ヌクレオチド配列である。
配列番号445~453は、修飾されたmiR-338ガイド鎖ヌクレオチド配列である。
配列番号454は、修飾されたmiR-338パッセンジャー鎖ヌクレオチド配列である。
配列番号455~463は、修飾されたmiR-375ガイド鎖ヌクレオチド配列である。
配列番号464は、修飾されたmiR-375パッセンジャー鎖ヌクレオチド配列である。
配列番号465は、操作されたガイド鎖ヌクレオチド配列である。
配列番号466は、操作されたパッセンジャー鎖ヌクレオチド配列である。
配列番号901~949は、アンチセンスヌクレオチド配列である。
配列番号467~619、621~623、826~834、950~1120は、標的ヌクレオチド配列である。
定義
別途明示しない限り、非限定用語、例えば「含有する(contain)」、「含有すること(containing)」、「含む(include)」、「含むこと(including)」等とは、「含むこと(comprising)」を意味する。
本明細書で使用される場合、「約」または「およそ」という用語は、当業者によって決定される特定の値に対する許容誤差範囲内を意味し得、これは、値が測定または決定される方法、例えば、測定システムの限界に部分的に依存するであろう。例えば、「約」は、当技術分野における実施ごとに、プラスマイナス10%を意味し得る。あるいは、「約」は、所定の値のプラスもしくはマイナス20%、プラスもしくはマイナス10%、プラスもしくはマイナス5%、またはプラスもしくはマイナス1%の範囲を意味し得る。あるいは、特に生物システムまたはプロセスに関しては、この用語は、ある値の1桁以内、5倍以内、または2倍以内を意味し得る。本出願および特許請求の範囲に特定の値が記載されている場合、特に示さない限り、特定の値について許容される誤差範囲内を意味する「約」という用語が想定されるべきである。また、値の範囲および/または部分的な範囲が提供される場合、範囲および/または部分的な範囲は、範囲および/または部分的な範囲の終点を含み得る。
「相同性」という用語は、参照配列に対する配列の%同一性を意味し得る。実際問題として、あらゆる特定の配列が本明細書に記載のあらゆる配列と少なくとも50%、60%、70%、80%、85%、90%、92%、95%、96%、97%、98%または99%同一であり得るか(これは本明細書に記載の特定の核酸配列に対応し得る)、このような特定のポリペプチド配列は、伝統的な方法で、Bestfitプログラム(Wisconsin Sequence Analysis Package, Version 8 for Unix、Genetics Computer Group, University Research Park、575 Science Drive, Madison, Wis. 53711)等の公知のコンピュータプログラムを使用して決定し得る。Bestfitまたは他の配列アラインメントプログラムを使用して、特定の配列が例えば参照配列と95%同一であるかどうかを決定する場合、パラメータは、同一性の割合が参照配列の全長にわたって計算され、参照配列全体の5%までの相同性のギャップが許容されるように設定し得る。
miRNAは配列類似性に基づいてファミリーに分類されるため、変異配列は「非天然」または「人工」のmiRNAファミリーメンバーであり得る。
オリゴヌクレオチドは糖修飾を含み得る。オリゴヌクレオチドは、複数の糖修飾を含み得る。糖修飾は、グルコースまたはその誘導体を含み得る。糖修飾は、リボースまたはデオキシリボースを含み得る。糖修飾は、単糖、二糖、三糖、またはそれらのあらゆる組み合わせを含み得る。
いくつかの例では、操作されたオリゴヌクレオチドは、2’位で化学修飾され得る、化学修飾されたヌクレオチドを含み得る。化学修飾されたオリゴヌクレオチドは、2’炭素原子において置換基を含むことが可能であり、この置換基は、ハロゲン、アルコキシ基、水素、アリールオキシ基、アミノ基またはアミノアルコキシ基、例えば2’-水素(2’-デオキシ)、2’-O-メチル、2’-O-メトキシエチル、2’-フルオロ、2’メトキシエチル、2’-フルオロ、ロックド核酸またはそのあらゆる組み合わせを含み得る。
いくつかの例では、操作されたオリゴヌクレオチドは、少なくとも1個の化学修飾ヌクレオチドを含む場合があり、操作されたオリゴヌクレオチドに組み込まれ得るリン酸骨格が修飾され得る。骨格の1個または複数のリン酸基は、例えば、1個または複数の酸素原子を異なる置換基で置換することによって、修飾され得る。さらに、修飾ヌクレオチドは、本明細書に記載されるように、非修飾リン酸部分の修飾リン酸への完全な置換を含み得る。修飾リン酸基の例としては、ホスホロチオエート、メチルホスホネート、ホスホロセレネート、ボラノホスフェート、ボラノホスフェートエステル、ホスホン酸水素、ホスホロアミデート、アルキルホスホネート、アリールホスホネートまたはホストリエステルを含み得る。リン酸リンカーは、連結酸素を窒素(架橋ホスホロアミデート)、硫黄(架橋ホスホロチオエート)および炭素(架橋メチレンホスホネート)に置換することによっても修飾し得る。
本明細書に記載の第2の鎖は、操作されたオリゴヌクレオチドについて本明細書に記載の方法と同じ方法で化学修飾し得る。いくつかの例では、第2の鎖は、化学修飾される場合、配列番号51、95~99のいずれか1つに対して、少なくとも90%の配列同一性を有し得る。
配列番号500~531、829~831(表6)は、COVID-19コロナウイルス(SARS-CoV-2)ゲノムRNA中のmiR-29標的配列を示す。例えば、配列番号500または配列番号502で示されるCOVID-19ゲノムの標的配列は、1種以上のmiR-29構築物等、本明細書に記載される1種または複数種の構築物によって標的とされ得る。
配列番号532~554(表6)は、MERSコロナウイルス(MERS-CoV)ゲノムRNAにおけるmiR-29の標的配列を示す。例えば、配列番号535または配列番号537で示されるMERSゲノムの標的配列は、1種以上のmiR-29構築物等、本明細書に記載される1種または複数種の構築物によって標的とされ得る。
本開示は、本開示の方法を実施するようにプログラムされたコンピュータ制御システムを提供する。図29は、がん治療薬または抗ウイルス治療薬等の治療効果に対する種々の構築物の有効性を予測または確認するようにプログラムされるか、または他の方法で構成されたコンピュータシステム101を示す。コンピュータシステム101は、例えば、種々の治療標的に対する構築物のモデリングまたは同定、構築物の有効性または安定性のモデリング、またはそれらのあらゆる組み合わせ等、本開示の種々の態様を調節し得る。コンピュータシステム101は、ユーザーの電子デバイス、または電子デバイスに関して遠隔に位置するコンピュータシステムであり得る。電子デバイスは、モバイル電子デバイスであり得る。
CPU105は、回路、例えば集積回路の一部であり得る。システム101の1または複数の他のコンポーネントを回路に含み得る。いくつかの例では、回路は、特定用途向け集積回路(ASIC)である。
コンピュータシステム101は、ネットワーク130を介して1または複数のリモートコンピュータシステムと通信し得る。例えば、コンピュータシステム101は、ユーザーのリモートコンピュータシステムと通信し得る。リモートコンピュータシステムの例には、パーソナルコンピュータ(例えば、ポータブルPC)、スレートもしくはタブレットPC(例えば、Apple(登録商標)iPad、Samsung(登録商標)Galaxy Tab)、電話、スマートフォン(例えば、Apple(登録商標)iPhone、アンドロイド対応機器、Blackberry(登録商標))、または携帯情報端末等が挙げられる。ユーザーは、ネットワーク130を介してコンピュータシステム101にアクセスし得る。
Claims (119)
- ポリヌクレオチド配列を含む操作されたオリゴヌクレオチドまたはその塩であって、操作されたオリゴヌクレオチドまたはその塩は、疾患または状態に関連する2種の遺伝子座に由来する少なくとも第1のRNAおよび第2のRNAの少なくとも一部と少なくとも部分的に相補的であり、操作されたオリゴヌクレオチドまたはその塩が第1のRNAに少なくとも部分的に結合する場合、操作されたオリゴヌクレオチド中の少なくとも7個の連続した塩基の第1の領域は、第1のRNA内に含まれる連続した核酸に相補的であり、操作されたオリゴヌクレオチド中の少なくとも5個の連続した塩基の第2の領域は、第1のRNA内に含まれる連続した核酸に相補的であり、操作されたオリゴヌクレオチドまたはその塩が第2のRNAに少なくとも部分的に結合する場合、操作されたオリゴヌクレオチド中の少なくとも7個の連続した塩基の第1の領域は、第2のRNA内に含まれる連続したヌクレオチドに相補的であり、操作されたオリゴヌクレオチド中の少なくとも5個の連続した塩基の第2の領域は、第2のRNA内に含まれる連続したヌクレオチドに相補的であり、操作されたオリゴヌクレオチドの第1のRNAおよび第2のRNAへの結合の予測されるギブス自由エネルギー(ΔG)は、個別に、約37℃および約7.2~約7.6の範囲のpHで約-17~約-36kcal mol-1の範囲である、操作されたオリゴヌクレオチドまたはその塩。
- アンチセンスオリゴヌクレオチド、合成マイクロRNA(miRNA)、または低分子干渉RNA(siRNA)である、請求項1に記載の操作されたオリゴヌクレオチドまたはその塩。
- 1個または複数の他の同等な非コードRNA(ncRNA)に対して、1個または複数のヌクレオチド挿入、ヌクレオチド欠失、ヌクレオチド置換、またはそのあらゆる組み合わせを含む、請求項1に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAに少なくとも部分的に結合した場合、約37℃および約7.2~約7.6の範囲のpHで、第1のRNAまたは第2のRNAに結合する他の同等なncRNAの結合のギブス自由エネルギー(ΔG)と比較して、約37℃および約7.2~約7.6の範囲のpHでの結合のΔGが少なくとも約10%低い、請求項3に記載の操作されたオリゴヌクレオチドまたはその塩。
- 約5~約50ヌクレオチド長である、請求項1~4のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩。
- リボース糖を含む、請求項1~5のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩。
- デオキシリボース糖を含む、請求項1~6のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩。
- ncRNAが、miR-30マイクロRNA(miRNA)、miR-29miRNA、miR-26miRNA、miR-27miRNA、miR-101miRNA、miR-145miRNA、miR-205miRNA、miR-338miRNA、またはmiR-375miRNAである、請求項4~7のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩。
- BLASTペアワイズ配列アラインメントアルゴリズムによって決定した時に、配列番号1、配列番号2、配列番号3、配列番号4、配列番号5、配列番号12、配列番号13、配列番号14、配列番号19、配列番号20、配列番号24、配列番号25、配列番号28、配列番号30、配列番号32、配列番号34、配列番号36、配列番号38、配列番号39、配列番号40、配列番号41、配列番号42、配列番号43、配列番号44、配列番号45、配列番号100、配列番号101、配列番号102、配列番号103、配列番号104、配列番号105、配列番号106、配列番号107、配列番号108、配列番号109、配列番号110、配列番号111、配列番号112、配列番号113、配列番号114、配列番号115、配列番号116、配列番号117、配列番号118、配列番号119、配列番号120、配列番号121、配列番号122、配列番号123、配列番号124、配列番号125、配列番号126、配列番号245、配列番号246、配列番号247、配列番号248、配列番号249、配列番号250、配列番号251、配列番号252、配列番号253、配列番号254、配列番号255、配列番号256、配列番号257、配列番号258、配列番号259、配列番号260、配列番号261、配列番号262、配列番号263、配列番号465、配列番号624、配列番号625、配列番号626、配列番号627、配列番号628、配列番号629、配列番号630、配列番号631、配列番号632、配列番号633、配列番号634、配列番号635、配列番号636、配列番号637、配列番号638、配列番号639、配列番号640、配列番号641、配列番号642、配列番号643、配列番号840、配列番号841、配列番号842、配列番号843、配列番号844、配列番号845、配列番号901、配列番号902、配列番号903、配列番号904、配列番号905、配列番号906、配列番号907、配列番号908、配列番号909、配列番号910、配列番号911、配列番号912、配列番号913、配列番号914、配列番号915、配列番号916、配列番号917、配列番号918、配列番号919、配列番号920、配列番号921、配列番号922、配列番号923、配列番号924、配列番号925、配列番号926、配列番号927、配列番号928、配列番号929、配列番号930、配列番号931、配列番号932、配列番号933、配列番号934、配列番号935、配列番号936、配列番号937、配列番号938、配列番号939、配列番号940、配列番号941、配列番号942、配列番号943、配列番号944、配列番号945、配列番号946、配列番号947、配列番号948、または配列番号949のいずれか1つに対して少なくとも90%の配列同一性を有する、請求項1~8のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩。
- 操作されたオリゴヌクレオチドが、約6.5~約7.6の範囲のpH、約15℃~約37℃の範囲の温度で、水溶液中にステムループを含む二次構造を形成する、請求項1~9のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩。
- 天然に存在する塩基、糖、骨格、またはリン酸結合に対して化学修飾された塩基、化学修飾された糖、化学修飾された骨格またはリン酸結合、またはそれらのあらゆる組み合わせを含む、請求項1~10のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩。
- 化学修飾が、メチル基、フルオロ基、メトキシエチル基、エチル基、ヒドロキシメチル基、ホルミル基、架橋型核酸、ロックド核酸、カルボン酸またはその塩、ホスホチオネート修飾骨格、メチルホスホネート修飾骨格、アミノアルキル鎖修飾、およびこれらのあらゆる組み合わせからなる群から選択される、請求項11に記載の操作されたオリゴヌクレオチドまたはその塩。
- 化学修飾された場合、
式:
(N)a(mN)b(N)cNN;
(N)a(mN)b(N)csfNsmN;または
(fNmN)h(mN)i(fNmN)jsfNsmN(式中、
各Nは独立して、ウラシル、グアニン、アデニン、シトシン、または他の天然ヌクレオチドであり;
各mNは独立して2’-Oメチル修飾ウラシル、グアニン、アデニン、またはシトシンであり;
各sは独立して、ホスホチオネート修飾骨格であり;
各fNは独立して、2’フルオロ修飾ウラシル、グアニン、アデニン、またはシトシンであり;
各aは8~10であり、各bは7~10であり、各cは2~4であり、各hは5~7であり、各iは0または1であり、各jは3~4である)
を含む、請求項11または12に記載の操作されたオリゴヌクレオチドまたはその塩。 - BLASTペアワイズ配列アラインメントアルゴリズムによって決定した時に、配列番号52、配列番号53、配列番号54、配列番号55、配列番号56、配列番号57、配列番号58、配列番号59、配列番号60、配列番号61、配列番号62、配列番号63、配列番号64、配列番号65、配列番号66、配列番号67、配列番号68、配列番号69、配列番号70、配列番号71、配列番号72、配列番号73、配列番号74、配列番号75、配列番号76、配列番号77、配列番号78、配列番号79、配列番号80、配列番号81、配列番号82、配列番号83、配列番号84、配列番号85、配列番号86、配列番号87、配列番号88、配列番号89、配列番号127、配列番号128、配列番号129、配列番号130、配列番号131、配列番号132、配列番号133、配列番号134、配列番号135、配列番号136、配列番号137、配列番号138、配列番号139、配列番号140、配列番号141、配列番号142、配列番号143、配列番号144、配列番号145、配列番号146、配列番号147、配列番号148、配列番号149、配列番号150、配列番号151、配列番号152、配列番号153、配列番号154、配列番号184、配列番号185、配列番号186、配列番号187、配列番号188、配列番号189、配列番号190、配列番号191、配列番号192、配列番号193、配列番号194、配列番号195、配列番号196、配列番号197、配列番号198、配列番号199、配列番号200、配列番号201、配列番号205、配列番号206、配列番号207、配列番号208、配列番号209、配列番号210、配列番号211、配列番号212、配列番号213、配列番号214、配列番号215、配列番号216、配列番号217、配列番号218、配列番号219、配列番号220、配列番号221、配列番号222、配列番号225、配列番号226、配列番号227、配列番号228、配列番号229、配列番号230、配列番号231、配列番号232、配列番号233、配列番号235、配列番号236、配列番号237、配列番号238、配列番号239、配列番号240、配列番号241、配列番号242、配列番号243、配列番号264、配列番号265、配列番号266、配列番号267、配列番号268、配列番号269、配列番号270、配列番号271、配列番号272、配列番号273、配列番号274、配列番号275、配列番号276、配列番号277、配列番号278、配列番号279、配列番号280、配列番号281、配列番号282、配列番号283、配列番号284、配列番号285、配列番号286、配列番号287、配列番号288、配列番号289、配列番号290、配列番号291、配列番号292、配列番号293、配列番号294、配列番号295、配列番号296、配列番号297、配列番号298、配列番号299、配列番号300、配列番号301、配列番号302、配列番号303、配列番号304、配列番号305、配列番号306、配列番号307、配列番号308、配列番号309、配列番号310、配列番号311、配列番号312、配列番号313、配列番号314、配列番号315、配列番号316、配列番号317、配列番号318、配列番号319、配列番号320、配列番号321、配列番号322、配列番号323、配列番号324、配列番号325、配列番号326、配列番号327、配列番号328、配列番号329、配列番号330、配列番号331、配列番号332、配列番号333、配列番号334、配列番号335、配列番号336、配列番号337、配列番号338、配列番号339、配列番号340、配列番号341、配列番号342、配列番号343、配列番号344、配列番号345、配列番号346、配列番号347、配列番号348、配列番号349、配列番号350、配列番号351、配列番号352、配列番号353、配列番号354、配列番号355、配列番号356、配列番号357、配列番号358、配列番号359、配列番号360、配列番号361、配列番号362、配列番号363、配列番号364、配列番号365、配列番号366、配列番号367、配列番号368、配列番号369、配列番号370、配列番号371、配列番号372、配列番号373、配列番号374、配列番号375、配列番号376、配列番号377、配列番号378、配列番号379、配列番号380、配列番号381、配列番号382、配列番号383、配列番号384、配列番号385、配列番号386、配列番号387、配列番号388、配列番号389、配列番号390、配列番号391、配列番号392、配列番号393、配列番号394、配列番号395、配列番号396、配列番号397、配列番号398、配列番号399、配列番号400、配列番号401、配列番号402、配列番号403、配列番号404、配列番号405、配列番号406、配列番号407、配列番号408、配列番号409、配列番号410、配列番号411、配列番号412、配列番号413、配列番号414、配列番号415、配列番号416、配列番号417、配列番号418、配列番号419、配列番号420、配列番号421、配列番号422、配列番号423、配列番号424、配列番号425、配列番号426、配列番号427、配列番号428、配列番号429、配列番号430、配列番号431、配列番号432、配列番号433、配列番号434、配列番号435、配列番号436、配列番号437、配列番号438、配列番号439、配列番号440、配列番号441、配列番号442、配列番号443、配列番号445、配列番号446、配列番号447、配列番号448、配列番号449、配列番号450、配列番号451、配列番号452、配列番号453、配列番号455、配列番号456、配列番号457、配列番号458、配列番号459、配列番号460、配列番号461、配列番号462、配列番号463、配列番号620、配列番号644、配列番号645、配列番号646、配列番号647、配列番号648、配列番号649、配列番号650、配列番号651、配列番号652、配列番号653、配列番号654、配列番号655、配列番号656、配列番号657、配列番号658、配列番号659、配列番号660、配列番号661、配列番号662、配列番号663、配列番号664、配列番号665、配列番号666、配列番号667、配列番号668、配列番号669、配列番号670、配列番号671、配列番号672、配列番号673、配列番号674、配列番号675、配列番号676、配列番号677、配列番号678、配列番号679、配列番号680、配列番号681、配列番号682、配列番号683、配列番号684、配列番号685、配列番号686、配列番号687、配列番号688、配列番号689、配列番号690、配列番号691、配列番号692、配列番号693、配列番号694、配列番号695、配列番号696、配列番号697、配列番号698、配列番号699、配列番号700、配列番号701、配列番号702、配列番号703、配列番号704、配列番号705、配列番号706、配列番号707、配列番号708、配列番号709、配列番号710、配列番号711、配列番号712、配列番号713、配列番号714、配列番号715、配列番号716、配列番号717、配列番号718、配列番号719、配列番号720、配列番号721、配列番号722、配列番号723、配列番号724、配列番号725、配列番号726、配列番号727、配列番号728、配列番号729、配列番号730、配列番号731、配列番号732、配列番号733、配列番号734、配列番号735、配列番号736、配列番号737、配列番号738、配列番号739、配列番号740、配列番号741、配列番号742、配列番号743、配列番号744、配列番号745、配列番号746、配列番号747、配列番号748、配列番号749、配列番号750、配列番号751、配列番号752、配列番号753、配列番号754、配列番号755、配列番号756、配列番号757、配列番号758、配列番号759、配列番号760、配列番号761、配列番号762、配列番号763、配列番号764、配列番号765、配列番号766、配列番号767、配列番号768、配列番号769、配列番号770、配列番号771、配列番号772、配列番号773、配列番号774、配列番号775、配列番号776、配列番号777、配列番号778、配列番号779、配列番号780、配列番号781、配列番号782、配列番号783、配列番号784、配列番号785、配列番号786、配列番号787、配列番号788、配列番号789、配列番号790、配列番号791、配列番号792、配列番号793、配列番号794、配列番号795、配列番号796、配列番号797、配列番号798、配列番号799、配列番号800、配列番号801、配列番号802、配列番号803、配列番号804、配列番号805、配列番号806、配列番号807、配列番号808、配列番号809、配列番号810、配列番号811、配列番号812、配列番号813、配列番号814、配列番号815、配列番号816、配列番号817、配列番号818、配列番号819、配列番号820、配列番号821、配列番号822、配列番号823、配列番号824、配列番号825、配列番号835、配列番号836、配列番号837、配列番号846、配列番号847、配列番号848、配列番号849、配列番号850、配列番号851、配列番号852、配列番号853、配列番号854、配列番号855、配列番号856、配列番号857、配列番号858、配列番号859、配列番号860、配列番号861、配列番号862、配列番号863、配列番号864、配列番号865、配列番号866、配列番号867、配列番号868、配列番号869、配列番号870、配列番号871、配列番号872、配列番号873、配列番号874、配列番号875、配列番号876、配列番号877、配列番号878、配列番号879、配列番号880、配列番号881、配列番号882、配列番号883、配列番号884、配列番号885、配列番号886、配列番号887、配列番号888、配列番号889、配列番号890、配列番号891、配列番号892、配列番号893、配列番号894、配列番号895、配列番号896、配列番号897、配列番号898、または配列番号899のいずれか1つに対して少なくとも90%の配列同一性を有する、請求項11~13のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩。
- 操作されたオリゴヌクレオチド配列が、糖、塩基、または骨格の修飾を含む、請求項11に記載の操作されたオリゴヌクレオチドまたはその塩。
- 修飾がリンカーを含む、請求項15に記載の操作されたオリゴヌクレオチドまたはその塩。
- リンカーが共有結合性リンカーである、請求項16に記載の操作されたオリゴヌクレオチドまたはその塩。
- リンカーが、切断可能なリンカーである、請求項16に記載の操作されたオリゴヌクレオチドまたはその塩。
- リンカーは、コンジュゲートを含むようにさらに修飾されている、請求項16~18のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩。
- コンジュゲートが、抗体、天然に存在するリガンド、低分子、またはペプチドである、請求項19に記載の操作されたオリゴヌクレオチドまたはその塩。
- コンジュゲートが、薬物またはその塩である、請求項19に記載の操作されたオリゴヌクレオチドまたはその塩。
- 操作されたオリゴヌクレオチドが、グリカンでグリコシル化されているヌクレオチドの塩基を含む、請求項1~21のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAが、mRNA配列を少なくとも部分的に含む、請求項1~22のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩。
- mRNA配列と接触させた場合、
a. mRNA配列を含む第1の単離された哺乳動物細胞に、操作されたオリゴヌクレオチドまたはその塩をトランスフェクトし、
b. mRNA配列を含む第2の単離された哺乳動物細胞に、ncRNAをトランスフェクトし、
c. 同じタイプの哺乳動物細胞である、第1の単離された哺乳動物細胞および第2の単離された哺乳動物細胞中に発現するポリペプチドの量を測定すること
により決定した時に、等量のncRNAをmRNA配列と接触させた場合と比較して、mRNA配列によりコードされるポリペプチドの発現が約1.2分の1以下となるように産生する、請求項23に記載の操作されたオリゴヌクレオチドまたはその塩。 - mRNA配列と接触させた場合、
a. mRNA配列を含む第1の単離された哺乳動物細胞に、操作されたオリゴヌクレオチドまたはその塩をトランスフェクトし、
b. mRNA配列を含む第2の単離された哺乳動物細胞に、ncRNAをトランスフェクトし、
c. 同じタイプの哺乳動物細胞である、第1の単離された哺乳動物細胞および第2の単離された哺乳動物細胞中に発現するポリペプチドからの活性量を測定すること
により決定した時に、等量のncRNAをmRNA配列と接触させた場合と比較して、mRNA配列によりコードされるポリペプチドの活性が約1.2分の1以下となるように産生する、請求項23に記載の操作されたオリゴヌクレオチドまたはその塩。 - mRNA配列と接触させた場合、
a. mRNA配列を含む第1の単離された哺乳動物細胞に、操作されたオリゴヌクレオチドまたはその塩をトランスフェクトし、
b. mRNA配列を含む第2の単離された哺乳動物細胞に、ncRNAをトランスフェクトし、
c. 第1の単離された哺乳動物細胞および第2の単離された哺乳動物細胞中に発現するポリペプチドの量を測定すること
により決定した時に、等量のncRNAを接触させた場合と比較して、mRNA配列によりコードされるポリペプチドの発現が約1.2分の1~約10分の1となるように産生する、請求項24に記載の操作されたオリゴヌクレオチドまたはその塩。 - mRNA配列と接触させた場合、
a. mRNA配列を含む第1の単離された哺乳動物細胞に、操作されたオリゴヌクレオチドまたはその塩をトランスフェクトし、
b. mRNA配列を含む第2の単離された哺乳動物細胞に、ncRNAをトランスフェクトし、
c. 第1の単離された哺乳動物細胞および第2の単離された哺乳動物細胞中に発現するポリペプチドからの活性量を測定すること
により決定した時に、等量のncRNAを接触させた場合と比較して、mRNA配列によりコードされるポリペプチドの活性が約1.2分の1~約10分の1となるように産生する、請求項25に記載の操作されたオリゴヌクレオチドまたはその塩。 - 第1の単離された哺乳動物細胞および第2の単離された哺乳動物細胞が、ヒト細胞またはマウス細胞である、請求項24~27のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1の単離された哺乳動物細胞がヒト細胞であり、ヒト細胞が、がん細胞、線維芽細胞、白血球、上皮細胞、扁平上皮細胞、筋芽細胞、筋肉細胞である、請求項28に記載の操作されたオリゴヌクレオチドまたはその塩。
- 約23℃、相対大気湿度約50%で少なくとも約1カ月の期間、閉鎖した保存容器中で保存する場合、操作されたオリゴヌクレオチドまたはその塩の初期量の少なくとも約80%が残存する、請求項1~29のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩。
- 期間が約1カ月~約1年である、請求項30に記載の操作されたオリゴヌクレオチドまたはその塩。
- 疾患または状態ががんを含む、請求項1~31のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAの少なくとも一部ががん遺伝子によってコードされている、請求項32に記載の操作されたオリゴヌクレオチドまたはその塩。
- がん遺伝子が、ABL1、ABL2、AKT1、AKT2、AKT3、ATF1、BCL11A、BCL2、BCL3、BCL6、BCR、BRAF、CARD11、CBLB、CBLC、CCND1、CCND2、CCND3、CDX2、CTNNB1、DDB2、BBIT3、BBX6、DEK、EGFR、ELK4、ERBB2、ERBB3、E2F1、ZEB1、ETV4、ETV6、EVI1、EWSR1、FEV、FGFR1、FGFR1OP、FGR2、FUS、GOLGA5、GOPC、HMGA1、HMGA2、HRAS、IRF4、ITGA6、JUN、KIT、KRAS、LCK、LMO2、MAF、MAFB、MAML2、MDM2、MET、MITF、MLL、MPL、MYB、MYC、MYCL1、MYCN、NCOA4、NFKB2、NRAS、NTRK1、NUP214、PAX8、PDGFB、PIK3CA、PIM1、PLAG1、PPARG、PTPN11、RAF1、REL、RET、ROS1、SETDB1、SERPINE1、SMO、SS18、TCL1A、TET2、TFG、CDK6、ATG9A、TLX1、TPR、USP6、CSNK1G、KLF17、ARHGAP26、RAB11FIP1、RBJ、SERBP1、CTBP1、CRKL、ITGA3、ITGAV、LAMC1、G6PC2、PPP2R5Eまたはそれらのあらゆる組み合わせを含む、請求項33に記載の操作されたオリゴヌクレオチドまたはその塩。
- がん遺伝子が、ITGA6、BCL2、DEK、PLAG1、SERPINE1、MYCN、LMO2、PIM1、EGFR、IRS1、NT5E、GLDC、SOCS1、STAT1、LOX、PDGFRB、WNT5A、CD80、CCNA1、THBS2、IGF1R、AFAP1L2、CTHRC1、MET、FAP、IL1A、GJA1、MYBL2またはそれらのあらゆる組み合わせを含む、請求項33に記載の操作されたオリゴヌクレオチドまたはその塩。
- 多数のRNA配列のうち、ITGA6、SERPINE1、EGFR、MDTHまたはそれらのあらゆる組み合わせをコードするRNA配列に対して選択的である、請求項33に記載の操作されたオリゴヌクレオチドまたはその塩。
- 疾患または状態が線維症を含む、請求項1~31のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAの少なくとも一部が、コラーゲンスーパーファミリー遺伝子、血小板由来成長因子遺伝子、TGF-βシグナル伝達遺伝子、コラーゲンリモデリング遺伝子、細胞外マトリックスリモデリング遺伝子、Wntシグナル伝達遺伝子、肝癌由来成長因子(HDGF)シグナル伝達遺伝子またはそれらのあらゆる組み合わせによってコードされている、請求項37に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAの少なくとも一部がコラーゲンスーパーファミリー遺伝子によってコードされ、コラーゲンスーパーファミリー遺伝子がCOL1A1、COL11A1、COL2A1、COL5A3、COL5A2、COL4A4、COL21A1、COL7A1、COL9A1、COL19A1、COL5A1、COL22A1、COL8A1、COL4A2、COL6A2、COL24A1、COL4A3、COL4A6、COL25A1、COL16A1、COL15A1およびこれらのあらゆる組み合わせからなる群から選択される、請求項38に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAの少なくとも一部が血小板由来成長因子遺伝子によってコードされ、血小板由来成長因子遺伝子が、PDGFB、PDGFC、PDGFRB、およびそれらのあらゆる組み合わせからなる群から選択される、請求項38に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAの少なくとも一部がTGF-βシグナル伝達遺伝子によってコードされ、TGF-βシグナル伝達遺伝子が、WISP1、TGFB2、またはそれらのあらゆる組み合わせである、請求項38に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAの少なくとも一部がコラーゲンリモデリング遺伝子によってコードされ、コラーゲンリモデリング遺伝子がLOXL2である、請求項38に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAの少なくとも一部が細胞外マトリックスリモデリング遺伝子によってコードされ、細胞外マトリックスリモデリング遺伝子がCOL1A1、COL11A1、COL2A1、COL5A3、COL5A2、COL4A4、COL21A1、COL7A1、COL9A1、COL19A1、COL5A1、COL22A1、COL8A1、COL4A2、COL6A2、COL24A1、COL4A3、COL4A6、COL25A1、COL16A1、COL15A1、LOXL2、エラスチン、およびそれらのあらゆる組み合わせからなる群から選択される、請求項38に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAの少なくとも一部が、Wntシグナル伝達遺伝子によってコードされ、Wntシグナル伝達遺伝子がWISP1を含む、請求項38に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAの少なくとも一部がHDGFシグナル伝達遺伝子によってコードされ、HDGFシグナル伝達遺伝子がHDGFを含む、請求項38に記載の操作されたオリゴヌクレオチドまたはその塩。
- 疾患または状態がウイルス感染を含む、請求項1~31のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩。
- ウイルス感染がHCV遺伝子型1感染である、請求項46に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAの少なくとも一部がHCV遺伝子型1ゲノムにコードされている、請求項47に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAが、BLASTペアワイズ配列アラインメントアルゴリズムによって決定した時に、配列番号587、配列番号588、または配列番号589に対して少なくとも約90%の配列同一性を含む、請求項47または48に記載の操作されたオリゴヌクレオチドまたはその塩。
- ウイルス感染が、コロナウイルス感染である、請求項46に記載の操作されたオリゴヌクレオチドまたはその塩。
- コロナウイルスがSARS-CoV-2である、請求項50に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAの少なくとも一部がSARS-CoV-2ゲノムにコードされている、請求項50に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAが、配列番号500~配列番号531、配列番号829、配列番号830、または配列番号831のいずれか1つに対して少なくとも約90%の配列同一性を含む、請求項51または52に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAが、BLASTペアワイズ配列アラインメントアルゴリズムによって決定した時に、配列番号500、配列番号513、または配列番号518に対して少なくとも約90%の配列同一性を含む、請求項51または52に記載の操作されたオリゴヌクレオチドまたはその塩。
- コロナウイルスがSARS-CoVである、請求項50に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAの少なくとも一部がSARS-CoVゲノムにコードされている、請求項50に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAが、配列番号474~配列番号499、配列番号826、配列番号827、または配列番号828のいずれか1つに対して少なくとも約90%の配列同一性を含む、請求項55または56に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAが、BLASTペアワイズ配列アラインメントアルゴリズムによって決定した時に、配列番号476、配列番号481、または配列番号495に対して少なくとも約90%の配列同一性を含む、請求項55または56に記載の操作されたオリゴヌクレオチドまたはその塩。
- コロナウイルスがMERS-CoVである、請求項50に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAの少なくとも一部がMERS-CoVゲノムにコードされている、請求項50に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAが、配列番号532~配列番号554のいずれか1つに対して少なくとも約90%の配列同一性を含む、請求項59または60に記載の操作されたオリゴヌクレオチドまたはその塩。
- コロナウイルスがCoV-HKU1である、請求項50に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAの少なくとも一部がCoV-HKU1ゲノムにコードされている、請求項50に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAが、配列番号555~配列番号586のいずれか1つに対して少なくとも約90%の配列同一性を含む、請求項62または63に記載の操作されたオリゴヌクレオチドまたはその塩。
- ウイルス感染がHIV感染である、請求項46に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAの少なくとも一部がHIVゲノムによってコードされている、請求項46に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAが、BLASTペアワイズ配列アラインメントアルゴリズムによって決定した時に、配列番号470に対して少なくとも約90%の配列同一性を含む、請求項65または66に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAが、BLASTペアワイズ配列アラインメントアルゴリズムによって決定した時に、配列番号471、配列番号472、または配列番号473に対して少なくとも約90%の配列同一性を含む、請求項65または66に記載の操作されたオリゴヌクレオチドまたはその塩。
- 疾患または状態が、筋ジストロフィーまたはミオパチーを含む神経筋障害を含む、請求項1~31のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩。
- 疾患または状態が、デュシェンヌ筋ジストロフィー(DMD)、筋緊張性ジストロフィー(MD)、顔面肩甲上腕筋ジストロフィー(FSHD)、肢帯型筋ジストロフィー(LGMD)、ベッカー筋ジストロフィー、眼咽頭型筋ジストロフィー、エメリ・ドレフュス筋ジストロフィー、または遠位型筋ジストフィーである、請求項69に記載の操作されたオリゴヌクレオチドまたはその塩。
- 疾患または状態が、遺伝性または自然発生の常染色体優性突然変異に起因する、請求項69または70に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAの少なくとも一部が、ジストロフィン、DMPK、CLCN1、CNBP、D4Z4リピート、DUX4、SMCHD1、DBET、SVIL、GAL3ST2、FRG1、CAPN3、DYSF、LMNA、PABPN1、PYGM、MYOD1、MYH7、HNRNPC、HNRNPA2B1、ACVR1、ASIC2、ATG14、ATP1A1、B3GTNL1、BANF1、BPTF、CASP8AP2、CDX4、CELF2、CHMP7、CKMT1B、CLASP1、CNOT3、COL15A1、CYP3A4、DCAF15、DCN、DLX5、DUSP7、DUX1、DUX5、EMILIN1、EPG5、FAM13A、FBX03、FBXL22、FMNL3、FREM2、FRMPD2、GADD45A、GID4、GJD3、GMPR、GNAT1、GOSR1、GPRC6A、HERC1、HGF、HOOK3、HOXC9、HSP40、IRF9、IRX5、ITGA10、ITGA3、ITGA9、KCNC3、KLHL3、KLK6、LARP6、MALT1、MAP3K4、MAPK10、MIR4661、MIR8078、MTSS1、NDUFAF6、NEBL、NKX2、NR2F1、PCID2、PDE10A、PKD1L2、PKHD1、PPP1R12B、PTPRN2、PYY、RABGAP1L、RBCK1、RFX3、RHBDF2、SCRIB、SEMA3B、SETD4、SHFL、SHH、SLC37A4、SLC9A8、SMAD1、SPEF1、SPRED3、ST3GAL6、STAG1、SUPV3L1、TBC1D26、TCEA2、TCF3、TM6SF1、TMEM108、TMEM259、TNFSF4、TNIP1、TRNP1、USH1G、WRNIP1、XIAP、ZNF574遺伝子またはそれらのあらゆる組み合わせにコードされている、請求項69~71のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩。
- 第1のRNAまたは第2のRNAが、BLASTペアワイズ配列アラインメントアルゴリズムによって決定した時に、配列番号901~配列番号949のいずれか1つに対して少なくとも約90%の配列同一性を含む、請求項69~72のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩。
- 約5ヌクレオチド~約50ヌクレオチドのポリヌクレオチド配列を含む操作されたオリゴヌクレオチドまたはその塩であって、
操作されたオリゴヌクレオチドまたはその塩は、第1の領域、第1の領域に隣接する第2の領域、および第2の領域に隣接する第3の領域を含み、領域が5’から3’まで次の順序:第1の領域、第2の領域、および第3の領域で配置されており;
操作されたオリゴヌクレオチドまたはその塩がmRNA配列に結合している場合、第1の領域および第3の領域はmRNA配列に相補的であり、第2の領域はmRNA配列に相補的ではない少なくとも一つの塩基を含み;
操作されたオリゴヌクレオチドまたはその塩は、37℃および約7.2のpHでmRNA配列に結合する他の同等のオリゴヌクレオチドの結合のギブス自由エネルギー(ΔG)と比較して、約37℃および約7.2のpHでのmRNA配列への結合について決定した時に、少なくとも約10%低い結合のΔGを含み、他の同等のオリゴヌクレオチドが、mRNA配列と相補的でない操作されたオリゴヌクレオチド内で少なくとも1個の塩基を欠失している、操作されたオリゴヌクレオチドまたはその塩。 - BLASTペアワイズ配列アラインメントアルゴリズムによって決定した時に、配列番号1~5、12~14、19~20、24~25、28、30、32、34、36、38~45、52~89、100~154、184~201、205~222、225~233、235~243、245~443、445~453、455~463、465、620、624~825、835~837、840~899、および901~949のいずれか1つに対して少なくとも約90%の配列同一性を有するポリヌクレオチド配列を含む、操作されたオリゴヌクレオチドまたはその塩であって、mRNA配列と接触させた場合、
a. mRNA配列を含む第1の単離されたヒト細胞に、操作されたオリゴヌクレオチドまたはその塩をトランスフェクトし、
b. mRNA配列を含む第2の単離されたヒト細胞に、miR-29またはmiR-30オリゴヌクレオチドをトランスフェクトし、
c. 第1の単離されたヒト細胞および第2の単離されたヒト細胞中に発現するポリペプチドの量を測定すること
により決定した時に、ヒト細胞中に自然に存在する等量のmiR-29もしくはmiR-30オリゴヌクレオチド、またはその塩を接触させた場合と比較して、mRNA配列によりコードされるポリペプチドの発現が約1.2分の1以下となるように産生する、操作されたオリゴヌクレオチドまたはその塩。 - 構造および化学が、未修飾配列または同等のncRNAと比較して、天然ヌクレアーゼに対して100倍以上の安定性を付与するように最適化されている、請求項1~75のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩。
- ポリヌクレオチド配列を含む操作されたパッセンジャーオリゴヌクレオチドまたはその塩であって、請求項1~76のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩の少なくとも一部と少なくとも部分的に相補的である、操作されたパッセンジャーオリゴヌクレオチドまたはその塩。
- 約5~約50ヌクレオチド長である、請求項77に記載の操作されたパッセンジャーオリゴヌクレオチドまたはその塩。
- リボース糖を含む、請求項77または78に記載の操作されたパッセンジャーオリゴヌクレオチドまたはその塩。
- デオキシリボース糖を含む、請求項77~79のいずれか1項に記載の操作されたパッセンジャーオリゴヌクレオチドまたはその塩。
- BLASTペアワイズ配列アラインメントアルゴリズムによって決定した時に、配列番号6、配列番号7、配列番号8、配列番号9、配列番号10、配列番号11、配列番号15、配列番号16、配列番号17、配列番号18、配列番号21、配列番号22、配列番号23、配列番号26、配列番号27、配列番号29、配列番号31、配列番号33、配列番号35、配列番号37、配列番号46、配列番号47、配列番号48、配列番号49、配列番号50、配列番号51、配列番号155、配列番号156、配列番号157、配列番号158、配列番号159、配列番号160、配列番号161、配列番号162、配列番号163、配列番号164、配列番号165、配列番号166、配列番号167、配列番号168、配列番号169、または配列番号466のいずれか1つに対して少なくとも90%の配列同一性を有する、請求項77~80のいずれか1項に記載の操作されたパッセンジャーオリゴヌクレオチドまたはその塩。
- 操作されたパッセンジャーオリゴヌクレオチドが、ステムループを含む二次構造を形成する、請求項77~81のいずれか1項に記載の操作されたパッセンジャーオリゴヌクレオチドまたはその塩。
- 天然に存在する塩基、糖、骨格、またはリン酸結合に対して化学修飾された塩基、化学修飾された糖、化学修飾された骨格またはリン酸結合、またはそれらのあらゆる組み合わせを含む、請求項77~82のいずれか1項に記載の操作されたパッセンジャーオリゴヌクレオチドまたはその塩。
- 化学修飾が、メチル基、フルオロ基、メトキシエチル基、エチル基、ヒドロキシメチル基、ホルミル基、カルボン酸またはその塩、ホスホチオネート修飾骨格、メチルホスホネート修飾骨格、アミノアルキル鎖修飾、およびこれらのあらゆる組み合わせからなる群から選択される、請求項83に記載の操作されたパッセンジャーオリゴヌクレオチドまたはその塩。
- 化学修飾された場合、
式:CAP-mNmNmN(N)kmNmNmN(式中、
CAPは、5’-末端メチル基(5’-Oメチル)またはアミノ炭素6鎖(5’-アミノC6)のようなアルキルアミノ基から選択され;
各Nは独立してウラシル、グアニン、アデニンまたはシトシンであり;
各mNは独立して2’-O-メチル修飾ウラシル、グアニン、アデニン、またはシトシンであり;
各kは12~19である)
を含む、請求項83または84に記載の操作されたパッセンジャーオリゴヌクレオチドまたはその塩。 - BLASTペアワイズ配列アラインメントアルゴリズムによって決定した時に、配列番号90、配列番号91、配列番号92、配列番号93、配列番号94、配列番号95、配列番号96、配列番号97、配列番号98、配列番号99、配列番号170、配列番号171、配列番号172、配列番号173、配列番号174、配列番号175、配列番号176、配列番号177、配列番号178、配列番号179、配列番号180、配列番号181、配列番号182、配列番号183、配列番号202、配列番号203、配列番号204、配列番号223、配列番号224、配列番号234、配列番号244、配列番号444、配列番号454、配列番号464、配列番号838、配列番号839、または配列番号900のいずれか1つに対して少なくとも90%の配列同一性を有する、請求項83~85のいずれか1項に記載の操作されたパッセンジャーオリゴヌクレオチドまたはその塩。
- 糖修飾を含む、請求項77~86のいずれか1項に記載の操作されたパッセンジャーオリゴヌクレオチドまたはその塩。
- 糖修飾がグリコシル化塩基を含む、請求項87に記載の操作されたパッセンジャーオリゴヌクレオチドまたはその塩。
- 構造および化学が、未修飾配列または同等のncRNAと比較して、天然ヌクレアーゼに対して100倍以上の安定性を付与するように最適化されている、請求項77~88のいずれか1項に記載の操作されたパッセンジャーオリゴヌクレオチドまたはその塩。
- (a)請求項1~75のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩を含む第1の鎖、および(b)第1の鎖の少なくとも一部に相補的な配列を有する請求項77~89のいずれか1項に記載の操作されたパッセンジャーオリゴヌクレオチドまたはその塩を含む第2の鎖を含む核酸構築物。
- 請求項1~76のいずれか1項に記載の操作されたオリゴヌクレオチドもしくはその塩、または請求項90に記載の核酸構築物を含むベクター。
- リポソーム、ナノ粒子、またはそれらのあらゆる組み合わせで存在する、請求項91に記載のベクター。
- ウイルスベクターである、請求項91に記載のベクター。
- ウイルスベクターがアデノ随伴ウイルス(AAV)ベクターである、請求項93に記載のベクター。
- 請求項1~76のいずれか1項に記載の操作されたオリゴヌクレオチドもしくはその塩、請求項90に記載の核酸構築物、または請求項91~94のいずれか1項に記載のベクターを含む単離された細胞。
- (a)請求項1~76のいずれか1項に記載の操作されたオリゴヌクレオチドもしくはその塩、請求項90に記載の核酸構築物、または請求項91~94のいずれか1項に記載のベクターと、(b)薬学的に許容される賦形剤、希釈剤または担体とを含む、医薬組成物。
- 単位用量形態である、請求項96に記載の医薬組成物。
- カプセル化されている、請求項96または97に記載の医薬組成物。
- 液体の形態である、請求項96~98のいずれか1項に記載の医薬組成物。
- 治療的有効量の請求項1~76のいずれか1項に記載の操作されたオリゴヌクレオチドもしくはその塩、請求項90に記載の核酸構築物、請求項91~94のいずれか1項に記載のベクター、または請求項96~99のいずれか1項に記載の医薬組成物を対象に投与する工程を含む、それを必要とする対象を処置する方法。
- 投与が、静脈内注射、筋肉内注射、髄腔内注射、眼窩内注射、皮下注射、またはそれらのあらゆる組み合わせによるものである、請求項100に記載の方法。
- 投与が、経口、耳介、眼球、直腸、またはそれらのあらゆる組み合わせである、請求項100に記載の方法。
- 対象への第2の療法を含む第2の投与をさらに含む、請求項100~102のいずれか1項に記載の方法。
- 投与および第2の投与が同時的である、請求項103に記載の方法。
- 投与および第2の投与が逐次的である、請求項103に記載の方法。
- 対象が、疾患または状態を有するか、または発症する危険性がある、請求項100~105のいずれか1項に記載の方法。
- 疾患または状態ががんである、請求項106に記載の方法。
- がんが、頭部がん、頸部がん、皮膚がん、子宮頸がん、前立腺がん、またはそれらのあらゆる組み合わせである、請求項107に記載の方法。
- 疾患または状態がウイルス感染である、請求項106に記載の方法。
- ウイルス感染が、SARS-CoV感染、SARS-COV-2感染、MERS-CoV感染、CoV-HKU1感染、HIV感染、またはHCV感染である、請求項109に記載の方法。
- 疾患または状態が線維症である、請求項106に記載の方法。
- 疾患または状態が筋ジストロフィーである、請求項106に記載の方法。
- 対象が哺乳動物である、請求項100~112のいずれか1項に記載の方法。
- 哺乳動物がヒトである、請求項113に記載の方法。
- 対象が、診断検査によって疾患または状態であると診断されている、請求項100~114のいずれか1項に記載の方法。
- 診断検査が、画像化法、血球数分析、組織病理学的分析、バイオマーカー分析、またはそれらのあらゆる組み合わせを含む、請求項115に記載の方法。
- 請求項1~76のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩、請求項90に記載の核酸構築物、または請求項91~94のいずれか1項に記載のベクターを、単離された細胞または単離された組織と接触させることを含む方法。
- 容器内の請求項1~76のいずれか1項に記載の操作されたオリゴヌクレオチドまたはその塩、容器内の請求項90に記載の核酸構築物、請求項91~94のいずれか1項に記載のベクター、または容器内の請求項96~99のいずれか1項に記載の医薬組成物を含むキット。
- 操作されたオリゴヌクレオチド中のヌクレオチドの少なくとも1個の塩基が、第1のRNAまたは第2のRNAと相補的でない、請求項1~76のいずれか1項に記載の操作されたオリゴヌクレオチド。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063004045P | 2020-04-02 | 2020-04-02 | |
US63/004,045 | 2020-04-02 | ||
PCT/US2021/025639 WO2021203043A2 (en) | 2020-04-02 | 2021-04-02 | Targeted inhibition using engineered oligonucleotides |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023521042A true JP2023521042A (ja) | 2023-05-23 |
JPWO2021203043A5 JPWO2021203043A5 (ja) | 2024-04-15 |
Family
ID=77927597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022560272A Pending JP2023521042A (ja) | 2020-04-02 | 2021-04-02 | 操作されたオリゴヌクレオチドを使用する標的化された阻害 |
Country Status (12)
Country | Link |
---|---|
US (4) | US20230132602A1 (ja) |
EP (1) | EP4127175A2 (ja) |
JP (1) | JP2023521042A (ja) |
KR (1) | KR20230023612A (ja) |
CN (1) | CN116096890A (ja) |
AU (1) | AU2021246530A1 (ja) |
BR (1) | BR112022019889A2 (ja) |
CA (1) | CA3174286A1 (ja) |
CO (1) | CO2022015141A2 (ja) |
IL (1) | IL296957A (ja) |
MX (1) | MX2022012265A (ja) |
WO (1) | WO2021203043A2 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117677698A (zh) | 2021-07-14 | 2024-03-08 | 米雷楚来股份有限公司 | 用于神经肌肉障碍的寡核苷酸及其组合物 |
WO2023122347A2 (en) | 2021-12-23 | 2023-06-29 | Mirecule, Inc. | Compositions for delivery of polynucleotides |
KR20230102595A (ko) * | 2021-12-30 | 2023-07-07 | 주식회사 이노제닉스 | 포스파티딜이노시톨 3-키나아제 촉매 소단위 알파 유전자의 3'비번역 부위에 특이적으로 결합하는 핵산 절편 및 그 응용 |
CN117402251B (zh) * | 2023-12-15 | 2024-02-23 | 中国医学科学院基础医学研究所 | 一种抗小g蛋白rbj的抗体及其应用 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
ES2465574T3 (es) | 2002-05-03 | 2014-06-06 | Duke University | Un método para regular la expresión génica |
US8106180B2 (en) * | 2003-08-07 | 2012-01-31 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro RNAs |
WO2005017145A1 (ja) | 2003-08-13 | 2005-02-24 | Japan Biological Informatics Consortium | 機能性rnaが制御する被制御遺伝子の同定・予測方法及びその利用方法 |
US7795419B2 (en) * | 2004-05-26 | 2010-09-14 | Rosetta Genomics Ltd. | Viral and viral associated miRNAs and uses thereof |
EP1959012A3 (en) * | 2004-12-29 | 2009-12-30 | Exiqon A/S | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAs and their target mRNAs |
JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
WO2006133022A2 (en) | 2005-06-03 | 2006-12-14 | The Johns Hopkins University | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
ITMI20051248A1 (it) | 2005-07-01 | 2007-01-02 | Vimar Spa | Modem per bus per impianti elettrici civili ed industriali |
AU2006291165B2 (en) | 2005-09-12 | 2013-03-14 | The Ohio State University Research Foundation | Compositions and methods for the diagnosis and therapy of BCL2-associated cancers |
US8603991B2 (en) | 2005-11-18 | 2013-12-10 | Gradalis, Inc. | Individualized cancer therapy |
JP2009519339A (ja) | 2005-12-12 | 2009-05-14 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 筋細胞増殖及び分化を調節するマイクロrna |
CA2633754C (en) | 2006-01-05 | 2013-06-18 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis and treatment of solid cancers |
WO2007143752A2 (en) | 2006-06-09 | 2007-12-13 | The Regents Of The University Of California | Targets in breast cancer for prognosis or therapy |
WO2007149521A2 (en) | 2006-06-20 | 2007-12-27 | The Johns Hopkins University | Nucleotide motifs providing localization elements and methods of use |
WO2008069940A2 (en) | 2006-12-06 | 2008-06-12 | Albert Einstein College Of Medicine Of Yeshiva University | Multi-microrna methods and compositions |
JP2010516249A (ja) | 2007-01-17 | 2010-05-20 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 腫瘍治療のためのミクロrnaに関する組成物及び方法 |
WO2009012263A2 (en) * | 2007-07-18 | 2009-01-22 | The Trustees Of Columbia University In The City Of New York | Tissue-specific micrornas and compositions and uses thereof |
NZ583025A (en) | 2007-07-31 | 2012-06-29 | Univ Texas | Micro-rnas that control myosin expression and myofiber identity |
WO2009075817A1 (en) | 2007-12-06 | 2009-06-18 | Minerva Biotechnologies Corporation | Method for treating cancer using interference rna |
JP2010094122A (ja) | 2008-06-12 | 2010-04-30 | Keio Gijuku | バイオマーカーとしてのマイクロrnaを用いた頭頸部腫瘍の診断・治療選択 |
WO2010065630A2 (en) | 2008-12-03 | 2010-06-10 | The Johns Hopkins University | Compositions and methods for treating hepatic neoplasia |
NZ597078A (en) | 2009-06-08 | 2013-11-29 | Miragen Therapeutics | CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS |
WO2011034811A1 (en) | 2009-09-17 | 2011-03-24 | Sigma-Aldrich Co. | Short rna mimetics |
US20120302626A1 (en) * | 2009-12-04 | 2012-11-29 | Sandeep Dave | Microrna and use thereof in identification of b cell malignancies |
US8768630B2 (en) * | 2010-02-19 | 2014-07-01 | The Regents Of The University Of Michigan | miRNA target prediction |
WO2011143660A2 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
DK2426203T3 (en) | 2010-09-02 | 2016-11-07 | Université de Mons | Agents that are useful in the treatment of muscular dystrophy, facioscapulohumeral |
SG10201600836PA (en) | 2011-02-03 | 2016-03-30 | Mirna Therapeutics Inc | Synthetic mimics of mir-34 |
EP2670849A1 (en) | 2011-02-03 | 2013-12-11 | Mirna Therapeutics, Inc. | Synthetic mimics of mir-124 |
WO2013016352A1 (en) | 2011-07-25 | 2013-01-31 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of dux4 |
US20140242093A1 (en) | 2011-07-29 | 2014-08-28 | Fred Hutchinson Cancer Research Center | Methods and compositions for modulating the innate immune response and/or myogenesis in a mammalian subject |
JP6177243B2 (ja) | 2011-10-06 | 2017-08-09 | ミラゲン セラピューティクス, インコーポレイテッド | マイクロrnaの調節による全身エネルギーホメオスタシスの制御 |
TWI516267B (zh) | 2011-11-07 | 2016-01-11 | 臺北榮民總醫院 | 抑制癌症或腫瘤細胞之類癌幹細胞特性及抗化學及放射治療特性的醫藥組合物 |
WO2013120038A2 (en) | 2012-02-10 | 2013-08-15 | Regents Of The University Of Minnesota | Morpholino targeting dux4 for treating fshd |
US11293064B2 (en) * | 2013-05-02 | 2022-04-05 | Thomas Jefferson University | Human miRNAs for use in diagnosis, prognosis, and therapy of human conditions and diseases |
US9518300B2 (en) | 2014-04-14 | 2016-12-13 | Dana-Farber Cancer Institute, Inc. | Composition and method for treating a hematological malignancy |
JP6514717B2 (ja) | 2014-04-25 | 2019-05-15 | ザ チルドレンズ メディカル センター コーポレーション | 異常ヘモグロビン症を治療するための組成物および方法 |
WO2016115490A1 (en) | 2015-01-16 | 2016-07-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of dux4 |
US20180305689A1 (en) | 2015-04-22 | 2018-10-25 | Mina Therapeutics Limited | Sarna compositions and methods of use |
US20170009230A1 (en) | 2015-07-08 | 2017-01-12 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting dux4 gene expression and uses thereof |
CN117757795A (zh) * | 2016-03-07 | 2024-03-26 | 美国政府(由卫生和人类服务部的部长所代表) | 微小rna及其使用方法 |
EP3684378A4 (en) | 2017-09-19 | 2021-06-16 | Children's National Medical Center | GAPMERS AND THEIR USES IN THE TREATMENT OF MUSCLE DYSTROPHY |
MA49923A (fr) * | 2017-10-02 | 2020-06-24 | Res Inst Nationwide Childrens Hospital | Système de déciblage de miarn pour interférence spécifique d'un tissu |
US10676744B2 (en) * | 2017-10-13 | 2020-06-09 | University Of South Carolina | Modulation of adipose tissue macrophage phenotype by use of MicroRNA-30 |
US11268305B2 (en) | 2018-05-17 | 2022-03-08 | Kiekert Ag | Latching system for a motor vehicle |
WO2020028864A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
CA3198063A1 (en) | 2019-03-29 | 2020-10-08 | Mitsubishi Tanabe Pharma Corporation | Compound, method and pharmaceutical composition for modulating expression of dux4 |
CA3142925A1 (en) | 2019-07-12 | 2021-01-21 | Daiichi Sankyo Company, Limited | Antisense oligonucleotide capable of altering splicing of dux4 pre-mrna |
IL294480A (en) | 2020-01-10 | 2022-09-01 | Dyne Therapeutics Inc | Muscle-oriented complexes and their uses for the treatment of atrophy of the muscles of the face, shoulder blades, and arms |
JP2023537798A (ja) | 2020-03-19 | 2023-09-06 | アビディティー バイオサイエンシーズ,インク. | 顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法 |
US20230174958A1 (en) | 2020-04-17 | 2023-06-08 | Nevada Research & Innovation Corporation | Crispr-inhibition for facioscapulohumeral muscular dystrophy |
GB202009618D0 (en) | 2020-06-24 | 2020-08-05 | Ucl Business Ltd | Therapeutics for the treatment of FSHD |
WO2022020106A1 (en) | 2020-07-23 | 2022-01-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
WO2022020108A1 (en) | 2020-07-23 | 2022-01-27 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
WO2022043566A1 (en) | 2020-08-31 | 2022-03-03 | Merck Patent Gmbh | Method and device for manufacturing of solid oral dosage forms |
US20230348906A1 (en) | 2020-09-01 | 2023-11-02 | Ultragenyx Pharmaceutical Inc. | Dux4 inhibitors and methods of use thereof |
WO2022056269A1 (en) | 2020-09-11 | 2022-03-17 | Arrowhead Pharmaceuticals, Inc. | Skeletal muscle delivery platforms and methods of use |
CA3189065A1 (en) | 2020-09-11 | 2022-03-17 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use |
JP2022055361A (ja) | 2020-09-28 | 2022-04-07 | 田辺三菱製薬株式会社 | Dux4の発現を調節するための医薬組成物 |
-
2021
- 2021-04-02 CA CA3174286A patent/CA3174286A1/en active Pending
- 2021-04-02 WO PCT/US2021/025639 patent/WO2021203043A2/en active Application Filing
- 2021-04-02 EP EP21780542.3A patent/EP4127175A2/en active Pending
- 2021-04-02 CN CN202180040335.4A patent/CN116096890A/zh active Pending
- 2021-04-02 AU AU2021246530A patent/AU2021246530A1/en active Pending
- 2021-04-02 KR KR1020227038205A patent/KR20230023612A/ko unknown
- 2021-04-02 MX MX2022012265A patent/MX2022012265A/es unknown
- 2021-04-02 JP JP2022560272A patent/JP2023521042A/ja active Pending
- 2021-04-02 US US17/915,215 patent/US20230132602A1/en active Pending
- 2021-04-02 IL IL296957A patent/IL296957A/en unknown
- 2021-04-02 BR BR112022019889A patent/BR112022019889A2/pt unknown
-
2022
- 2022-03-11 US US17/692,630 patent/US11795459B2/en active Active
- 2022-03-11 US US17/692,644 patent/US11597930B2/en active Active
- 2022-10-24 CO CONC2022/0015141A patent/CO2022015141A2/es unknown
-
2023
- 2023-01-17 US US18/155,163 patent/US20230295626A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20230023612A (ko) | 2023-02-17 |
IL296957A (en) | 2022-12-01 |
CN116096890A (zh) | 2023-05-09 |
US20230295626A1 (en) | 2023-09-21 |
EP4127175A2 (en) | 2023-02-08 |
AU2021246530A1 (en) | 2022-11-03 |
US20220213480A1 (en) | 2022-07-07 |
US11597930B2 (en) | 2023-03-07 |
WO2021203043A3 (en) | 2021-11-11 |
CA3174286A1 (en) | 2021-10-07 |
CO2022015141A2 (es) | 2022-12-30 |
US20220213481A1 (en) | 2022-07-07 |
WO2021203043A2 (en) | 2021-10-07 |
MX2022012265A (es) | 2023-01-11 |
US11795459B2 (en) | 2023-10-24 |
BR112022019889A2 (pt) | 2023-03-07 |
US20230132602A1 (en) | 2023-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11795459B2 (en) | Targeted inhibition using engineered oligonucleotides | |
CN102239260B (zh) | 通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病 | |
CN102639151B (zh) | 通过针对hbf/hbg的天然反义转录物的抑制治疗血红蛋白(hbf/hbg)相关疾病 | |
CN102317458B (zh) | 通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗 | |
US20210292761A1 (en) | Compositions comprising circular polyribonucleotides and uses thereof | |
US20120263740A1 (en) | Aptamer-targeted sirna to inhibit nonsense mediated decay | |
TW201639962A (zh) | Rna干擾劑 | |
TW201200138A (en) | Treatment of Atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1 | |
JP2017527277A (ja) | 修飾オリゴヌクレオチドおよびそれらの合成のための方法 | |
CA2827533A1 (en) | Enhanced biodistribution of oligomers | |
CN107257858A (zh) | 乳酸脱氢酶的治疗性抑制及其试剂 | |
TW201210611A (en) | Treatment of Nicotinamide Phosphoribosyltransferase (NAMPT) related diseases by inhibition of natural antisense transcript to NAMPT | |
US20150238515A1 (en) | Organic compositions to treat kras-related diseases | |
JP6158833B2 (ja) | ベータ−カテニン関連疾患を処置するための有機組成物 | |
TW201219569A (en) | Treatment of Sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4 | |
TW201143780A (en) | Treatment of Colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3 | |
CA3124664A1 (en) | Compositions and methods for inhibiting hmgb1 expression | |
US20240141346A1 (en) | Targeted inhibition using engineered oligonucleotides | |
JP7017193B2 (ja) | Rna作用抑制剤及びその利用 | |
US20220186229A1 (en) | Methods and compositions for inhibiting expression of cyp27a1 | |
CA3209418A1 (en) | Compositions and methods for modulating pnpla3 expression | |
KR20240032998A (ko) | 신경근육장애를 위한 올리고뉴클레오티드 및 이의 조성물 | |
JP2010189276A (ja) | オリゴヌクレオチド誘導体、オリゴヌクレオチド誘導体を用いたオリゴヌクレオチド構築物、オリゴヌクレオチド誘導体を合成するための化合物及びオリゴヌクレオチド誘導体の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20240220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240220 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240329 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240329 |